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Abstract 
The study broadly aimed to identify the potential of existing as well as newly designed novel 
advanced materials for the preparation of novel nano-drug delivery systems to combat MRSA 
infections. In this study, dextran sulfate was explored for the preparation of nanoplexes (VCM-
DXT5). Two new materials (OLA and StBAclm) were also designed, synthesised and 
employed for the formulation of nano-drug delivery systems for efficient delivery of 
vancomycin (VCM) to treat MRSA infections. The materials were characterised by FTIR, 1H 
NMR, 13C NMR and HR-MS. The nanoplexes (VCM-DXT5), nanovesicles (VM-OLA-
LPHVs1) and quatsomes (VCM-StBAclm-Qt1) were characterised for their physicochemical 
properties (Zetasizer), in vitro drug release (dialysis bag), morphology (HR-TEM), in vitro cell 
viability studies (flow cytometry), in vitro  time killing assay (broth dilution), in vitro 
cytotoxicity (MTT assay), in vitro antibacterial activity (broth dilution method) and in vivo 
antibacterial activity (mice skin infection model).  
In this study, high molecular weight dextran sulfate sodium salt was explored for the 
preparation of vancomycin nanoplexes (VCM-DXT5). The nanoplexes were found to be non-
toxic against different mammalian cell lines adenocarcinoma human alveolar basal epithelial 
cells (A549), embryonic kidney cells (HEK-293) and liver hepatocellular carcinoma (Hep G2) 
tested and may confirm its biosafety. The size, polydispersity index (PDI), and zeta potential 
(ZP) of the optimized VCM nanoplexes were 84.6±4.248nm, 0.449±0.024 and -33.0±4.87mV 
respectively, with 90.4±0.77% complexation efficiency (CE%) and 62.3 ± 0.23% drug loading. 
The in vitro drug release studies demonstrated slower sustained release as compared to bare 
VCM.  A 6.24-fold enhancement was observed for VCM nanoplexes via in vitro antibacterial 
studies and 67% effective killing from VCM nanoplexes compared to 32.98% from the bare 
vancomycin at the minimum inhibitory concentration (MIC) of 1.25μg/mL using flow-
cytometric analysis.  The in vivo studies using BALB/c mouse skin infection model revealed 
that nanoplexes reduced MRSA burden by 2.3-folds compared to bare VCM.  
The novel zwitterionic pH-responsive lipid (OLA) was synthesised and its structure confirmed. 
The OLA and the chitosan-based pH-responsive lipid- polymer hybrid vancomycin 
nanovesicles (VM-OLA-LPHVs1) demonstrated biocompatibility of greater than 75% in three 
different cell lines adenocarcinoma human alveolar basal epithelial cells (A549), embryonic 
kidney cells (HEK-293), liver hepatocellular carcinoma (Hep G2) and liver hepatocellular 
carcinoma cell lines (MCF-7). The nano drug was evaluated for their hydrodynamic diameter 
(DH), PDI, zeta potential (ζ), entrapment efficiency (EE%), and drug loading capacity (DLC%), 
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surface morphology, drug release, in vitro and in vivo antibacterial activity. The VM-OLA-
LPHVs had a (DH), PDI, EE%, DLC%, of 198.0 ± 14.04nm, 0.137±0.02, 45.61±0.54% and 
8.92±2.34% respectively at physiological pH (7.4) with negative surface-charged switching to 
positive at pH 6.0. The VM release from the VM-OLA-LPHVs was found to be faster and 
sustained at pH 6.0 with 97% VM release in 72 hours compared to physiological pH 7.4. The 
in vitro antibacterial activity demonstrated a lower MICs values at pH 6.0 of 52.9-fold 
enhancement compared to bare VM against MRSA, while the in vitro flow cytometry study of 
the VM-OLA-LPHVs revealed 7-fold effective MRSA cells dead compared to the treatment 
with bare VM. Additionally, higher fluorescence intensity indicated higher biofilm eradication 
by the VM-OLA-LPHVs. The in vivo studies in BALB/c mouse infected skin model revealed 
1.83-fold reduction in MRSA burden (CFU) compared to treatment with bare VM. These 
findings suggest that OLA can be used as a novel material with significant potential for 
complexation with biodegradable moieties to form pH-responsive LPHVs to enhance antibiotic 
therapy and improve treatment of infections.  
The novel quaternary bicephalic surfactant (StBAclm) was synthesised and its structure 
confirmed. The StBAclm demonstrated higher biocompatibility than 75% cells viability in 
three different cell lines adenocarcinoma human alveolar basal epithelial cells (A549), 
embryonic kidney cells (HEK-293), liver hepatocellular carcinoma (Hep G2) and liver 
hepatocellular carcinoma cell lines (MCF-7). The quatsomes prepared had a size, PDI and EE% 
of 122.9 ± 3.78nm, 0.169 ± 0.02mV and 45.61 ± 0.539% respectively, while the surface charge 
revealed a switching from negative to positive at physiological pH 7.4 and acidic environment 
pH 6.0, respectively. The in vitro drug release from the quatsomes was found to be higher at 
pH 6.0 compared to pH 7.4. The MICs against MRSA revealed 32-folds in pH 6.0 as compared 
to the bare VCM. The higher electrical conductivity and decreases in protein and 
deoxyribonucleic acid (DNA) concentration, confirmed greater MRSA membrane damage 
with VCM-StBAclm-Qt1 quatsomes compared to bare VCM. The in vitro flow cytometry study 
of the quatsomes confirmed higher MRSA dead cells when using the VCM-StBAclm-Qt1 
compared to the bare VCM at quatsomes MIC value with higher fluorescence enhancement in 
the biofilm. The in vivo studies with the VCM-StBAclm-Qt1 quatsomes revealed a 1.83-fold 
decreased in MRSA CFUs compared to the corresponding bare VCM.  
In summary, the high molecular weight dextran, OLA and StBAclm were shown to be biosafe 
and demonstrate the potential for developing novel nano drug delivery systems of antibiotics 
with superior efficacy against bacterial infections.  
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CHAPTER ONE 
INTRODUCTION 
1.1 Introduction  
This chapter consists of a brief background to the study indicating the status of infectious 
diseases and the various challenges of antibiotics therapy.  The chapter further provides details 
on several strategies used to improve antibiotic therapy. It also highlight the aims, objectives, 
novelty of the study and structure of the thesis.  
1.2 Background 
Since the discovery of penicillin by Alexander Fleming in 1928, the development of antibiotics in 
20th century have decreased with increase in antibiotics resistance as shown in Figure 1. After the 
discovery, it was believed that bacterial diseases would be effortlessly controlled. However, since 
the 1950’s, physicians are faced with newly emerging infectious diseases (EIDs) that have led to 
significant economic and public health challenges [1, 2]. Infectious diseases continue to be at the 
forefront concern for health workers globally [3] and are considered to be responsible for high 
morbidity and mortality rates in both developed and developing countries [4]. Generally, infectious 
diseases are caused by pathogenic microorganisms, including viruses, bacteria, parasites, and fungi. 
Compared to other diseases, infectious diseases can be exponentially transmitted among 
populations in a relatively short period, thus threatening the general public health sector and 
potentially causing massive economic cost [5]. It is estimated that over half of the world’s 
population are at risk of infectious diseases, causing disproportionally disease burden [6]. The 
World Health Organization (WHO) estimated that by 2050, antibiotic resistance would result in 
approximately 300 million death rates causing nearly $100 trillion global economic loss. These 
concerns have generated a search for innovative strategies in antimicrobial therapies [7, 8]. In 
recent years, the challenges of developing new antibiotics for bacterial infection treatment has 
become a massive problem, especially in the 21st century as shown in Figure 2. These figures 
demonstrated that only few classes of antibiotics have reached patients in the last four decades, and 
the appearance of multidrug-resistant bacteria have worsened the scenario [9]. Thus, there is an 
urgent call for new ways to prevent, treat and control infectious diseases. 
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Figure 1: History of antibiotics and resistance [10] 
 
Figure 2: Novel FDA-approved antibacterial and non-bacterial drugs in the last 15 years [9]. 
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Antimicrobial resistance is known to be one of the greatest threats to human health globally 
[11] and several antibiotics are compromised for infectious diseases treatment due to resistance 
[12]. Since Alexander Fleming discovered penicillin in 1928, hundreds of antibacterial drugs 
have been introduced into clinical use to combat infectious diseases [13]. However, 
extensive misuse and underuse of antibiotics have led to the development of resistance 
which limit their therapeutic effect to combat infectious diseases caused by MRSA bacteria 
[13].  O’Neill in 2016 reported that 10 million deaths would be recorded globally due to 
antimicrobial resistance by 2025 [14] and MRSA resistance will affect greater than 2 million 
persons every year [15].  
Methicillin-resistant Staphylococcus aureus (MRSA) considered as a superbug is reported to 
be resistant to many drugs, including the last-resort antibiotic vancomycin for bacteria 
treatment leading to vancomycin-resistant strains problems [16, 17]. This problem will 
continue to rise unless multidimensional global research attention is adopted towards 
antimicrobial chemotherapy to combat and target the deadly bacteria [18]. According to the 
Centers for Disease Control and Prevention (CDC), globally nearly 80,641 severe MRSA 
infections occur every year, leading to nearly 11,285 deaths [19]. Similarly, study by Wozniak 
et al. suggested that the global economic cost output of antimicrobial resistance (AMR) 
infections is estimated to be around $100 trillion by 2050. Wozniak et al. reported that 
Australian hospitals spent nearly AUD$5.5 million per year treating MRSA patients [20]. The 
European Union Member States reported about 5,400 deaths with increased economic loss of 
US$672 [21]. While the European Centre for Disease Prevention and Control (ECDC), 
estimated nearly 33,000 people die each year in Europe due to infections caused by antibiotic-
resistant bacteria (MRSA). Furthermore, in the United States and Africa, death rate are 
expected to reach nearly 19, 000 [11] and  4,150,000 [22] respectively, from infectious diseases 
caused by MRSA as shown in Figure 3. An in-depth review by Iqbal et al. in the United 
Kingdom (UK) revealed that MRSA is one of the main health care problems. The studies 
revealed that, the UK government and the health care organisation had taken significant 
measure to reduce MRSA bacteremia by setting targets in the hospitals. The target was set by 
the UK government health care organization in the hospitals instructed to use universal MRSA 
screening exercised for admitted patients in the hospital which replaced the targeted screening 
policy based on risk factors [21].  
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Figure 3: Expected global antimicrobial resistance death rates to occur every year by 2050 
[23]. 
Antibiotics are a class of secondary metabolites produced by microorganisms, which are 
synthesised or semi-synthesised analogous compounds that can inhibit the growth and survival 
of microorganisms [24]. The discovery of antibiotics have saved millions of lives over the past 
decades [10, 25] by preventing and treating bacterial infections [10] due to their cost-
effectiveness and powerful outcomes since the Second World War giving substantial benefits 
in public health [26]. However, several studies have provided direct evidence that the 
widespread use of antibiotics has led to the emergence of multidrug-resistant bacterial strains 
[27]. Several factors such as overuse of antibiotics for systemic infections, improper dosing 
regimens, misuse of antibiotics for nonbacterial infections and inadequate drug concentrations 
at the infection sites [28, 29] have contributed to antibiotics resistance developments [30, 31]. 
Furthermore, faster drug degradation leading to quick elimination in the bloodstream [32] and 
extended duration of therapy poor patients compliance due to side effects [33, 34], exposure of 
healthy cells to antibiotics [35] and poor adherence to prescribed regimens demanding for 
frequent administration prolonged drug usage have contributed to antibiotics resistance [30, 
36]. These factors have left a large gap between the introduction of antibiotics and resistance 
development. The need to develop additional bactericidal nano-drugs have significantly 
increased due to the growing concern regarding multidrug-resistant bacterial strains associated 
with infections [37]. The use of cutting-edge nanotechnologies in drug delivery are critical 
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alternative needed to facilitate the enhancement of conventional antibiotics against infectious 
disease [11].  
Novel nano-drug delivery systems using nanotechnology provide solutions to several modern 
conventional drugs challenges in the treatment of infectious diseases [38, 39]. These involve 
the manipulation of matters on atomic, molecular and supramolecular scales to fabricate 
products macroscopically for drug use beyond regular materials capacity [40]. Nano-sized drug 
delivery systems offer greater versatility due to size, composition, stimuli-responsiveness [39], 
biocompatibility, biodegradability, decreased side effects [41, 42] and decreased exposure of 
antibiotics to healthy sites [43]. Additionally, drug nanosystems enhance antibacterial activities 
[37, 44-46], cellular internalization [47-50], drug solubility [51], protect drug against 
degradation [52], prevent exposure of drug molecules to healthy sites, ensure controlled and 
sustained release and improved cellular internalization [53]. In recent years, billions of dollars 
was invested in the nanoparticles global market for life sciences, especially in drug delivery 
systems accounting to nearly 76% of nanotechnology research publications in 2014 [54]. Since 
the development of the first drug carrier systems, a large number of nanosystems such as 
polymeric nanoparticles [55], micelles [56], lipid nanovesicles [57], solid lipid nanoparticles 
(SLN) [58] and liposomes [59, 60] have been developed for targeted delivery of antibiotics 
[61] revealing less toxicity [62], improve biological activities [63] and enable drug controlled 
release [64]. Therefore, for biomedical application, nanotechnology is considered as a 
“responsible benchtop to the bedside” [38] to address conventional dosage forms of antibiotics 
limitations and decrease bacterial resistance. 
The urgency to formulate novel nano-antibiotics systems with suitable properties to target 
infectious disease for prolonged delivery and enhance antibacterial activity are needed. In this 
study, three novel approaches for designing nanosystem was explored: i) nanoplexes 
synthesized with high molecular weight dextran sulfate sodium salt, ii) chitosan-based pH-
responsive lipid-polymer hybrid nanovesicles (OLA-LPHVs), iii) quaternary bicephalic 
surfactant (StBAclm) and cholesterol pH-responsive quatsomes to efficiently enhance 
vancomycin activity against Methicillin-resistant Staphylococcus aureus (MRSA) and 
infections.  
Nanoplexes are drug- nanoparticles complexed with an oppositely charged polyelectrolyte with 
an excellent alternative to conventional dosage forms antibiotics [65]. These novel 
nanosystems offer several advantages which include high complexation efficiency (CE%), 
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higher drug loading capacities (DLC%), solvent-free conditions, feasibility in scale-up, 
minimal energy expenses and drug wastage [65, 66]. Several studies have reported different 
advantages of nanoplexes such as minimal energy requirement during nanoplexes preparation 
[66, 67], decrease frequent drug administration, drug protection from the chemical environment 
[68] and increase drug molecule targetability [69-71]. Recently, antibiotics nanoplexes of 
several drugs such as streptomycin [72], gentamicin [73], ciprofloxacin [74], ofloxacin and 
levofloxacin [75], itraconazole [76], curcumin [77, 78] complexed with polymers such as 
chitosan, and dextran sulfate sodium salt are employed for combating bacterial resistance. 
These nanoplexes have demonstrated higher and enhanced antibacterial activity leading to 
reductions in infections burden reduction. 
The zwitterionic pH-responsive lipid (OLA) and the quaternary bicephalic surfactant 
(StBAclm) nanosystems were efficient for drug delivery and antibacterial enhancement [79, 
80]. Additionally, the ability to functionalize the oleylamine and stearylamine terminal groups 
makes them useful to enhance antibacterial activity [81, 82], biodegradable [83, 84], and ideal 
for sustained drug release [85]. Although several reports are available for pH-responsive 
LPHVs [86-88] and zwitterionic lipid [89-91], these are the only reports on pH-responsive 
LPHVs synthesised from oleylamine and quaternary bicephalic surfactant pH-responsive 
quatsomes for antibiotics delivery. This highlights the feasibility and importance of developing 
LPHVs and quatsomes for antibiotics delivery. Nano drug delivery systems are designed to 
respond to several disease conditions for targeted delivery.  
Nano-antibiotic systems have demonstrated the ability to overcome several conventional 
antibiotics challenges. These are achieved by increasing localised drug concentration at the 
sites of infection and decrease drug exposure to healthy sites leading to improved infectious 
disease treatment with minimum side effects and improved patients’ compliance. Lipid-
polymer hybrid nanovesicles (LPHVs) are core-shell nanoparticle structures comprising of 
polymer cores and lipid shells, which exhibit complementary characteristics of both polymeric 
nanoparticles and liposomes, in terms of their physical structure and stability [61]. This 
nanosystems demonstrated pH-sensitive linkages [92, 93], biocompatibility, higher EE%, drug 
loading capacity (DLC%) and good stability.  
Quatsomes are composed of sterols/cholesterol and quaternary ammonium materials that self-
assemble into bilayers nanovesicles [94, 95]. Several quaternary materials such as cationic 
hexadecyltrimethylammonium bromide (CTAB) [96-98] and myristalkonium chloride (MKC) 
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[99-101] has been used for quatsomes formulation. They are confirmed to be stable with 
uniform reproducible, lamellarity [97, 99, 102-104], and revealed enhanced antimicrobial 
activity against S. aureus [105-107]. Furthermore, quatsomes have shown to protect drugs 
against premature degradation to improve intracellular penetration [108], and ideal for 
membrane functionalization for drug delivery and targetability [109-111]. The nanosystems 
ability to encapsulate drug, protect from degradation and enhance their therapeutic efficacy 
makes them important candidates for drug delivery [112]. Therefore, designing a pH-
responsive quaternary bicephalic surfactant (StBAclm) quatsomes to enhance the activity of 
antibiotics against MRSA, disrupt bacterial membrane to eradicate infectious disease are 
urgently needed. 
To achieve the proposed nano-drug delivery systems, particularly nanoplexes, nanovesicles 
and quatsomes for vancomycin, is urgently needed. Vancomycin a glycopeptide antibiotic act 
by inhibiting the biosynthesis of peptidoglycan layer by disrupting the assembly of N-acetyl 
muramic acid and N-acetyl glucosamine (NAM-NAG)-polypeptide [113]. It is presently used 
for the prevention, treatment and prophylaxis of Gram-positive bacteria such as the 
community-acquired Methicillin-resistant Staphylococcus aureus (MRSA), Methicillin-
susceptible Staphylococcus aureus (MSSA), and Vancomycin-Resistant Enterococci (VRE) 
[114]. With the increasing occurrence of MRSA, MSSA, and VRE, the potential ability of 
vancomycin to treat life-threatening infections are becoming difficult due to resistance thus, 
demand for new treatment approach [115-117]. Therefore, these studies aimed to enhance 
antibacterial activity and performance of vancomycin (VCM) against MRSA using high 
molecular weight dextran sulfate sodium salt (DXT), zwitterionic lipid (OLA) and quaternary 
bicephalic surfactant (StBAclm) derived from nanoplexes, pH-responsive lipid polymer-hybrid 
nanovesicles (LPHVs), and quaternary bicephalic pH-responsive quatsomes, respectively, 
against MRSA. Chapters two, three and four represent the first efforts undertaken on the 
development of new nanosystem to efficiently deliver vancomycin against Methicillin-resistant 
Staphylococcus aureus (MRSA). 
1.3 Problem Statement 
Infectious diseases, including bacterial infections, continue to be a significant cause of high 
morbidity and mortality rates globally. Regrettably, conventional dosage forms (CDFs) have 
demonstrated several limitations, including inadequate drug concentration at infection sites, 
exposure to beneficial flora to healthy side, fast degradation and quick elimination of the drug 
in the bloodstream, frequency of drug administration, severe side effects and poor patient 
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compliance. These limitations have contributed to suboptimal therapeutic outcomes and the 
current global antimicrobial resistance crisis. Nano-drug delivery systems are showing 
significant potential for overcoming challenges associated with conventional antibiotics dosage 
form. The identification of novel nano-based strategies to enhance antibacterial activity and 
therapy, and to target infection sites, therefore, contribute to the enhancement of patient disease 
treatments. The design and synthesis of advanced materials for nano-based strategies for 
developing novel nano-formulations are urgently needed to improve the antibacterial activity 
of current conventional antibiotics. 
1.4 Aims and Objectives of this Study  
The study broadly aimed to design novel, advanced materials and explore their potential for 
the preparations of nano-based drug delivery systems to treat infectious disease caused by 
Methicillin-resistant Staphylococcus aureus (MRSA) infections. The research aims and 
objectives of the three developed nanosystems in this study are highlighted below. 
Aim 1 
This study aimed to explore the potential of higher molecular weight dextran sulfate sodium 
salt for complexation with vancomycin into stable nanoplexes formulation and explore its 
potential for delivering antimicrobials via nanoplexes. To achieve this aim, the objectives of 
the study were to:  
1. Screen different concentrations of conventional antibiotic vancomycin to identify a 
suitable size for stable nanoplexes.  
2. Determine the in vitro cytotoxicity of the synthesised VCM-DXT5 nanoplexes to 
confirm its safety in three different cell lines [adenocarcinoma human alveolar basal 
epithelial cells (A-549), human embryonic kidney cells (HEK-293) and human liver 
hepatocellular carcinoma cell (HepG-2)].  
3. Perform molecular dynamics simulation between VCM and DXT in order to understand 
the mechanism behind the nanoplexes formation with salts.  
4. Perform and evaluate the formulated nanoplexes in terms of size, PDI, zeta potential, 
complexation efficiency, drug loading, morphology, in vitro drug release, flow 
cytometry in vitro and in vivo antibacterial activity. 
Aim 2  
This study aimed to synthesise a novel zwitterionic pH-responsive lipid (OLA) from 
oleylamine and explore its potential to formulate chitosan-based pH-responsive vancomycin-
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loaded lipid polymer-hybrid nanovesicles (VM-OLA-LPHVs) through a modified ionic 
gelation method for VM delivery and antibacterial activity enhancement. To achieve this aim, 
the objectives of the study were to:  
1. Synthesise novel zwitterionic pH-responsive lipid (OLA) and confirm its structure 
using 1H NMR, 13C NMR, FT-IR, HR-MS. 
2. Determine the in vitro biocompatibility of the synthesised zwitterionic pH-responsive 
lipid (OLA) and the chitosan-based pH-responsive vancomycin-loaded lipid polymer-
hybrid nanovesicles (VM-OLA-LPHVs) to study its safety margin on different cell-
lines  [adenocarcinoma human alveolar basal epithelial cells (A-549), liver 
hepatocellular carcinoma cell lines (MCF-7), human embryonic kidney cells (HEK-
293) and human liver hepatocellular carcinoma cells (HepG-2)].  
3. Formulate the novel chitosan-based pH-responsive vancomycin-loaded lipid-polymer 
hybrid nanovesicles (VM-OLA-LPHVs) and evaluate their physicochemical 
properties in terms of hydrodynamic diameter (DH), polydispersity index (PDI), zeta 
potential (ZP), entrapment efficiency (EE %), drug-loading capacity (DLC), surface 
morphology, in vitro drug release, in vitro and in vivo antibacterial activities.  
4. Perform quantification analysis using electrical conductivity, deoxyribonucleic acid 
(DNA) and protein concentration using the VM-OLA-LPHVs nanovesicles to 
increase electrical conductivity and decrease DNA and protein concentration, 
respectively towards MRSA infections.  
5. Perform bactericidal assay, MRSA membrane disruption and cell wall disruption and 
observe the rate of bacterial death per hour. 
6. Perform quantitative analysis of bacteria cell viability and biofilms reduction after 
exposure to VM-OLA-LPHVs nanovesicles using flow cytometry and fluorescence 
microscopy respectively to quantify the percentage of MRSA eliminated and 
determine MRSA biofilms disruption.  
Aim 3  
This study aimed to synthesise a novel quaternary bicephalic surfactant (StBAclm) from 
stearylamine and formulate quaternary bicephalic pH-responsive vancomycin quatsomes 
(VCM-StBAclm-Qt) to deliver and enhance VCM antibacterial activity against MRSA. To 
achieve this aim, the objectives of the study were to:  
1. Synthesise novel quaternary bicephalic surfactant (StBAclm) and confirm its structure 
using 1H NMR, 13C NMR, FT-IR and HR-MS. 
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2. Determine the in vitro biocompatibility of the synthesised quaternary bicephalic 
surfactant (StBAclm) and the quaternary bicephalic pH-responsive vancomycin 
quatsomes (VCM-StBAclm-Qt) in adenocarcinoma human alveolar basal epithelial 
cells (A-549), liver hepatocellular carcinoma cell lines (MCF-7), human embryonic 
kidney cells (HEK-293) and human liver hepatocellular carcinoma cell (HepG-2) to 
confirm its use in biological systems.  
3. Formulate quaternary bicephalic pH-responsive vancomycin-loaded quatsomes and 
evaluate their physiochemical properties in terms of mean hydrodynamic diameter 
(MHD), polydispersity index (PDI), zeta potential (ZP), entrapment efficiency (EE 
%), drug-loading capacity (DLC %), surface morphology, in vitro drug release, in 
vitro and in vivo antibacterial activity.  
4. Perform quantification analysis in terms of electrical conductivity, deoxyribonucleic 
acid (DNA) and protein concentration to quantify electrical conductivity, DNA and 
protein concentration in MRSA using the VCM-StBAclm-Qt quatsomes. 
5. Perform bactericidal assay, MRSA membrane disruption and cell wall disruption and 
observe the rate of bacterial death per hour. 
6. Perform quantitative analysis of cell viability and biofilms reduction after the 
exposure of VM-StBAclm-Qt quatsomes to MRSA and MRSA biofilm using flow 
cytometry and fluorescence microscopy and percentage of MRSA dead cells, MRSA 
membrane disruption, and elimination of biofilms revealed by the VM-StBAclm-Qt 
quatsomes.  
1.5 Novelty of the study  
The novelty of the research undertaken is described below.  
Aim 1  
The experimental research in Chapter two performed in this study is to the best of our 
knowledge novel due to the following reasons:  
• It is the first antibiotic nanoplex formulation comprising of a polysaccharide based 
architecture using dextran sulphate.   
• It is the first formulated VCM nanoplex formulation.  
• It is the first reported antibiotic nanoplex formulation with smaller sizes and high 
complexation efficiencies than those reported so far.  
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• It is the first antibiotic nanoplex formulation confirming bactericidal efficacy against 
MRSA. 
Aim 2  
The experimental research in Chapter three performed in this study is to the best of our 
knowledge novel due to the following reasons:  
• The synthesis of OLA as a novel zwitterionic pH-responsive lipid is reported for the 
first time.   
• This is the first reported pH-responsive nanovesicles (VM-OLA-LPHVs1) formulated 
using the novel synthesised zwitterionic pH-responsive lipid (OLA) for any class of 
drug.  
• This is the first reported study using electrostatic complexation to form pH-responsive 
nanovesicles for targeted delivery of antibiotics. 
• This is the first report of bactericidal assay and biofilm eradication studies with pH-
responsive nanovesicles for bacterial infections.  
Aim 3 
The experimental research in Chapter four performed in this study is to the best of our 
knowledge novel due to the following reasons:  
• The synthesis of (StBAclm) as a quaternary bicephalic surfactant is reported for the 
first time. 
• This is the first reported pH-responsive quatsomes (VCM-StBAclm-Qt1) formulated 
using the novel synthesised quaternary bicephalic surfactant (StBAclm).   
• This study reports the first antibiotic quatsomes formulation.  
1.6 Significance of the study  
The nanosystems drug delivery approaches established in this studies are novel and can 
contribute to the overwhelming antibiotics, bacterial resistance problems and limitations 
associated with conventional dosage forms (CFD). The significance of this study is highlighted, 
as shown below:  
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New pharmaceutical products: The proposed VCM-DXT5, VM-OLA-LPHVs, and VCM-
StBAclm-Qt are new pharmaceutical products which have not been reported and can inspire 
the local pharmaceutical industries to manufacture cost-effective and superior medicines.  
Improved patient therapy and disease treatment: All the novel proposed formulations can 
improve patient therapy; treatment of various diseases associated with bacterial infections and 
reduce hospital stay by patients. These are advantageous due to enhance antibacterial 
performance, minimising doses, lowering side effects and improving patient compliance. 
Therefore, contribute to the enhancement of patient quality of life.  
Creation of new knowledge to the scientific community: The studies proposed can lead to new 
knowledge being produced in Pharmaceutical Sciences. These can include the following:  
• Synthesis schemes for new materials, preparation procedures for the novel drug delivery 
systems and their properties in vitro, in silico, and in vivo can contribute to the creation 
of new scientific knowledge. 
• The extensive in vivo testing of these novel systems on infected mice models can offer 
knowledge for in vivo correlations in human.  
Stimulation of new research: The proposed VCM-DXT5, VM-OLA-LPHVs, and VCM-
StBAclm-Qt nanosystems can generate new potential research ideas which include the 
following: 
• The newly proposed VCM-DXT5, VM-OLA-LPHVs, and VCM-StBAclm-Qt 
nanosystems could be used for delivery of other classes of drugs to treat various disease 
conditions. 
• The newly designed and formulated VCM-DXT5, VM-OLA-LPHVs and VCM-
StBAclm-Qt could stimulate intensive research in the development and manufacturing 
of nanosuspensions in the pharmaceutical industry to develop novel dosage forms that 
can decrease major challenges associated with conventional dosage forms.    
• The elimination of intracellular MRSA with the novel VM-OLA-LPHVs nanovesicles 
and VCM-StBAclm-Qt quatsomes will stimulate research in the elimination of other 
bacteria that hide intracellularly acting as reservoirs and sources of chronic infections 
and resistant strains.  
• The in vitro evaluation of electrical conductivity, deoxyribonucleic acid (DNA) and 
protein concentration quantification in the MRSA using the novel VM-OLA-LPHVs and 
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VCM-StBAclm-Qt nanosystems will drastically demonstrate a massive reduction of the 
higher DNA and protein concentration in MRSA. 
1.7 Overview of dissertation  
The research work performed during these studies presented in this thesis is in a publication 
format, according to the University of KwaZulu-Natal, College of Health Sciences guidelines. 
It specifies the inclusion of a brief introductory chapter, published papers and a closing chapter 
on the conclusions. A PhD degree requires at least three first-authored papers, two of which 
must be experimental. 
CHAPTER TWO: EXPERIMENTAL PAPER ONE: This chapter addresses Aim 1, 
Objectives 1 - 4 and is a first-authored experimental article published in an ISI International 
Journal: International Journal of Pharmaceutics (Impact Factor = 3.862). This article highlights 
the formulation of the novel nanoplexes, the in vitro toxicity evaluation, formulation of the 
ultra-small vesicles (VCM-DXT5) to deliver VCM, molecular dynamics simulation of the self-
assembly of nanoplexes, characterisation of its physical properties and in vitro and in vivo 
antibacterial properties. 
CHAPTER THREE: EXPERIMENTAL PAPER TWO: This chapter addresses Aim 2, 
Objectives 1 - 6 and is a first-authored experimental article communicated to the International 
Journal of Biological Macromolecules (Impact Factor 4.784) an ISI International Journal 
(Manuscript ID: IJBIOMA_2019_7211). This article highlights the synthesis of a novel 
OLAtBAc lipid from oleylamine, the in vitro toxicity evaluation, hemolytic study, formulation 
of the pH-responsive nanovesicles (VM-OLA-LPHVs) for targeted delivery of VM, 
characterisation of it’s physical and antibacterial properties both in vitro and in vivo activity 
and the quantification of DNA and protein concentration. 
CHAPTER FOUR: EXPERIMENTAL PAPER THREE: This chapter addresses Aim 3, 
Objectives 1 - 6 and is a first-authored experimental article communicated to the European 
International Journal of Pharmaceutics (Impact Factor = 3.408) with an ISI International 
Journal (Manuscript ID: JDT-2019-OR-0382). This article highlights the synthesis of a novel 
quaternary bicephalic surfactant (StBAclm), in vitro toxicity evaluation, hemolytic study, 
formulation of the quaternary bicephalic pH-responsive quatsomes (VCM-StBAclm-Qt) for 
targeted delivery of VCM. The formulation was characterised for its physicochemical 
properties, in vitro DNA and protein quantification, in vitro time killing assay, membrane 
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disruption, in vitro, and in vivo antibacterial properties of the drug-loaded quatsomes against 
Methicillin-resistant Staphylococcus aureus (MRSA). 
CHAPTER FIVE: CONCLUSION: This chapter includes the overall conclusions from 
research findings in the study which, provides information on the potential significance of the 
findings and makes recommendations for future research work in the field of strategic solutions 
to combat bacterial resistance of antibiotics. 
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CHAPTER TWO: EXPERIMENTAL PAPER ONE 
2.1 Introduction  
This chapter addresses Aim 1 and Objectives 1 - 6. It is a first authored experimental article 
published highlights the formulation and characterisation of vancomycin nanoplexes (VCM-
DXT5) from high molecular weight dextran sulfate sodium salt. The nanoplexes was evaluated 
for in vitro toxicity, physicochemical properties, in-silico study, in vitro and in vivo 
antibacterial properties. 
The ethical approval is attached in Appendix I. 
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2.2 Graphical abstract 
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2.4 Abstract  
The development of novel antibiotic systems is needed to address the methicillin-resistant 
Staphylococcus aureus (MRSA) infections. The aim of the study was to explore the novel 
nanoplex delivery method for vancomycin (VCM) against MRSA using dextran sulfate sodium 
salt (DXT) as a polyelectrolyte complexing agent. Nanoplexes were formulated by the self-
assembling amphiphile polyelectrolyte complexation method and characterized. The size, PDI, 
and ZP of the optimized VCM nanoplexes were 84.6 ± 4.248 nm, 0.449 ± 0.024 and -33.0 ± 
4.87 mV respectively, with 90.4 ± 0.77 % complexation efficiency (CE %) and 62.3 ± 0.23 % 
drug loading. The in vitro MTT studies of the nanoplexes using different cell lines showed 
VCM nanoplexes to be non-cytotoxic and demonstrated sustained delay release. The in-silico 
study confirmed the spontaneous interaction of VCM with DXT in presence of sodium 
chloride. A 6.24-fold enhancement was observed for VCM nanoplexes in in vitro antibacterial 
studies. Flow-cytometric analysis showed effective cell killing of 67 % from VCM nanoplexes 
compared to 32.98 % from the bare vancomycin at the MIC of 1.25 μg/mL. The in vivo studies 
using BALB/c mouse skin infection model revealed that nanoplexes reduced MRSA burden by 
2.3-folds compared to bare VCM. The novel nanoplexes show the potential to be a promising 
delivery system to combat MRSA infections for improved treatment of bacterial infections.  
 
Keywords: Vancomycin, dextran sulfate sodium salt (DXT), nanoplexes, antibacterial, 
methicillin-resistant Staphylococcus aureus. 
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2.5 Introduction  
Infectious diseases caused by methicillin-resistant Staphylococcus aureus (MRSA) continues 
to be a major concern globally. Statistics by the United State Center for Disease Control and 
Prevention specifically reported approximately 80 000 invasive MRSA infections and 11 285 
associated deaths in 2017 [118]. The effectiveness of conventional antibiotics, such as β-lactam 
antibiotics (penicillins and cephalosporins) and trimethoprim against MRSA, is compromised 
due to antibiotic resistance [119]. Currently, vancomycin (VCM), a tricyclic glycopeptide, is 
one of the main drugs widely used to combat MRSA infections [120, 121]. However, its 
frequent use and misuse as well as limitations of current dosage forms such as inadequate drug 
concentration at disease site [122], increased exposure of healthy sites to the drug, higher doses 
required and side effects, increased frequency of administration, poor patient adherence leads 
to poor disease treatment outcomes and development of resistance [123-125]. Furthermore, 
vancomycin suffers from several major drawbacks, such as inducement of nephrotoxicity, on 
prolonged and persistent usage [126].  
Nano-antibiotic delivery systems can help to overcome the problems associated with 
vancomycin treatment and reduce MRSA infections by offering several advantages, such as 
increased localized concentration at the infection sites, decreased exposure of the drug to 
healthy sites, resulting in improved infection treatment, minimized side effects and improved 
patient compliance [43]. Vancomycin encapsulation in liposomes [127, 128],  solid lipid 
nanoparticles [129], nanostructured lipid carriers [130], polymersomes [131] and  polymeric 
nano carriers [132] has been reported to be an effective method to increase drug accumulation 
at the site of infection with reduced toxicity and side effects. However, some of these 
formulations are less feasible due to a number of limitations, such as poor scalability, use of 
toxic solvents and expensive materials, and high material wastage during preparation [66, 67]. 
Amorphous VCM–nanoplexes, which involve drug nanoparticles complexed with an 
oppositely charged polyelectrolyte, can be a good alternate to conventional solid dosage forms 
and the afore-mentioned nano-formulation strategies [66]. The advantages of nanoplexes 
include easy preparation methods with high drug loading capacities, solvent free conditions, 
feasibility in scale-up, minimal energy expenses and drug loss or wastage. Recently, Sikwal et 
al reported VCM polyacrylic acid nanoplexes, with size ranges of 229.7 ± 47.76 nm and 
complexation efficiency up to 75 %, using the anionic polymer polyacrylic acid sodium and 
VCM hydrochloride [133]. To the best of our knowledge, this is the only nanoplexes 
formulation of VCM reported in the literature and hence, there is a need to identify other 
complexing agents to widen their applicability. While other nanoplexes for drugs, such as 
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curcumin [134], ciprofloxacin [135], streptomycin [72], ofloxacin, levofloxacin [75], ibuprofen 
[75], gentamicin [73] and doxorubicin [136], have been reported, there is no data on VCM-
dextran sulfate sodium salt (DXT) nanoplexes. Herein we extend the investigation of VCM 
nanoplexes to a different anionic polysaccharide polymer dextran sulfate sodium salt (DXT) 
for improved preparation efficiencies. 
Dextran sulfate sodium salt (DXT) is widely used in pharmaceutical formulation applications, 
due to its biodegradable and biocompatible properties [137-139]. The anionic electrostatic 
interaction, arising from sulfate-groups, enables dextran sulfate sodium salt to readily undergo 
electrostatic complexation with oppositely charged drug molecules, while hydrophobic 
interaction from glucoside rings plays an important role in the formation of nanoplexes with 
small molecule drugs [140]. Dextran sulfate sodium salt (DXT) has been reported to be a useful 
agent in nanoplexes preparation and for delivering nucleic acids, antibacterial and anticancer 
drug molecules [66, 137-141]. The use of natural polysaccharides-based polyelectrolyte 
architectures could offer VCM nanoplexes desirable pharmaceutical properties for commercial 
applications. 
The aim of this study was to explore the potential of dextran sulfate sodium salt for 
complexation with vancomycin into a stable nanoplexes formulation. In this study, VCM-DXT 
binary nanoplexes were successfully formulated and characterized for their physicochemical 
properties, followed by in-silico, in vitro and in vivo antibacterial activity to assess their 
potential in VCM delivery. 
2. Materials and Methods   
2.1. Materials 
VCM hydrochloride (VCM) was obtained from Sinobright Import and Export Co. Ltd. (China), 
Dextran sulfate sodium salt (MW = 500,000) was purchased from Millipore/Calbiochem® 
(Japan). Dialysis tubing of MWCO 14,000 Da (Sigma-Aldrich, USA) was employed for drug 
release studies and 3-(4, 5-dimethylthiazole-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) 
used in cytotoxicity study was obtained from Merck Chemicals (Germany). Mueller-Hinton 
Agar (MHA), Mueller-Hinton Broth (MHB) and Nutrient Broth used for antibacterial assay 
were Biolab (South Africa) products. The bacteria culture used were MRSA (Rosenbach ATCC 
BAA 1683), while propidium iodide (PI) and Syto9 cell were obtained from Thermofisher 
Scientific (USA).  
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2.2. Preparation of VCM-DXT nanoplexes 
VCM-DXT nanoplexes were prepared by a previously reported self-assembling amphiphile 
polyelectrolyte complexation method, with minor modifications [142]. Briefly, 0.45 % (w/v) 
of DXT in 0.1 M sodium chloride solution and 1 % (w/v) VCM solution in milli-Q water were 
prepared separately. Varying amounts of VCM solution of 2.5, 5, 10, 15 and 20 mL were added 
drop wise to 5 mL of DXT solution (0.45 % w/v) under gentle and constant stirring at ambient 
condition. The mixture was left for one hour under ambient stirring conditions for the formation 
of VCM-DXT nanoplexes.  
The effect of the VCM concentrations on the nanoplexes formation were explored at an initial 
DXT concentration of 4.5 mg/mL. The VCM concentration in the formulation varied from 3.3 
mg/mL to 8 mg/mL, resulting in the VCM-DXT nanoplexes formation with charge ratios 
(RVCM/DXT) ranges from 0.31 - 2.49. The charge ratios were calculated from the molecular 
weights of VCM and DXT and the number of charged groups per molecule for both VCM and 
DXT (Supplementary material). The 24-OSO3
  groups per DXT molecule, that contribute to ־
charge density of 4.8 × 10-6 mol.charge/mg for DXT [76] and two amine groups (-NH3
+) per 
VCM molecule, resulting in 1.3 × 10-6 mol.charge/mg for VCM [133] (Supplementary 
materials). 
2.3. Physical characterizations of VCM-DXT nanoplexes 
2.3.1. Particle size, polydispersity index, zeta potential and morphology 
The VCM-DXT nanoplexes, before and after lyophilization were analysed for particles size 
(PS), polydispersity index (PDI) and zeta potential (ZP) using a zeta sizer (Nano ZS, Malvern 
Instruments Corp, UK) at 25 °C after diluting the dispersion to an appropriate volume with 
deionized water. All measurement was done in triplicate. The morphology of VCM-DXT 
nanoplexes was observed using transmission electron microscope (TEM, Jeol, JEM-1000) at 
an accelerated voltage of 100 Kv. Samples for TEM analysis were prepared by loading a small 
amount of nanoplex dispersion onto a carbon coated grid and dried for approximately three 
minutes to ensure the adherence of sample to grid, with the excess dispersion being removed 
by filter paper. 
2.3.2. Complexation efficiency CE % 
The complexation efficiency (CE) is characterized as the mass percentage of drug that forms  
nanoplexes relative to the initial amount of drug added [75]. Unentrapped drug from the VCM-
DXT formulations was separated after centrifuging (Beckman Coulter OptimaTM MAX XP 
Centrifuge) at 1300 x g for 30 min at 4 °C. The free drug from the supernatant was collected 
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and estimated using UV spectrophotometry (Shimadzu UV 1601, Japan) at 280 nm. The 
complexation efficiency percentage (CE %) was calculated based on Equation 1. 
𝐶𝐸 % =
(𝑇𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑉𝐶𝑀 − 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑉𝐶𝑀 𝑖𝑛 𝑠𝑢𝑝𝑒𝑟𝑛𝑎𝑡𝑎𝑛𝑡)
𝑇𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑉𝐶𝑀 
 ×  100 − − − − − 𝐸𝑞. 1 
2.3.3. Drug loading (DL) 
Drug loading was determined by measuring the amount of drug released when a known amount 
of nanoplexes was completely dissolved in PBS [75]. The freeze dried VCM-DXT nanoplexes 
concentration was calculated after re-dispersion in the deionized water. The drug percentage 
loading was determined using UV spectrophotometry (Shimadzu UV 1601, Japan) at 280 nm 
using Equation 2.  
𝐷𝐿 =
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑉𝐶𝑀 𝑖𝑛 𝑛𝑎𝑛𝑜𝑝𝑙𝑒𝑥𝑒𝑠
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑛𝑎𝑛𝑜𝑝𝑙𝑒𝑥𝑒𝑠
  × 100 − − − − − − − − − − − − − − − − − −𝐸𝑞. 2 
2.3.4. Percentage yield  
A previously reported method was employed to determine the percentage yield of the total 
nanoplexes mass produced [75, 143]. The VCM-DXT nanoplexes was centrifuged following 
three washing cycles to remove un-complexed VCM and DXT. The obtained nanoplex 
dispersion was freeze dried. The resulted amount of nanoplex was weighed, and the percentage 
yield calculated using Equation 3.  
𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑦𝑖𝑒𝑙𝑑 =
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑛𝑎𝑛𝑜𝑝𝑙𝑒𝑥𝑒𝑠 𝑜𝑏𝑡𝑎𝑖𝑛𝑒𝑑 𝑎𝑓𝑡𝑒𝑟 𝑓𝑟𝑒𝑒𝑧𝑒 𝑑𝑟𝑦𝑖𝑛𝑔
𝑇𝑜𝑡𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑉𝐶𝑀 𝑎𝑛𝑑 𝐷𝑋𝑇 𝑎𝑑𝑑𝑒𝑑
  × 100 − − − 𝐸𝑞. 3 
2.3.5. Solid state characterisation of nanoplexes  
The melting and crystallization behaviour of DXT, VCM, physical mixtures (DXT and VCM) 
and lyophilized VCM-DXT nanoplexes was determined using differential scanning 
calorimetry (DSC) [133]. The powder X-ray diffraction (XRD) patterns of DXT, VCM, 
physical mixture (DXT and VCM) and nanoplexes VCM-DXT were recorded on a Bruker D8 
Advance instrument that was equipped with an Anton-Paar XRK 900 reaction chamber and a 
Cu radiation source with a wavelength of 1.5406 Å at ambient temperature. Fourier Transform 
Infrared Spectroscopy (FT-IR) was adopted to investigate the structural changes in the VCM-
DXT nanoplexes compared to the VCM and DXT using a Bruker Alfa Spectrophotometer 
(Germany). The spectrum of all samples was recorded within the wave number range of 550-
3700 cm-1 at an average of 16 scans and resolution of 4 cm-1.  
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2.4. In vitro drug release  
An in vitro release study was performed to understand the release pattern by applying sink 
conditions [144]. Briefly, a dialysis bag of approximately 10 mm (MWCO 14,000 Da) was 
filled with 1 mL of nanoplexes dispersion. The dialysis bag was tied at both ends and immersed 
into 40 mL bottle filled with phosphate buffers saline (PBS) pH 7.4 and placed in a mechanical 
shaker at 37 °C and 100 rpm. At designated time intervals (0.5, 1, 2, 3, 4, 5, 6, 7, 8, 12, 24, and 
48 h), 3 mL of sample solution was withdrawn and substituted with fresh PBS (pH 7.4) solution 
that had been kept at the same temperature. The VCM concentration from the triplicate samples 
was quantified at 280 nm using a UV Spectrophotometer using appropriate blanks [145]. Thus 
obtained release data of the bare VCM and VCM-DXT nanoplexes were kinetically studied 
using several mathematical models, with the correlation coefficient (R2), root mean square 
error (RMSE) and mean dissolution time (MDT) being calculated using excel add-in DDSolver 
program (China) [146].  
2.5. Molecular modelling  
In order to investigate the interaction between VCM and DXT at different ion concentrations, 
MD simulations were performed. The structure of  Vancomycin  (Figure 1A) was taken from 
PDB id: 1QD8 [147], and the DXT structure was extracted  from PDB  id: 5OCA [148]. The 
obtained DXT structure contained two units, which were replicated to four units using the 
VMD software [149] (Figure 1B), with universal Force Field (UFF) [150] parameters being 
used for VCM and DXT. The UFF parameters were  generated using the OBGMX server [151], 
and the VCM and DXT simulations were performed at two different ion concentrations (12 
Na+ and 12 Cl-, 24 Na+ and 24 Cl-). The SPC water model was used for solvation, and the 
system with 12 Na+ and 12 Cl- contained 3982 water molecules, while the 24 Na+ and 24 Cl- 
system contained 3958 water molecules. VCM and DXT were placed at ~ 30.00 Å centre of 
mass distance (COM) in the systems, both of which were first energy minimized using the 5000 
steps of steepest descent method [152]. Two short equilibration simulations were performed 
using canonical ensemble (NVT), followed by an isobaric-isothermic ensemble (NPT) for 100 
ps, each. The production run for both systems was performed using the NPT ensemble for 1 ns 
each (total 2 ns), at 323 K temperature with a velocity-rescale thermostat [153] at 1 atm 
pressure using the Parrinello-Rahman pressure coupling method [154]. The pressure coupling 
time was 2.0 ps while that of the temperature was 0.1 ps. The particle Mesh Ewald (PME) 
method [155] was used for long-range electrostatic interactions, and for both the short-range 
coulombic and VdW interactions, a 10 Å cut-off was used. The simulations were performed 
34 
 
using GROMACS [156], and the COM were calculated between VCM and DXT using in-
house Tcl script , while the interaction energies were calculated using a rerun option of the 
“MDRUN” package of GROMACS. 
 
Figure 1: Structure of A) VCM and B) DXT used in present study. 
2.6. Stability 
The short-term physical stability of the VCM-DXT nanoplexes was evaluated at 4 °C and at 
room temperature (RT) for 90 days. The evaluation of the formulations physical appearance, 
particle sizes, PDI and ZP was performed at the end of 30, 60 and 90 days. This study was 
performed in triplicate, and the effects of cryoprotectant at 5 % was explored on their sizes, 
PDI and ZP. 
2.7. In vitro cytotoxicity 
The MTT assay was employed to determine the cytotoxicity of the bare VCM and the VCM-
DXT nanoplexes using adenocarcinoma human alveolar basal epithelial cells (A549), 
embryonic kidney cells (HEK-293) and liver hepatocellular carcinoma (Hep G2) cell lines. The 
cells were cultured and seeded as per previously reported procedure (n = 6)  [157].  The 
different concentration of bare VCM and VCM-DXT nanoplexes (20, 40, 60, 80 and 100 
μg/mL) were introduced into the wells seeded with cells [133]. The positive control wells (with 
culture medium containing cells only) and the negative control (with culture medium without 
cells) were also included. The sample were incubated for 48 h, there after sample-laden 
medium was replaced with 100 μL of fresh culture medium and 20 μL of MTT solution (5 
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mg/mL in PBS) in each well. Cell viability was determined at absorbance wavelength of 540 
nm (Spectrostar Nano, Germany) and the percentage cell viability was calculated using 
Equation 4. 
% Cell Viability =
(A540 nm treated cells)
(A540 nm untreated cells)
    × 100 − − − − − − − − − − − −Eq. 4 
2.8. In vitro antibacterial activity 
The minimum inhibitory concentration (MIC) of the VCM-DXT nanoplexes and bare VCM 
were evaluated against Methicillin resistant Staphylococcus aureus Rosenbach ATCC®BAA-
1683 (MRSA) using the broth dilution technique [131].  The bacterial cultures were grown in 
Nutrient Broth (Biolab, South Africa) at 37 °C for 18 h in a shaking incubator set at 100 rpm. 
The bacterial cultures were adjusted with sterile distilled water to achieve a concentration 
equivalent to 0.5 McFarland Standard using a DEN-1B McFarland densitometer (Latvia). The 
bacterial cultures were further diluted 1:150 with sterile distilled water to obtain a final 
concentration of 5 × 105 colony forming units (CFU)/mL. Serial dilutions of the VCM-DXT 
nanoplexes and VCM were prepared in Mueller-Hinton Broth 2 (MHB) (Sigma-Aldrich, USA) 
using 96 well plates. These were then inoculated with the diluted bacterial cultures and 
incubated at 37 °C for 18 h in a shaking incubator set at 100 rpm. After incubation, 10 uL of 
the VCM-DXT nanoplex and bare VCM were spotted onto the Mueller-Hinton Agar (MHA) 
(Biolab, South Africa) plates and incubated for a further 18 h at 37 °C. This procedure was 
repeated daily for three days, and all MIC studies were carried out in triplicate. The blank 
formulation of dextran was used as a negative control the while bare VCM served as a positive 
control. 
2.9. Bacterial cell viability assay  
Cell viability studies on the MRSA cells were performed using a flow cytometry method a 
previously reported procedure [158-160]. The processing of the bacteria and percentage cell 
viability was determined after six hours of incubation of the bacteria with VCM and VCM-
DXT following our previously reported procedure [161]. The VCM and VCM-DXT broths  
(50 μL) were added to the flow cytometry tubes, each containing 350 μL of the sheath fluid, 
and vortexed for 5 min [161, 162]. The mixture was incubated for 30 min with 5 μL of the non-
cell wall permeant Propidium iodide (PI) and the Syto9 cell permeant dye. Thereafter, study 
and analysis was performed on BD FACSCANTO II (Becton Dickinson, CA, USA) following 
our previously reported protocol [157]. 
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2.10. In vivo antibacterial activity and histological evaluation  
A mouse skin infection model was used to determine the in vivo antibacterial activity of the 
VCM-DXT nanoplex [131] with ethical clearance from the University of KwaZulu-Natal’s 
Animal Research Ethics Committee (Approval number: AREC/104/015PD). The guidelines of 
the AREC of UKZN and the South African National Standard SANS 10386:2008 were 
followed for humane care and animal use. BALB/c mice weighing 18 - 20 g obtained and 
housed in Biomedical Research Unit, University of KwaZulu-Natal. A day preceding the study, 
the mice back hair was shaved, and the shaven area disinfected 70 % ethanol. On the following 
day, the mice were intradermally infected with 50 μL MRSA of 1.5 × 108 CFU/mL then divided 
into three groups, (negative control, positive control and treatment) (n = 4). 30 min post-
infection, 50 μL of bare VCM, DXT and VCM-DXT nanoplexes were injected at the same site 
of infection to all the three groups.  The mice were kept under observation for 48 h with normal 
12 h light and dark condition at 19 – 23 °C, and 55 ± 10 % relative humidity with adequate 
ventilation.  
The mice were euthanized, and the infected skin was harvested and processed to prepare tissue 
homogenates [131]. The obtained homogenates were spotted (20 μL) on nutrient agar plates, 
incubated at 37 °C for 24 h, before being analysed for number of colonies forming units (CFU). 
For histological investigations the skin samples were processed and stained following reported 
procedure [131], then sections were examined and captured with a Leica Microscope DM 500 
that was fitted with a Leica ICC50 HD camera (Leica Biosystems, Germany).  
2.11. Statistical analysis  
Statistical analysis of data was performed using one-way analysis of variance (ANOVA), 
followed by Bonferroni’s multiple comparison test using GraphPad Prism 6 (GraphPad 
Software Inc., USA). Statistical significance was based on a P value < 0.05, and the data was 
expressed as mean ± standard deviation (SD). 
3. Results and Discussion  
3.1. Preparation of VCM-DXT nanoplexes 
Preparation of the VCM-DXT nanoplexes was evaluated as a function of charge ratios 
R(VCM/DXT) (0.31, 0.62, 1.24, 1.86 and 2.49) using a solution of DXT in 0.1 M NaCl. For all the 
tested charge ratios, a complexation efficiency of higher than 90 % of the VCM were observed, 
and the particle size varied with varying concentrations of VCM. The different charge ratios 
R(VCM/DXT) of 0.31, 0.62, 1.24, 1.86, and 2.49, which correspond to the varying concentration 
of VCM, resulted in nanoplexes with particle sizes of 84.6 ± 4.24, 247.7 ± 28.0, 404.0 ± 13.24, 
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429.4 ± 40.24 and 500.6 ± 0.33 respectively (Table 1). The ZP was proportional to the 
concentration of VCM and changed from −33.0 ± 4.87 to −23.1 ± 4.71 mV as the VCM 
concentration varied. The negative ZP was an indication of the colloidal stability in the aqueous 
suspension formed, as shown in Figure 2. The above studies showed that the VCM-DXT could 
be successfully prepared at different charge ratios.  
 
Figure 2: Effect of charge ratio on particle sizes and zeta potential of VCM-DXT. Values are 
expressed as mean ± SD (n=3). 
The percentage of CEs at the different charge ratio R(VCM/DXT) were found to be in the range of 
90 – 98 % (Table 1). The CE % increased when charge ratio varied from R(VCM/DXT) of 0.31 to 
1.24, after which, as the charge ratio increased, a slight reduction in CE % was observed. At a 
higher charge ratio the sizes of the VCM-DXT nanoplexes obtained were similar to other 
studies, where ciprofloxacin was complexed with DXT [66, 142]. At higher charge ratio, the 
amount of DXT being completely utilised in complexation process, does not favour the 
aggregation of excess VCM added and hence decreasing CE  % at higher concentration VCM 
[75]. Thus, the ratio of R(VCM/DXT) had a significant influence on CE % and ZP. The higher 
complexation efficiency of the VCM in VCM-DXT nanoplexes was attributed to the higher 
charge density of the DXT [75]. However, the particle sizes were different for various charge 
ratios, with an increase in the particle sizes being observed with an increase in charge ratio 
(Table 1).  
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Table 1: Effect of charge ratios on sizes, PDI, ZP and CE % of nanoplexes (n = 3). 
Formulation R(VCM/DXT) Size (nm) PDI ZP (mV) CE % 
VCM-DXT1 2.49 500.6 ± 0.33 0.29 ± 0.07 -23.1 ± 4.71 95.26 ± 0.18 
VCM-DXT2 1.86 429.4 ± 40.28 0.24 ± 0.03 -28.0 ± 3.75 96.86 ± 0.29 
VCM-DXT3 1.24 404.0 ± 13.23  0.22 ± 0.02  -26.3 ± 3.40 98.67 ± 0.14 
VCM-DXT4 0.62 247.7 ± 28.0  0.45 ± 0.08 -28.4 ± 4.40 95.87 ± 0.20 
VCM-DXT5 0.31 84.6 ± 4.240 0.45 ± 0.02 -33.0 ± 4.87 90.40 ± 0.77 
 
3.2. Characterization of the optimized VCM-DXT5 nanoplexes formulation 
From the Table 1, the addition of 2.5 mL of the VCM solution (1 % w/v) to 5 mL DXT (0.45 
% w/v) under magnetic stirring for 1 h, was concluded as optimal nanoplexes preparation 
method. Thus obtained, VCM-DXT5 nanoplexes formulation, with particle size of 84.55 ± 4.24 
nm, PDI 0.45 ± 0.02, and ZP of - 33.0 ± 4.87 mV at the lowest charge ratio R(VCM/DXT) of 0.31, 
was therefore considered as the optimized formulation due to its lower sizes, higher ZP value 
and CE %. In other studies, where polyacrylic acid sodium was complexed with VCM, a sizes 
greater than 220 nm with only ~74 CE % were observed [133]. Thus, the VCM nanoplexes 
obtained in this study with DXT were found to have better size, stability and CE % compared 
to previous reports. Similar CE % for other drugs, such as ofloxacin, levofloxacin and 
ciprofloxacin, using DXT as a polyelectrolyte [75], indicating that DXT could be a suitable 
complexing agent for antibiotics, with further studies therefore being performed on the 
optimized formulation. 
To prevent aggregation of the VCM-DXT5 nanoplexes , the formulation was lyophilized in 
presence of different  cryoprotectants i.e 0.5 % of mannitol, sucrose,  D(+) glucose and D(-) 
glucose [133, 163]. The effect of lyophilisation on its stability of nanoplexes was determined 
in terms of size, PDI and ZP, after dispersing 10 mg of the freeze-dried formulation in 10 mL 
of distilled water, with the results being depicted in Table 2. Interestingly, lyophilisation in the 
presence of cryoprotectant improved the PDI values of nanoplexes formulation, while there 
were no significant changes in ZP indicating their stability in the dry form. The VCM-DXT5  
nanoplexes in dry form  can be a great advantage for its pharmaceutical applications as 
lyophilized solid nano drug delivery systems have been found to be more stable than those is 
liquid dosage forms [75, 164]. 
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Table 2: Effects of cryoprotectant on sizes, PDI and ZP of VCM-DXT5 nanoplexes before and 
after lyophilization (n=3). 
BLZ=before lyophilisation, ALZ=after lyophilisation, NCP= No cryoprotectant. 
3.2.2. Drug loading (DL) 
Drug loading calculated was 62.27 ± 0.23 %, which was relatively higher than that obtained 
using  polyacrylic acid sodium (PAA) in a previous study [133]. Higher drug loading in the 
VCM-DXT5 indicates a stronger affinity between the positively charged amines in the VCM 
and the negatively charged sulfate groups in the DXT, leading to a stable polyelectrolyte 
complexation. 
3.2.3. Percentage yield  
The percentage yield of VCM-DXT5 calculated was found to be 84.52 ± 0.31 %, this result was 
similar to other studies where DXT was employed as a polyelectrolyte further indicating mass 
efficiency of the technique [74, 76]. 
3.2.4. Morphology  
The morphological analysis of the VCM-DXT5 nanoplexes was performed using TEM.  TEM 
images showed that the VCM-DXT5 nanoplexes were discrete and homogeneous, with an 
almost spherical shape (Figure 3). The images were similar in previous studies [66, 76, 142]. 
The sizes were also comparable to that observed in dynamic light scattering studies. 
Parameters BLZ ALZ 
(Mannitol) 
 ALZ 
(Sucrose) 
ALZ 
(D+ glucose) 
ALZ 
(D-glucose) 
ALZ 
NCP 
Size (nm) 84.55± 4.24 91.33± 4.62 91.44± 6.08 93.17± 13.13 104.8± 17.14 97.37± 8.10 
PDI 0.450± 0.02 0.330± 0.09 0.320± 0.09 0.240± 0.16 0.380± 0.15 0.220± 0.07 
ZP (mV) -33.0± 4.87 -34.6 ± 3.13 -33.4± 1.36 -33.9± 0.46 -33.3± 1.23 -32.4± 4.26 
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Figure 3: Morphology of VCM-DXT5 nanoplexes  
3.2.5. Differential scanning calorimetry (DSC) 
An overview of the DSC thermograms of DXT, VCM, physical mixture (VCM and DXT) and 
nanoplexes (VCM-DXT5) is shown in Figure 4. The DSC thermograms of the VCM and DXT 
contained characteristics peak at 106 °C and 239 °C respectively, with  Cevher et al. (2006) 
observing  a similar VCM thermogram profile [165] . The profile of the physical mixture 
revealed no major shifts in the thermal peaks of the DXT, while the VCM did not show any 
theta values. In contrast, no sharp thermal events were observed for the lyophilized nanoplexes, 
indicating its conversion from crystalline form into amorphous form upon complexation with 
DXT.  
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Figure 4: DSC profiles of (A) DXT, (B) VCM, (C) Physical mixture of VCM and DXT, and 
(D) VCM-DXT5 nanoplexes. 
3.2.6. X-ray diffraction (XRD) 
The inter- and intra-molecular interactions involved during the formation of the nanoplexes, 
effects the crystal properties of both the VCM and DXT, which can be studied by changes in 
the diffraction pattern. Figure 5 represents the comparative diffraction pattern of the DXT, 
VCM, their physical mixture and the nanoplexes. The powder XRD pattern of the DXT 
contained several sharp peaks indicating its crystalline nature, while the bare VCM did not 
show any sharp peaks similar phenomenon has also been reported in other literatures [166, 
167] due to its transformation from crystalline states into amorphous states after complexation 
in the nanoplexes. The physical mixture of the DXT and VCM contained sharp peaks, 
indicating that the simple mixing did not result in nanoplexes formation. In liquid state the 
crystalline of the ingredients are broken and free ions are available for complexation unlike in 
the solid state where there are no charges to induce electrostatic interactions [168-170]. In 
contrast, the freeze dried VCM-DXT5 nanoplexes did not show any noticeable peaks in the 
spectra, confirming the nanoplexes formation. This is in good agreement with the DSC results, 
and can be attributed to the amorphous nature of VCM in the VCM-DXT5.  
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Figure 5: Diffractograms of (A) DXT, (B) VCM, (C) Physical mixture (DXT and VCM) and 
(D) VCM-DXT5 nanoplexes. 
3.2.7. Fourier transform-infrared (FT-IR) analysis 
The FT-IR spectroscopy analysis was performed to confirm the presence of VCM in the 
nanoplexes formulation and its complexation with DXT, the comparative infrared (IR) spectra 
being presented in Figure 6.  The IR spectra of dextran sulfate sodium salt contained peaks at 
1219, 980, 798 and 574 cm-1, arising due to the vibrations of S=O and O-S-O chemical bonds 
[171]. These bands shifted to 1229, 1017, 695 and 578 cm-1 respectively in the nanoplexes, 
indicating that the sulfate group interacted with the oppositely charged VCM molecules. In 
addition, the peak at 1585 cm-1 (aromatic C=C) for VCM shifted to 1587 cm-1, which could be 
due to the π–π stacking interaction between the aromatic rings of VCM during the self-
assembly process. These changes in IR frequencies confirmed the formation of nanoplexes in 
a polyelectrolyte directed self-assembly process. 
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Figure 6: FT-IR spectra for (A) DXT, (B) VCM, (C) Physical mixture of VCM and DXT, and 
(D) VCM-DXT5 nanoplexes. 
3.3. In vitro drug release  
The in vitro release of VCM from the optimized nanoplexes and the nanoplex with high charge 
ratio which resulted to high particles (VCM-DXT1) was studied in PBS pH 7.4 over 48 h at 37 
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°C and are shown in Figure 7. At the end of the first two hours, the cumulative percentage of 
bare VCM released was 40.9 ± 2.77 %, whereas for VCM-DXT5 it was 20.7 ± 1.9 % and 20.63 
± 1.54 % for VCM-DXT1. The bare VCM reached nearly 94.9 ± 2.59 % release at the end of 
eight hours, while only 60.4 ± 1.70 % was achieved from the optimized VCM-DXT5 and 20.63 
± 1.54 % for the nanoplex with higher charge ratio. By the end of the 48 h, approximately 86 
% and 39.76 ± 0.10 % of the VCM was released from the VCM-DXT5, and VCM-DXT1 
respectively indicating slower release pattern from the nanoplexes compared to the bare drug. 
This slower release profile could be beneficial for reducing the dosage frequency of VCM-
DXT5 nanoplexes formulation.  
Additionally, the erodibility of DXT, owing to its biodegradability properties, possibly 
contributed to the release of VCM from VCM-DXT5 nanoplexes. The high molecular weight 
of VCM could be an obstacle to its passage through the DXT matrix, while the unique 
properties of DXT to swell and erode provided the sustained release pattern of the VCM-DXT5 
nanoplexes over the 48 h compared to 12 h and 15 min in similar studies [133, 142].  The 
slower release profile displayed by the VCM-DXT5 nanoplexes compared to the bare drug 
could provide an effective drug delivery system that, reduces the frequency of administration 
and increases patient adherence, which could lead to better patient treatment outcomes.   
 
Figure 7: Drug release profile of bare VCM, VCM-DXT5 and VCM-DXT5 nanoplexes. The 
values are expressed as mean ± SD, n = 3. 
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3.4. Stability study 
The novel VCM-DXT5 nanoplexes formulation was studied for its stability for three months at 
both room temperature (RT) and 4 °C. The stability of the formulation was assessed in terms 
of the PS, PDI and ZP, with the results being presented in Table 3. The VCM-DXT5 were 
stable for the period of three months at 4 °C (P value > 0.05), as no change in physical 
appearance of the formulation was observed. At room temperature (RT), change in size and 
zeta potential was observed after the second month of the study (P value < 0.05), indicating 
that the physical stability was achieved only for the first month. The instability of the VCM-
DXT5 nanoplexes at room temperature could be associated with the non-fickian release 
mechanism, which may have caused the structural changes and relaxation behaviour of the 
DXT due to the  swelling process in the aqueous medium [172].  
Table 3: Effect of storage conditions on physicochemical characteristics of VCM-DXT5 
nanoplexes. The values are expressed as mean ± SD, n = 3 
 Particle sizes PDI        ZP 
Time (days) 4 ºC RT 4 ºC RT 4 ºC RT 
0 84.53 ± 4.24 84.55 ± 4.24 0.449 ± 0.02 0.449 ± 0.02 -33.0 ± 4.87 -33.0 ± 4.87 
30 84.90 ± 6.01 88.13 ± 6.23 0.448 ± 0.03 0.456 ± 0.08 -29.0 ± 3.19 -23.9 ± 2.34 
60 87.33 ± 1.77 89.51 ± 2.30 0.433 ± 0.09 0.459 ± 0.01 -22.0 ± 3.47 -22.2 ± 6.27 
90 88.92 ± 1.46 90.20 ± 1.43 0.457 ± 0.01 0.455 ± 0.01 -35.2 ± 1.52 -22.21 ± 2.2 
 
3.5. In vitro cytotoxicity  
Biosafety being an essential criteria to establish the nontoxic dosages of formulation for 
biomedical applications, MTT assay based cytotoxicity study was employed to evaluate and 
quantify the cytotoxicity of the bare VCM and newly derived nanoplexes formulation [173]. 
The viability of cells after exposure to the bare VCM and the VCM-DXT5 nanoplexes were 
assessed by quantifying crystalline blue formazan formation [51]. Figure 8 shows the bar chart 
breakdown of the cytotoxicity assay of the VCM-DXT5 against the A549, HEK 293 and HEP 
G2 cells. The bare VCM demonstrate cell viability from 77.05 - 93.71 % for A549, 77.31 - 
95.18 % for HEK-293 and 76.37 - 91.48 % for HEP G2 cell across all concentration 
(Supplementary Material 2: Figure S1). The results indicate a high percentage of cell 
viability, from 77.9 to 90.6 % for A549 cells, 78.1 to 85.6 % for HEK 293, and 76.0 to 92.6 % 
for HEP G2 cell for all concentrations of nanoplexes tested. The results indicating the  non-
cytotoxic nature of the VCM-DXT5 nanoplexes, with greater than 75 %  cell viabilities 
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indicating nontoxicity of the material to the mammalian cells [133]. Based on these results, the 
VCM-DXT5 can therefore be considered as a nontoxic and safe drug delivery system. 
 
Figure 8: Percentage cell viabilities of A549, HEK-293 and HEP G2 cells, after being exposed 
to different concentration of VCM-DXT5 nanoplexes. Results are presented as mean ± SD (n 
= 6). 
3.6. Molecular modelling (Spontaneous interaction between VCM and DXT) 
In the experiments, conducted as shown in Figure 1, it was observed that spontaneous 
interaction between the VCM and DXT to form nanoplexes occurred only in the presence of a 
higher concentration of ions. To investigate the interaction between VCM and DXT at different 
ion concentrations MD simulations were performed.  In the system with 12Na+ and 12 Cl- ions, 
there was no noticeable interaction between the VCM and the DXT unit at the end of the 
simulations (Figure: 9). However, in the system with 24 Na+ and 24 Cl- ions, the VCM and 
DXT formed a spontaneous interaction during equilibration simulation, which was further 
strengthened during the production run, with both molecules remained bound to each other 
until the end of the simulation time (Figure: 10A and 10C). The interaction energy between 
VCM and DXT was ~-80 kJ/mol in the presence of 24 Na+ and 24 Cl- ions (Figure: 10B). 
Thus, the simulations data corroborated to the experimental data.  
Previous in silico studies indicated that VCM complexation could have been through the π-π 
stacking and alkyl-alkyl hydrophobic interactions [133]. A balance between the attractive and 
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repulsive forces could be the reason for the salt-induced spontaneous interaction between VCM 
and DXT.  The -OSO4 functional group of DXT being negatively charged in presence of sodium 
salt, might have complexed with ammonium groups (NH3
+) positively charge groups of VCM 
[174]. Thus, the anionic DXT might have neutralized the positive charge on the VCM 
molecules and reducing the repulsive forces between them [66]. The ionic concentration could 
have enhanced the mutual inter molecular interaction between the hydrophobic VCM counter 
ions by reducing their aqueous solubility [175], and thus supporting antibiotic formation of the 
nanoplexes with polyelectrolyte DXT. The electrostatic charge shielding function of the 
sodium salt also might have helped to reduce the inter-molecular repulsions between the like-
charges of the DXT chains, and promoting the conformational arrangements to the favoured 
nanoplexes formation [74, 174]. Thus, a series of salt driven mechanism might have led to 
nanoplexes formation.  
 
Figure 9: A) Shows time evolution of COM distance between VCM and DXT; B) Shows time 
evolution of interaction energy between VCM and DXT; C) Shows two representative images 
from the simulations at two different time points in presence of 12 Na+ and 12 Cl-. 
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Figure 10: A) Shows time evolution of COM distance between VCM and DXT; B) Shows 
time evolution of interaction energy between VCM and DXT; C) Shows two representative 
images from the simulations at two different time points in presence of 24 Na+ and 24 Cl-. 
3.7. In vitro antibacterial activity  
The in vitro antibacterial activity of the bare VCM, the DXT, VCM-DXT1 and the VCM-DXT5 
was determined by using the 96 well plate-broth dilution technique to confirm and compare the 
potency and enhancement of VCM upon its transformation into a nanoplexes formation (Table 
4). The DXT alone did not show any activity, even at the highest concentration tested. After 
24 hrs, the MIC values for bare VCM, VCM-DXT1 and VCM-DXT5 against MRSA at 
physiological pH 7.4 were 7.8 μg/mL, 62.5 μg/mL and 1.25 μg/mL respectively, indicating 
0.14-fold and 6.24-fold increase in activity of VCM-DXT1 and VCM-DXT5 when compared to 
the bare VCM. Although, VCM-DXT1 demonstrated slower sustained release compared to 
VCM-DXT5, its MIC was shown to be higher. We couldn’t fully explain this result however, 
this could be attributed to very slow release of the drug limiting the amount of drug available 
to kill the bacteria due to retarded release however, more studies are needed to explain this 
phenomenon. The complexation of the VCM with DXT therefore did not adversely affect the 
antimicrobial activity of the VCM. The results were in good agreement with  previous studies, 
which reported no adverse changes in the antibacterial activity of ofloxacin and levofloxacin 
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after complexation with DXT [66, 75].   For the VCM nanoplexes derived from the polyacrylic 
acid sodium (PAA) [133], and for those involving other antibiotics (ofloxacin and 
ciprofloxacin) with DXT [66, 75], the activity remained the same as for the free drug, with no 
enhancement. Interestingly, an enhancement by 6.24-folds was observed for VCM-DXT 
nanoplexes, which could be attributed to a smaller size, high  CE % sustained release resulting 
in the continuous delivery of lethal concentration of the antibiotics to the bacteria for long 
periods of time thus resulting to complete elimination of the bacteria [176]. The improved 
activity could also be attributed to the small sizes of VCM-DXT5 that lead to an increase in the 
surface area volumes ratio, drug adsorption efficiency that lead higher penetration and uptake. 
Thus, the in vitro studies confirmed the ability of the VCM-DXT5 to enhance the activity of 
VCM against MRSA upon its complexation with DXT.  
 
Table 4: In vitro antibacterial activity of the formulations (VCM-DXT5) and (VCM-DXT1) 
against MRSA at PBS pH 7.4. The values are expressed as mean ± SD, n = 3 
 (MIC µg/mL) after 
24 hrs. 
(MIC µg/mL) after 
48 hrs. 
(MIC µg/mL) 
after 72 hrs. 
Bare VCM 7.8 7.8 7.8 
DXT NA NA NA 
VCM-DXT5 nanoplexes 1.25 1.25 1.25 
VCM-DXT1 nanoplexes 62.5 62.5 62.5 
NA = No activity.  
3.8. Bacterial cell viability assay  
The percentage bacterial cell deaths after exposure to the bare VCM and VCM-DXT5 
nanoplexes at their respective MICs (7.8 μg/mL and 1.25 μg/mL VCM concentrations 
respectively) were quantified as shown in Figure 11. The results showed that the bare VCM 
and VCM-DXT5 nanoplexes at the MIC of formulation 1.25 μg/mL had a killing percentage of 
32.98 ± 1.49 % (Figure 11C) and 66.24 ± 0.56 % (Figure 11D) respectively. This indicates a 
2-fold higher killing activity of VCM-DXT5 compared to bare VCM at similar concentrations. 
When the MRSA cells were incubated with the VCM-DXT5 nanoplex and bare VCM at their 
respective MIC of 1.25 μg/mL and 7.8 μg/mL, they showed similar results of 66.24 ± 0.56 % 
(Figure 11D) and 65.27 ± 1.3 % (Figure 11B). Although the VCM concentration in the VCM-
DXT5 (MIC of 1.25 μg/mL) was 6.24-folds lower than that of the bare VCM treatment, it was 
still able to achieve a similar killing percent as that of the bare VCM (MIC of 7.8 μg/mL). This 
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result indicated that the VCM-DXT5 nanoplexes can be used at lower drug concentrations for 
treatment without affecting the desired therapeutic outcomes. Moreover, lower doses of 
treatment that could be achieved using the VCM-DXT5 nanoplexes could lead to an avoidance 
of a dose dependent nephrotoxicity of VCM [177] . This further confirmed the ability of the 
VCM-DXT5 nanoplexes to retain their potency and enhance the antibacterial activity of VCM. 
 
 
Figure 11: In vitro antibacterial activity of MRSA cells determined by flow cytometry 
analysis. A) Cell fluorescence of untreated MRSA; B) Overlay of fluorescence of treated 
MRSA cells with bare VCM at its MIC;  C) Overlay of fluorescence of MRSA cells treated 
with bare VCM at the MIC value of VCM-DXT5 nanoplexes; D) Overlay of percentage 
fluorescence of MRSA cells treated with VCM-DXT5 at its MIC values. 
3.9. In vivo antibacterial activity  
The in vivo studies were determined using a BALB/c mice skin infection model to confirm the 
antimicrobial activity of VCM-DXT5 nanoplexes. The number of colony-forming units (CFUs) 
from each treatment group were quantified and represented as log10, shown in Figure 12. The 
mean MRSA load (log10 CFU) retrieved from the VCM-DXT5 and bare VCM treatments, and 
untreated skin samples were 6.46 ± 0.15 (3,000,000 CFU/mL), 6.83 ± 0.13 (7,000,000 
CFU/mL) and 7.72 ± 0.11 (54,000,000 CFU/mL) respectively. The results showed that the bare 
VCM had a 7.7-fold lower CFUs when compared to the untreated group. However, when 
VCM-DXT5 nanoplexes treatment group was compared to the untreated group, the VCM-
DXT5 nanoplexes had an 18-fold reduction in CFUs with P = 0.001. When CFUs from the bare 
VCM treatment group were compared to the VCM-DXT5 nanoplexes, the latter had lowered 
CFUs of up to 2.3-fold, with a P value = 0.0324.  
The one-way ANOVA showed significant differences in CFUs, with a P value = 0.001 among 
all the groups. The groups treated with VCM-DXT5 nanoplexes significantly decreased the 
MRSA load in the skin samples by 2.5-fold compared to the bare VCM treated groups. This 
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result was in agreement with other in vivo results, for example: streptomycin, doxycycline and 
gentamicin nanoplexes against bacterial infections [72, 73].  As the DXT on its own does not 
demonstrate antibacterial activity, the experiment showcased the degree of VCM binding to 
the DXT, with the subsequent improved targeting by nanoplexes possibly having led to the 
enhanced activities [178]. Therefore, the VCM-DXT5 nanoplexes formulated in this study 
demonstrated the potential for combating MRSA infections.  
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Figure 12:  MRSA CFUs quantification post 48 h of treatment, the data represent the mean ± 
SD (n=3). *** denotes significant differences when compared untreated with VCM-DXT5 
nanoplexes. ** denotes untreated when compared to bare VCM, and * denotes significant 
difference between the bare VCM and VCM-DXT5 nanoplexes.  
 
The skin samples collected from all the groups were assessed for histomorphological changes 
that occurred on the experimental groups after infection and treatment, with the samples being 
stained with H&E and observed under a light microscope. The results indicated that the 
untreated skin samples showed tissue inflammation and abscess formation, as shown in Figure 
13A. The signs of swelling and abscess formation were observed for bare VCM treated group 
(Figure 13B), but to a lesser extent than the untreated group (Figure 13A). However, the 
VCM-DXT5 nanoplexes displayed minimal signs of tissue inflammation and abscess formation 
(Figure 13C). The extensive quantities of white blood cells (WBC) at the infection site were 
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present for the untreated and bare VCM groups. Nevertheless, lower WBCs were displayed for 
the group treated with VCM-DXT5 nanoplexes, as shown in Figure 13C. The histomorphology 
analysis was found to correlate with the CFU/mL calculated in the in vivo antibacterial study. 
The absence of abscess formation and reduced immune response mechanisms (lesser extent of 
inflammation and reduced number of white blood cells) at infection site for the skin samples 
of VCM-DXT5 treated group, when compared to that of untreated and VCM treated group, 
confirm the antimicrobial potency of the VCM-DXT5 nanoplexes. 
 
 
Figure 13: Photomicrographs of the skin lesions at the site of injection; A) control and B) 
treated mice. Histomorphology of controls and treated (Scale bar = 500 µm): C) 
control/untreated, D) Bare VCM treated, E) VCM-DXT5 nanoplexes treated. 
 
4. Conclusion  
With increasing rates of antimicrobial resistance, novel drug delivery systems, such as 
nanoplexes, which protect and enhance current antibiotics in the market are required. In this 
study, a novel VCM-DXT nanoplex was successfully formulated by polyelectrolyte 
complexation of VCM and DXT for the bio-safe delivery of vancomycin against MRSA. 
Complexation efficiency of greater than 90 % was achieved for the drug VCM, with the drug 
releases from nanoplexes occurring in a sustained manner. The molecular modelling studies 
proved that the presence of salt concentration is a prerequisite for nanoplex formation. In vitro 
antibacterial studies of the nanoplexes against MRSA showed enhanced activity for nanoplexes 
over bare VCM. The results were further confirmed by flow cytometry, where the VCM-DXT5-
nanoplexes had a better percentage killing compared to the bare VCM at similar applied 
concentrations. The in vivo BALB/c mouse, skin infection model revealed that treatment with 
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the VCM-DXT5-nanoplexes significantly reduced the MRSA burden compared to the bare 
VCM. The superior antimicrobial activity and nontoxicity/biosafety of the VCM-DXT 
nanoplexes formulation upholds its applicability as a promising novel nano-carrier for 
antibiotic delivery.  
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CHAPTER THREE: EXPERIMENTAL PAPER TWO 
3.1 Introduction  
This chapter addresses Aim 2 and Objectives 1 – 6. It is a first authored experimental article 
submitted and highlights the formulation and characterisation of chitosan-based pH-responsive 
lipid-polymer hybrid nanovesicles (VM-OLA-LPHVs) from the novel zwitterionic lipid 
(OLA). The nanovesicles was evaluated for in vitro toxicity, physicochemical properties, 
morphology, in vitro electrical conductivity, protein/DNA concentration quantification, 
membrane damage, time killing assay, membrane disruption, bacteria-killing percentage, 
biofilm eradication, in vitro and in vivo antibacterial properties. 
The ethical approval is attached in Appendix II. 
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Highlights 
• A novel zwitterionic lipid (OLA) was synthesized and characterized to confirm its structure. 
• The novel OLA was used to formulate a chitosan-based pH-responsive VM-loaded lipid-
polymer hybrid nanovesicles (VM-OLA-LPHVs1). 
• The biosafety of the OLA and VM-OLA-LPHVs1 was confirmed with four cell lines.  
• There was a higher VM release from VM-OLA-LPHVs1 at pH 6.0 compared to pH 7.4. 
• The VM-OLA-LPHVs1 showed an enhanced in vitro and in vivo antibacterial activity 
against MRSA compared to bare VM. 
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Abbreviation  
A-549    Adenocarcinoma human alveolar basal epithelial cells 
BCA     Bicinchoninic acid 
CHs    Chitosan  
CDC    Centers for Disease Control and Prevention 
CFU    Colony-forming unit 
DLC    Drug loading capacity 
DLS    Dynamic Light Scattering 
DCM    Dichloromethane 
DSC    Differential scanning calorimetry 
DNA    Deoxyribonucleic acids 
DH    Hydrodynamic diameter 
EE    Encapsulation efficiency  
FT-IT    Fourier transform infrared 
HEK-293   Human embryonic kidney cells 
HepG-2   Human liver hepatocellular carcinoma cell  
MICs     Minimum inhibitory concentrations 
MCF-7   Liver hepatocellular carcinoma cell lines 
MRSA    Methicillin-resistance Staphylococcus aureus  
MTT    3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
MHB    Mueller-Hinton Broth 
MHA    Mueller-Hinton agar 
MDT    Mean dissolution time 
MHA    Mueller–Hinton agar 
NaOH    Sodium hydroxide 
NB    Nutrient Broth 
OLM    Oleylamine  
PBS    Phosphate buffer saline 
pDNA    Plasmid deoxyribonucleic acid   
PDI    Polydispersity index 
PI    Propidium iodide 
R2    Correlation coefficient 
RMSE    Root mean square error 
siRNA    Small interfering ribonucleic acid 
tBA    Tert-butyl acrylate  
TIPs    Triisopropylsilane 
TFA    Trifluoroacetic acid 
TPP    Sodium tripolyphosphate  
UVis-Spec   UV Spectrophotometer  
VM    Vancomycin 
1H NMR   Proton nuclear magnetic resonance  
13C NMR   Carbon 13 nuclear magnetic resonance 
ζ    Zeta potential  
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Abstract  
The development of novel materials is necessary for adequate delivery of drugs to combat the 
Methicillin-resistant Staphylococcus aureus (MRSA) burden due to the limitations of 
conventional methods and challenges associated with antimicrobial resistance. Hence, this 
study aimed to synthesise a novel oleylamine based zwitterionic lipid (OLA) and explore its 
potential to formulate chitosan-based pH-responsive lipid-polymer hybrid nanovesicles (VM-
OLA-LPHVs1) to deliver VM against MRSA. The OLA was synthesised, and the structure 
characterised by 1H NMR, 13C NMR, FT-IR and HR-MS. The preliminary biocompatibility of 
OLA and VM-OLA-LPHVs1 was evaluated on HEK-293, A-549, MCF-7 and HepG-2 cell 
lines using in vitro cytotoxicity assay. The VM-OLA-LPHVs1 were formulated by ionic 
gelation method and characterized in order to determine the hydrodynamic diameter (DH), 
morphology in vitro and in vivo antibacterial efficacy. The result of the in vitro cytotoxicity 
study revealed cell viability of above 75% in all cell lines when exposed to OLA and VM-
OLA-LPHVs1, thus indicating their biosafety. The VM-OLA-LPHVs1 had a DH, 
polydispersity index (PDI), and EE% of 198.0 ± 14.04nm, 0.137 ± 0.02, and 45.61 ± 0.54% 
respectively at physiological pH, with surface-charge (ζ) switching from negative at pH 7.4 to 
positive at pH 6.0. The VM release from the VM-OLA-LPHVs1 was faster at pH 6.0 compared 
to physiological pH, with 97% release after 72-hour. The VM-OLA-LPHVs1 had a lower 
minimum inhibitory concentration (MIC) value of 0.59µg/mL at pH 6.0 compared to 2.39 
µg/mL at pH 7.4, against MRSA with 52.9-fold antibacterial enhancement. The flow cytometry 
study revealed that VM-OLA-LPHVs1 had similar bactericidal efficacy on MRSA compared 
to bare VM, despite an 8-fold lower VM concentration in the nanovesicles. Additionally, 
fluorescence microscopy study showed the ability of the VM-OLA-LPHVs1 to eliminate 
biofilms. The electrical conductivity, and protein/DNA concentration, increased and decreased 
respectively, as compared to bare VM which indicated greater MRSA membrane damage. The 
in vivo studies in a BALB/c mouse-infected skin model treated with VM-OLA-LPHVs1 
revealed 95-fold lower MRSA burden compared to the group treated with bare VM. These 
findings suggest that OLA can be used as an effective novel material for complexation with 
biodegradable polymer chitosan (CHs) to form pH-responsive VM-OLA-LPHVs1 
nanovesicles which show greater potential for enhancement and improvement of treatment of 
bacterial infections.  
Keywords: Antibacterial, Methicillin-resistant Staphylococcus aureus (MRSA), Lipid-
Polymer Hybrid Nanovesicles, Vancomycin  
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1.0 Introduction  
Infectious diseases caused by Methicillin-Resistant Staphylococcus aureus (MRSA) pose a 
serious global health challenge that affects more than two million people every year [179, 180], 
resulting in increased morbidity and mortality rates  [181, 182]. The Centers for Disease 
Control and Prevention (CDC) reported that nearly 80,461 severe infections are caused by 
MRSA every year, leading to 11,285 deaths [183], and costing approximately $34,657 to 
manage each person’s case [184]. In Europe, MRSA infections have led to longer hospital stays 
and have caused 5,400 deaths at an estimated cost of $700 million [21]. In Africa, by 2050, 
around 4,150,000 deaths are expected from antimicrobial resistance, with higher figures likely 
if proper measures are not taken by researchers and industries [185]. Therefore, proper and 
urgent measures are currently needed to develop a novel strategy to confront the emergence of 
antibiotic bacterial strains which are resistant to the existing conventional antibiotics [186]. 
Currently, antibiotics such as arylthiazoles [187], tetracycline, ofloxacin, penicillin [188], 
chloramphenicol [189] and linezolid used against MRSA are ineffective due to resistance 
thereby leaving vancomycin (VM) as one of the last-resort drugs [190-192] to use against 
MRSA [193-195]. Frequent misuse and the limitations of conventional dosage methods, such 
as inadequate concentration at the infection sites [122, 196]; rapid decrease of plasma 
concentration levels [197]; increased frequency of administration; higher dose requirements 
leading to side effects [123-125]; and prolonged treatment regimens [126] are factors that have 
significantly contributed to antibiotic resistance to these drugs. Thus, calls for immediate and 
better strategies for protecting and potentiating current antibiotics are being highlighted in the 
literature. 
Novel strategies using nano-delivery systems are being explored to tackle the antimicrobial 
resistance problem and have shown the potential to address the limitations of conventional 
dosage forms such as  increased localised drug concentration at infection sites; decreased 
exposure of drugs to healthy sites; and protection of the drug from premature enzymatic 
degradation [43]. The use of different nanosystems such as micelles [198], solid lipid 
nanoparticles [199], liposomes, nanoemulsions, and nanovesicles [200-202] has been reported 
for antibiotic delivery. Specifically, nanovesicles are showing the potential to efficiently 
deliver drugs and enhance their biological activity [203]. Such lipid-based nanovesicles have 
been formulated from phospholipids to form liposomes and successfully encapsulated both 
hydrophobic and hydrophilic drugs [204-206]. In the late 1990s, amphiphilic block polymers 
were found to self-assemble into vesicular structures that were referred to as polymersomes 
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[206-208]. The discovery of polymersomes greatly impacted the field of drug delivery due to 
their toughness, permeability and surface functionality [209, 210]. This has helped to overcome 
limitations such as instabilities and osmotic shocks associated with liposomes [211, 212]. The 
formulation of vesicles that can encompass the positive attributes of both polymersomes and 
liposomes, known as the lipid-polymer hybrid system, has been proposed [213]. The polymers 
are reported to demonstrate better drug release properties [214, 215]. The lipid increases drug 
loading efficiency and membrane permeability [216, 217]. 
One of the main objectives of designing such lipid-polymer hybrid vesicles (LPHVs) is the 
ability of the bio-functionalisation of their membrane properties to introduce targeted drug 
delivery. Stimuli-responsiveness of nanosystems can potentiate targeting by responding to the 
unique conditions at disease sites and increasing drug release and binding activity. Depending 
on the polymer and lipid chains and functional groups, various stimuli-responsive systems such 
as  pH-responsiveness have been reported [218] for targeted drug delivery for various diseases  
such as chronic obstructive pulmonary disease (COPD) [219], metastatic breast cancer therapy 
[88], and memory disorders [220]. However, there is limited research involving the delivery of 
antibiotics. Thus, there is a need to identify new materials to formulate pH-responsive LPHVs 
in the delivery of drugs for the treatment of bacterial infection.  
In this study, we propose a novel drug delivery system derived from Chitosan (CHs) and 
zwitterionic pH-responsive lipid (OLA) to formulate chitosan-based lipid-polymer hybrid 
nanovesicles (VM-OLA-LPHVs) for the efficient delivery of VM and the targeting of bacterial 
infection. CHs is a natural polysaccharide biopolymer [221, 222] which is widely employed in 
pharmaceutical research [223] due to its biocompatibility; biodegradability; antimicrobial 
activity [224-226]; mucoadhesive properties [221, 227]; and low immunogenicity [228, 229]. 
Oleylamine (OLM), a long-chain primary alkylamine, is reported in drug delivery due to 
enhanced antimicrobial activity [230-232]. However, due to its cationic properties, OLM 
shows dose-dependent toxicity [233, 234]. Modifying the lipid could result in forming a 
zwitterionic pH-responsive biomaterial with improved biosafety [235]. The application of 
zwitterionic lipids has been previously reported [235], with lipids such as 
phosphatidylethanolamine [236] and glycerophospholipids [237] indicating feasibility in drug 
delivery. Based on the literature survey, there are no reports of the application of this novel 
oleylamine based zwitterionic lipid (OLA) in the formulation of OLA-LPHVs for delivery of 
any class of drug [238]. 
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Therefore, this study aimed to synthesise a novel oleylamine based zwitterionic lipid (OLA) 
and formulate pH-responsive VM-OLA-LPHVs nanovesicles by polyelectrolyte complexing 
for the delivery of VM [239, 240]. This complex will result in a polyelectrolyte vesicles and 
we envisage the free hydroxyl groups and the amine group of CHs to be at the surface, while a 
carboxylic group of OLA will be electrostatically bonded to the VM [88, 241] and CHs. To the 
best of our knowledge, there is no report of the synthesis of this novel oleylamine based 
zwitterionic lipid and its formulation into a chitosan-based pH-responsive VM-OLA-LPHVs 
for the delivery of VM or any class of drug. This strategy could contribute to the alleviation of 
the current global antimicrobial resistance crisis and widen the pool of available novel pH-
responsive platforms for the delivery of antibiotics for the treatment of different diseases. The 
data resulting from the synthesis of the lipid, and the formulation of chitosan-based pH-
responsive LPHVs optimisation, in vitro, in vivo and in molecular antimicrobial studies, are 
herein reported.   
2.0 Materials and methods 
2.1 Materials  
Oleylamine (OLM); tert-butyl acrylate; dichloromethane (DCM); trifluoroacetic acid (TFA); 
triisopropylsilane (TIPs) silica gel; chitosan (CHs) (low mol. wt; 75-85% deacetylated; 
viscosity 200-300 cp) with an average molecular weight of 250 kDa; sodium tripolyphosphate 
(TPP); and sodium hydroxide (NaOH) were purchased from Sigma-Aldrich (USA). 
Vancomycin (VM) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
were purchased from Sinobright Import and Export Co., Ltd. (China), and Merck Chemicals 
(Germany), respectively. All other chemicals and solvents used were of analytical grade. NB, 
MHB and MHA were obtained from Biolab (South Africa). Propidium iodide and Syto9 dyes 
were purchased from Thermofisher (USA). The bacterial culture used was Methicillin-resistant 
Staphylococcus aureus (MRSA) (S. aureus ATCC 700669). Bacteria deoxyribonucleic acid 
(DNA) and bicinchoninic acid (BCA) kits were purchased from Zymo Research California, 
(USA) and Wako Chemicals, Virginia (USA), respectively. Sheep blood was obtained from 
Polychem Handelsges, South Africa. Purified water used during the study was produced in the 
laboratory with a Milli-Q water purification system (Millipore corp., USA).  
2.2 Instrumentation (FT-IR, 1H NMR, 13C NMR and HR-MS spectra) 
FT-IR spectra of all the major components involved in the synthesis of the compound (OLA) 
and structural changes of the all components were recorded on a Bruker Alpha-p spectrometer 
with a diamond ATR (Germany). The spectrum was recorded within the wavelength of 500-
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3500 cm-1 at a mean of 16 scans and resolution of 4 cm-1.  
1H NMR and 13C NMR measurements 
were performed on a Bruker 400 Ultra shield™ (United Kingdom) NMR spectrometer. Finally, 
high-resolution mass spectrometry (HR-MS) was performed on a Bruker Micro-TOF QII mass 
spectrometer (Bruker Daltonics, Bremen, Germany) fitted with an electrospray ionisation 
source and coupled to an Agilent 1100 series high-pressure liquid chromatography (Agilent 
Technologies, Japan).  
2.3 Synthesis and characterisation of the pH-responsive oleylamine based zwitterionic 
lipid (OLA). 
The lipid was synthesised as per Scheme 1. The synthesis and characterisation of the lipid are 
descried in Supplementary Materials 1.
 
Scheme 1. a). Dichloromethane (DCM), stirring at room temperature 24-hours, b). Compound 
3 dissolved DCM with the addition of trifluoroacetic acid/triisopropylsilane (TFA/TIPs) under 
constant stirring for 8-hours at room temperature.  
2.4 In vitro preliminary biocompatibility assay  
The biocompatibility of OLA and VM-OLA-LPHVs1 was evaluated using MTT assay as 
described in previously reported methods [242, 243] on four different cell lines. These included 
human embryonic kidney cells, liver hepatocellular carcinoma cell lines, adenocarcinoma 
human alveolar basal epithelial cells, and human liver hepatocellular carcinoma cells (HEK-
293, MCF-7, A-549, and HepG-2 respectively). Briefly, the cell lines of 5.0 × 103 /mL were 
grown exponentially for 24-hours at 37°C in a humidified atmosphere of 5% carbon dioxide 
(CO2), trypsinised when confluent, and seeded into 96-well plates. The samples OLA and VM-
OLA-LPHVs1 were prepared, respectively, by diluting with sterilised deionised water. A broad 
range of concentrations from 20, 40, 60, 80, 100 and 120μg/mL was obtained [242]. All the 
cell lines were treated with 100μL of these various concentrations and the control group was 
exposed to the culture media only. All groups were incubated for 48-hours and the solutions 
(treatments and media respectively) were decanted and replaced with 100 μL of fresh culture 
medium and MTT solution (5mg/mL in PBS). After 4-hours of incubation, both the culture 
medium and MTT assay solutions were immediately removed. This was followed by the 
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solubilisation of the MTT formazan by adding 100 μL of dimethyl sulfoxide. The optical 
density was measured at a wavelength of 540 nm using a microplate spectrophotometer 
(Spectrostar Nano, Germany). All experiments were repeated six time and the cell viability 
percentage calculated using equation 1 below:  
 Cell viability % = (
A540 nm treated cells
A540 nm untreated cells
) ×  100 … … … … … … … . 𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 1 
2.5 Formulation of the pH-responsive VM-OLA-LPHVs 
The VM-OLA-LPHVs were prepared using a slightly modified version of an ionic 
complexation technique [244]. TPP was employed to ionically complex CHs and the novel 
zwitterionic pH-responsive lipid to form blank formulation LPHVs and the VM-loaded LPHVs 
(VM-OLA-LPHVs). Preliminary studies with different ratios of the excipients and the drug 
were performed before arriving at an optimal formulation. The optimal blank formulation 
contained CHs: TPP: OLA in a ratio of 5:1:0.5 (w/w), while for the VM-loaded formulation 
1mg/mL of VM was added. Briefly, CHs (0.1% w/v) was dissolved in acetic acid (1% v/v) and 
the pH was adjusted to 5.5 using 1 M NaOH [245]. The mixture of TPP, OLA and VM (for 
drug loading) was then dropwisely added to the solution of CHs in acetic acid under stirring, 
and the process of complexation was allowed to occur for one-hour under constant magnetic 
stirring at 500rpm.    
2.6 Characterisation of the novel zwitterionic pH-responsive VM-OLA-LPHVs 
2.6.1 Hydrodynamic diameter size (DH), polydispersity index (PDI), zeta potential (ζ) 
and morphology 
The hydrodynamic diameter size (DH), PDI and ζ of the novel VM-OLA-LPHVs were 
determined by DLS using a Zetasizer Nano ZS90 (Malvern Instruments Ltd., UK) [246]. The 
surface morphology of the VM-OLA-LPHVs was examined using a High-resolution 
Transmission Electron Microscope, JEOL, HR-TEM-2100 (Japan), in a liquid nitrogen 
atmosphere and an accelerated voltage of 200kV. Briefly, to acquire HR-TEM images, a drop 
of appropriately 10μL of VM-OLA-LPHVs solution was placed on the 3mM coated carbon 
grid (300 mesh) and the excess removed using clean filter paper. The grids were allowed to dry 
for about 5-minutes, followed by negative staining with 2% uranyl acetate (UA) solution [247].  
2.6.2 Entrapment efficiency (EE%) and drug loading capacity (DLC%) 
The prepared VM-OLA-LPHVs formulation was further characterised for entrapment 
efficiency (EE%) and drug loading capacity (DLC%) using an ultrafiltration method [248]. The 
VM-OLA-LPHVs formulation of 3mL was loaded in Amicon® Ultra-4 centrifugal filter tubes 
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(Millipore Corp., USA) with 10kDa pore size and centrifuged at 3000rpm (25°C) for 30-
minutes. The amount of unentrapped VM in the filtrate was determined spectrophotometrically 
at 280nm using a UV Spectrophotometer Shimadzu UV 1601 (Japan). The regression equation 
of Y = 0.003X + 0.0031, with a linear regression coefficient (R²) of 0.9998, was used to obtain 
the unknown drug concentration values. The experiment was conducted thrice; the supernatant 
containing the unentrapped VM was calculated; and the EE% and DLC% were calculated using 
the following equations 2 and 3 respectively, as previously reported [249].  
 
EE% = (
VM weight in the VM − OLA − LPHVs
VM added  during VM − OLA − LPHVs  preparation
) × 100 … … . . … 𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 2 
 
DLC% = (
Complete weight of VM in VM − OLA − LPHVs  
Complete weight of VM − OLA − LPHVs  
) ×  100 … … … 𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 3 
2.6.3 Differential scanning calorimetry (DSC) 
Differential scanning calorimetry (DSC) Shimadzu DSC-60, (Japan) was used to determine the 
thermal profile of the bare VM, OLA, CHs, the physical combination (bare VM, OLA and 
CHs), and the lyophilised drug loaded LPHVs (VM-OLA-LPHVs). Briefly, approximately 
2mg of each sample was placed in an aluminium pan and sealed, followed by heating to 300 
oC at a constant rate of 10oC/minute under a constant nitrogen flow of 20mL/minute using an 
empty pan as a reference [250]. All samples were allowed to equilibrate at 25°C in a DSC 
chamber and were then exposed to a temperature run up of 25-300°C at a heating rate of 
10°C/minute under a nitrogen atmosphere. 
2.6.4 In vitro drug release of the VM-OLA-LPHVs  
The in vitro drug release study was employed to provide the release profile mechanism of the 
encapsulated VM from the VM-OLA-LPHVs. Drug release of VM was performed using the 
diffusion dialysis bag method, as in formerly reported methods [251, 252]. Two mL of the bare 
VM, the corresponding blank formulation (OLA-LPHVs) and drug-loaded formulation (VM-
OLA-LPHVs) were loaded into dialysis bags with a porosity size of 8,000-14,400Da. The 
dialysis bag was placed in a 40mL PBS (pH 6.0 and pH 7.4) receiver compartment at 37°C in 
a shaking incubator at 100rpm. During sampling, exactly 3mL was drawn at time intervals of 
0.5, 1, 2, 3, 4, 5, 6, 7, 8, 24, 48 and 72-hours from the receiver solution and replaced with an 
equal amount of fresh PBS to keep a constant volume of the compartment. The amount of VM 
released from the dialysis bags in the receiver compartment was measured 
73 
 
spectrophotometrically using Shimadzu UV 1601 (Japan), at the VM wavelength of 280nm 
with a regression equation Y = 0.003X + 0.0031 and a linear regression coefficient (R²) using 
OLA-LPHVs as the reference. During the study, experiments were done in triplicate, with the 
release fraction of VM from VM-OLA-LPHVs calculated using the following equation 4:   
𝐷𝑟𝑢𝑔 𝑐𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑣𝑒 𝑟𝑒𝑙𝑒𝑎𝑠𝑒 % = (
𝑄𝑡
𝑄𝑣
) ×  100% … … … … 𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 4 
where Qt is the quantity of VM released from the VM-OLA-LPHVs at time t, and Qv the 
quantity of VM previously-loaded in the VM-OLA-LPHVs.  
2.7 Stability studies 
The physical stability of drug-loaded-LPHVs was investigated by keeping the VM-OLA-
LPHVs in 4oC and 25oC environments for 90 days, and the physicochemical stability (size, 
PDI, ζ) and EE% were evaluated and measured at the end of 30, 60 and 90 days. These results 
were further analysed using one-way ANOVA.  
2.8 Bacterial characterisation of the VM-OLA-LPHVs 
2.8.1 Determination of the minimum inhibitory concentration (MIC)   
The in vitro antibacterial activity study was carried out in order to determine the MIC. This 
was done using the broth microdilution method, as previously described [253, 254]. Briefly, 
the bacteria culture was grown in MBH, with MHB-suitable dilutions being made to achieve 
colony forming units per mL (CFU/mL) of 5 × 105. The tested samples (bare VM, CHs, OLA, 
OLA-LPHVs and VM-OLA-LPHVs) were serially diluted in the MHB broth and then 
incubated with bacterial cultures containing 5 × 105 colony-forming units per mL (CFU/mL) 
for 24-hours in a shaking incubator at 37°C and 100 rpm. Afterwards, 10μL of the serially 
diluted solutions was spotted on Mueller–Hinton Agar (MHA) plates and incubated for another 
24-hours. The spot with no visible bacterial growth was regarded as the MIC for all tested 
samples.  
2.8.2 Time-killing analysis (plate colony count) against MRSA 
The time-killing assay of the VM-OLA-LPHVs was performed using the plate colony counting 
method, as a previously reported method [15]. The MRSA was placed in a shaking incubator 
and cultured for 48-hours at 37°C in nutrient broth (NB), followed by diluting the bacteria in 
sterile PBS to concentrations of 105-106 CFU/mL [25]. Subsequently, the prepared bare VM 
and VM-OLA-LPHVs were added to the PBS containing MRSA at a concentration of 5 × MIC. 
The PBS containing the same concentration bacteria (105-106 CFU/mL) was employed as a 
control. The samples were shaken at 37°C. Thereafter, periodically, 0.1mL of each suspension 
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from the sample was sub-cultured on nutrient agar (NA) plate for 18-hours and colonies were 
counted. The number of colonies counted was converted to log10 values and plotted on a graph. 
The experiment was done in triplicate in order to ensure accuracy and minimise standard 
deviation [15]. 
2.9 Molecular and mechanistic studies 
2.9.1 Bacterial membrane disruption 
MRSA suspensions of 1.5×108 CFU/mL in PBS were incubated with VM-OLA-LPHVs 
containing 2.39μg/mL of VM in a 50:50 ratio for 4-hours in an Eppendorf tube. The mixture 
was diluted appropriately and mounted onto the surface of a copper grid. The excess samples 
were removed by blotting off with filter paper and then dried at ambient temperature before 
measurement. The images were examined using a High-Resolution Transmission Electron 
Microscope (brightfield, darkfield, STEM- JEOL HR-TEM 2100 [255].  
2.9.2 Molecular and mechanistic studies of VM-OLA-LPHVs against MRSA  
The downstream physiological phenomena of the antibacterial mechanism were employed to 
evaluate the increase in membrane permeability of the formulation due to its ability to disrupt 
the bacteria cell membrane [15]. Briefly, MRSA (1%) was prepared and inoculated in 10mL 
NB with VM-OLA-LPHVs and bare VM, respectively, at a concentration of 2.39µg/mL and 
cultured for 16-hours; while MRSA (1%) without the drug-loaded LPHVs was used as control. 
Subsequently, the cultured solutions (3mL of each) were centrifuged for 15-minutes at 4000 
rpm and the supernatant collected and diluted to determine the conductivity using a 
conductivity meter. Furthermore, a UV Spectrophotometer Shimadzu UV 1601 (Japan) was 
used to detect the absorbance of the solutions at 260nm and the loss of cellular absorption of 
the materials was analysed. The electrical conductivity was measured using an electrical 
conductivity meter and calculated using the equation below. The experiment was performed 
and repeated three times and calculated using Equation 5. 
Q % = (
Qs − Qc
Qc
) ×  100 … … … … … … … … … . 𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 5 
where Q refers to the conductivity change rate, and Qs and Qc are the conductivity rates of the 
experiment and the control groups, respectively. The DNA concentration of the MRSA was 
determined and quantified using a bacterial DNA Kit according to the manufacturer’s 
procedure and the NANODROP 2000, Thermo Fisher Scientific, Waltham, MA, USA at a 
MRSA wavelength of 260nm (n = 6). The protein cellular concentration was quantified using 
the BCA Kit set at an absorbance of 563nm (n = 6) [15].  
75 
 
2.9.3 MRSA cell viability using flow cytometry 
Flow cytometry was employed to determine and separate the viable and non-viable bacteria 
after exposure to antibiotics [256]. The in vitro bacterial cell viability assay of MRSA after 
exposure to VM and VM-OLA-LHPVs at their respective MIC was studied using a previously 
reported flow cytometric method [158-160]. Nutrient Broth was used to grow the pure culture 
of MRSA overnight at 37°C in a shaking incubator (Labcon, USA)  at 100rpm. Dilutions were 
made to a achieve final bacterial concentration similar to the employed concentration in the in 
vitro antibacterial activity studies. Subsequently, 15μL of the bacterial suspension was added 
to a 96-well plate containing 135μL of bare VM (31.6μg/mL) and VM-OLA-LPHVs 
(2.39μg/mL) and then incubated at 37°C in a shaking incubator at 100rpm for 8-hours. The 
untreated MRSA cells were used as a negative control [161]. The bare VM and VM-OLA-
LPHVs broths  (50μL) were added to the flow cytometry tubes, each containing 350μL of the 
sheath fluid, and vortexed for 5-minutes. [161, 162]. The mixture was incubated again for 30 
minutes with 5μL of the non-cell permeate dye Propidium iodide (PI) and the Syto9. The PI 
fluorescence was excited by a 455nm laser and collected through a 636nm bandpass filter, 
while the Syto9 excitation laser was set at 485nm laser and collected through a 498nm bandpass 
filter [158-160]. The BD FACSCANTO II (Becton Dickinson, CA, USA) instrument used to 
perform this experiment was set at a sheath fluid flow rate of 16mL/minute and a sample flow 
rate of 0.1mL/minute and the data was collected using a flow cytometer (BD FACSDIVA 
V8.0.1 software [USA]). The voltage settings used for the fluorescence-activated cell sorting 
(FACS) analysis were: 731 (forward scatter [FSC]); 538 (side scatter [SSC]); 451 (Syto9); and 
444 for PI. The bacteria were at first gated using forward scatter. Afterwards, the cells were 
then gated with at least 10,000 cells being collected (n = 3). Then the position of the ‘live’ and 
‘dead’ cells gates was determined. To avoid background signals from the particles smaller than 
the bacteria, the detection threshold was set to 1,000 in the SSC analysis [257]. The data 
captured from the flow machine (flow cytometer) was analysed using Kaluza-1.5.20 (Beckman 
Coulter USA) flow cytometer software [159, 258]. 
2.9.4 Reduction of MRSA biofilm by VM-OLA-LPHVs using fluorescence microscopy 
The eradication of MRSA biofilms by VM-OLA-LPHVs was determined by fluorescence 
microscopy [259]. Briefly, coverslips were placed at the bottom of a 6-well plate. This was 
followed by the addition of 2mL of MRSA (1.5×108 CFU/mL) suspensions in NB and 
incubated for 4-days at 37oC to form a fully mature biofilm. Before treatment, the media was 
sucked out of the wells with a sterilised Pasteur pipette, and the wells were washed 4-times to 
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remove the non-adhered bacteria. Exactly 1mL of bare VM solution and the VM-OLA-LPHVs 
formulation containing 125μg/mL of VM were added to the wells and incubated for an 
additional 12-hours at 37oC. The wells were then washed with PBS to remove the treatments 
and the non-adhered MRSA cells. While still in the wells, the coverslips were stained with a 
solution of Syto9 and Propidium iodide (PI) containing 30μL of each in 1mL of sterilised 
distilled water for 30-minutes in total darkness. The 6-wells plates were further washed to 
remove excess dyes, then inverted on a microscope glass slide and the coverslips were carefully 
glued at the edges on the glass slides. The elimination of formed biofilm by bare VM and VM-
OLA-LPHVs were viewed on the Fluorescence microscope (Nikon Eclipse 80i FM Japan). 
Microscopic observations were performed in quadruplicate in an independent experiment. 
2.10 Intradermal in vivo antibacterial activity in BALB/c mice 
The in vivo antibacterial activity of the VM-OLA-LPHVs was evaluated against MRSA skin 
infection model mice. The BALB/c mice were obtained following the protocol approved by 
the University of KwaZulu-Natal’s (UKZN) Animal Research Ethics Committee (Approval 
number: AREC/104/015PD) [235, 260]. The humane welfare/endpoint and the use of the 
animals were according to the protocol of the AREC of UKZN and the South African National 
Standard SANS 10386:2008. Male BALB/c mice weighing approximately18-20g were 
collected from the Biomedical Research Unit (BRU) of UKZN. A day before the experiment, 
back hair of the mice was shaved and the exposed skin disinfected using 70% ethanol. The 
male BALB/c mice were separated into treatment, positive and negative control groups, with 
four mice in each group. On the day of the experiment, 50µL of MRSA (1.5 × 108CFU/mL) in 
saline was injected intradermally into the mice. Approximately 30-minutes after infecting with 
the bacteria, 50µL of VM-OLA-LPHVs and free VM were injected into the mice in the various 
groups via the same spot. Afterwards, the mice were kept under observation for 48-hours in 
12-hours of light and dark conditions at 19-23oC and 55 ± 10% relative humidity, with adequate 
ventilation. Immediately after the 48-hours, the mice were euthanised with halothane, and the 
infected areas of the mice skin were harvested and homogenized in 5mL PBS (pH 7.4). Finally, 
the homogenised tissues were serially diluted in PBS (pH 7.4), 50µL was spotted on nutrient 
agar plates and incubated at 37°C for 24-hours. The colony-forming units (CFU/mL) were 
counted and calculated using equation 5.  
CFU
mL
=
Number of colonies ×  dilution factor
Volume of a culture plate
… … … … … . . 𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 6 
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2.11 Statistical analysis 
All experiments were performed in triplicate and results summarised as mean values of the 
standard deviation. Data obtained from DH, PDI, ζ, EE%, and in vitro drug release were 
subjected to one-way ANOVA with a level of significance kept at P value > 0.05. 
3.0 Results and discussion  
3.1 Synthesis and characterisation 
The oleylamine based zwitterionic lipid (OLA) was synthesised in two steps as per Scheme 1. 
The first step involved Michael’s addition reaction, as described in Scheme 1. Compound 3 
was synthesised through the addition of tert-butyl acrylic acid (Compound 2) to Compound 
1 and the spectra was confirmed by 1H NMR, 13C NMR and HR-MS. The appearance of a 
strong multiplet at δ 1.37 ppm integrating for 18 protons in 1H NMR represents isobutyl 
protons, and the appearance of carbon peaks at δ 28, 35, 80 and 172 in 13C NMR, representing, 
-CH2C=O-, C(CH3)3-COO - and C=O, confirms the formation of Compound 3. The second 
step involved the cleaving of the tertbutyl protection on the carboxylic group. TFA/TIPs was 
added to Compound 3 to obtain Compound 4. The tertiary butyl esters of Compound 3 were 
cleaved to form OLA, using TFA and TIIPs as scavengers to avoid any possible side reactions. 
The product was confirmed by the appearance of aliphatic peaks at δ 0.808 (multiplet), δ 1.18 
(multiplet) and δ 1.53 (multiplet) and the disappearance of isobutyl peaks at 1.4ppm on 1H 
NMR and at 28ppm in 13C NMR and HR-MS.  
3.2 In vitro biocompatibility study (cytotoxicity) 
Non-toxicity is an essential prerequisite for any novel material used in pharmaceutical and 
biomedical applications [261]. The cytotoxicity associated with the OLA and VM-OLA-
LPHVs1 was determined using a 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) cell viability assay. This study was performed on HEK-293, MCF-7, A-549 
and Hep-G2 and the results are presented in Figure 1. The results showed that OLA maintained 
over 75% cell viability. According to the results, the percentage cell viability range obtained 
for the individual cell lines was 80.61- 96.03% for HEK-293; 77.62 - 86.74% for A-549; 80.43 
- 85.60% for HEP-G2; and 75.47-83.56% for MCF-7 across all concentrations, as shown in 
Figure 1A. The Two-way ANOVA analysis demonstrated that the OLA and VM-OLA-
LPHVs1 groups did not differ significantly (P>0.5). Furthermore, these revealed that there is 
no significant cytotoxicity effect on all the cell lines; thus, indicating it to be safe for biomedical 
application in the nano-drug delivery system.  
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The MTT assay results in Figure 1B indicated a high percentage of cell viability in all the cell 
lines exposed to VM-OLA-LPHVs1. The cell viabilities were from 78.60 to 87.85% for A-549 
cells; 79.85 to 98.20% for HEK-293; 79.85 to 96.98 % for HEP-G2; 75.89 to 97.95% for MCF-
7. The results indicated the non-cytotoxic nature of the VM-OLA-LPHVs1, as shown in a cell 
viability of more than 75% of the mammalian cells. This percentage of viability demonstrated 
by OLA and VM-OLA-LPNVs1 was above the minimum levels required for biocompatibility 
for synthesised biomaterial material [262-264]. Conclusively, the drug-loaded formulation 
showed no significant decrease in the number of viable cells, indicating suitability for 
biomedical applications. 
 
Figure 1: A) Percentage cell viability of different concentrations of OLA on A-549, HEK-293, 
Hep-G2 and MCF-7 cell lines; B) VM-OLA-LPHVs1 on A-549, HEK-293, Hep-G2 and MCF-
7 cell lines. All results are presented as mean ± SD (n = 6).  
3.3 Preparation, characterisation of VM-OLA-LPHVs  
The VM-OLA-LPHVs1 were formulated by a slightly modified ionic complexation method, 
as previously reported [265]. Preliminary studies were performed to obtain an optimal 
formulation (Supplementary Material Table S1 and Figure S9). The optimum formulation 
has DH, PDI and ζ, of 198.0 ± 14.04nm, 0.137±0.02 and -6.95 ± 6.50mV, respectively, at pH 
7.4; while at pH 6.0,  DH, PDI and ζ were 207.0 ± 6.69nm, 0.182 ± 0.03 and +13.3 ± 1.75mv 
respectively, as shown in (Supplementary Material Table S2). In addition, the surface-charge 
switched from negative pH 7.4 (at the physiological pH 7.4) to positive pH 6.0 (at acidic pH 
6.0). The negative ζ observed in physiological pH 7.4 could be due to the free hydroxyl groups 
on CHs, and the deprotonation of carboxylic acid group (COOH) in OLA, which might bond 
electrostatically with the amine group of CHs, thereby neutralising its cationic effect [266]. 
The positive charge of the VM-OLA-LPHVs1 at acidic pH could be advantageous for adhesion 
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to the negatively charged biological membranes of bacteria. Furthermore, OLA consists of a 
secondary amine which protonates in acidic media; this might have contributed to the positive 
charge of the system in the acidic medium [267-270]. The results suggest that the VM-OLA-
LPHVs could be successfully and effectively employed to deliver drugs to acidic infection 
sites. The EE% and DLC% of the optimised formulation were 44.62 ± 0.34% and 18.92 ± 
2.34% w/w, respectively. This encapsulation was comparable to other VM-loaded nanovesicles 
[271-273]. The morphology of the VM-OLA-LPHVs1 was further observed with TEM and the 
image obtained was spherically shaped, and discrete indicating vesicle formation with a similar 
to that size obtained using the DLS techniques (Figure 2). DSC studies showed that the 
lyophilised VM-OLA-LPHVs formulation showed the disappearance of the VM thermal peak, 
which confirms the successful encapsulation of VM. On the other hand, the physical mixture 
of the excipients and the VM did not reveal the disappearance of the VM thermal peak (Figure 
3A).  
 
Figure 2: TEM images of VM-loaded (VM-OLA-LPHVs1)  
3.4 In vitro drug release behaviour 
Having considered the physicochemical studies performed previously, VM-OLA-LPHVs1 was 
used for in vitro drug release. The cumulative amounts of VM released from the VM-OLA-
LPHVs1 at pH 6.0 and 7.4 are shown in Figure 3B. The cumulative amount of VM released 
from the VM-OLA-LPHVs1 nanovesicles occurred faster at pH 6.0, compared to pH 7.4 with 
12.61 ± 3.55% and 4.33 ± 1.40%, respectively, after the initial 30-minutes. The VM release 
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from VM-OLA-LPHVs1 at the end of 8, 24, 48 and 72-hours at pH 6.0 was 73.42 ± 0.12%, 
89.45 ± 0.21%, 92.12 ± 1.10% and 97.12 ± 0.11%, respectively; while at pH 7.4, it was 45.11 
± 0.05%, 54.41 ± 0.12%, 63.80 ± 0.01% and 73.22 ± 0.02%, respectively. As is clearly shown 
in Figure 3B, approximately 97% of the overall dose of VM was released in 72-hours, 
indicating an initial burst followed by the sustained release [274]. The initial burst release might 
be attributed to the diffusion of VM molecules that are localised at the surface of the VM-OLA-
LPHVs1 [272, 275, 276]; while the increased drug release at pH 6.0 could be due to the pH-
responsiveness of the VM-OLA-LPHVs1 via the protonation of nitrogen atoms in the amine 
group of OLA and CHs. Thus, at acidic pH there is a repulsion of the electrostaically bonded 
functional groups of the lipid and CHs, resulting in/from the disturbance and breakdown of the 
system. It is also possile that that at acidic pH there is increased hydrophilicity of the 
formulation due to the protocation of the amines, promoting faster drug release. This study 
indicates that VM releases from VM-OLA-LPHVs1 was pH dependent. 
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Figure 3: A) Thermal profile of (i) VM, (ii) OLA (iii) CHs (iv) physical mixture (VM, OLA 
and CHs) and (v) lyophilized VM-OLA-LPHVs1 and B) In vitro drug release profile of bare 
VM and VM-OLA-LPHVs1 in pH 7.4 and pH 6.0 (n = 3).  
3.5 Stability studies 
The physical colloidal stability of the VM-OLA-LPHVs1 was tested using DLS and a UV 
spectrophotometer [277, 278]. The DH, ζ and EE of VM-OLA-LPHVs1 remained stable for 90 
days with no significant changes. The experimental results indicated no significant increase in 
the DH, ζ and EE of the VM-OLA-LPHVs1 throughout the 90 days of storage, both at 4
oC and 
room temperature, as shown in Table 1.  
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Table 1: Effect of storage condition (4oC and ambient temperature 25oC) and time (days) on 
DH, PDI, ζ and EE% of VM-OLA-LPHVs1  
4oC Room temperature 25oC 
Time 
(days) 
DH (nm) PDI ζ (mV) EE% DH (nm) PDI ζ (mV) EE% 
0 207.0±6.69 0.137±0.02 -6.95±6.50 45.61±0.54 207.0±6.69 0.14±0.02 -6.95±6.50 45.6 ± 0.54 
30 199.0±3.04 0.123±0.02 -3.23±2.42 45.32±0.12 199.5±1.10 0.17±0.02 -3.17±2.56 44.6 ± 1.03 
60 198.4±0.40 0.132±0.41 -3.42±1.24 45.12±0.11 210.2±9.25 0.18±0.12 -4.74±4.26 44.0 ± 0.11 
90 203.6 ±8.32 0.142 ±1.32 -4.57± 1.52 44.25 ±1.34 214.1 ±5.22 0.26±1.33 -5.28 ± 3.21 42.9 ± 1.12 
 
3.6 Antibacterial activity 
3.6.1 MICs of the VM-OLA-LPHVs1  
A microbroth dilution method was used to determine the MIC of the VM-OLA-LPHVs1 
nanovesicles. The MICs values for bare VM against MRSA at both pH values (7.4 and 6.0) 
were 31.25µg/mL; while VM-OLA-LPHVs1 showed MICs values of 0.59 and 2.39µg/mL at 
pH 6.0 and 7.4, respectively (Table 2). The VM-OLA-LPHVs1 demonstrated 52.96-fold and 
13.07-fold antimicrobial enhancement activity at pH 6.0 and pH 7.4, respectively, when 
compared to bare VM. This could be due to the increase in the binding of VM-OLA-LPHVs1 
on the negative bacteria membrane. Overall, the increase in antibacterial activity of the systems 
is also attributed to the enhanced antimicrobial activity of CHs and OLA acting on the different 
sites of the bacterial membrane [279]. These results were in line with other drug-loaded CHs 
nanoparticles that have been reported to show enhanced antibacterial activity [280-282]. The 
obtained results suggested the potential relevance of VM-OLA-LPHVs1 in applications that 
target drugs to the acidic sites of infections due to the greater antibacterial activity observed in 
the acidic pH compared to the physiological pH. 
Table 2: The in vitro antibacterial activity of bare VM, CHs, OLA, OLA-LPHVs and VM-
OLA-LPHVs1 showing MICs against MRSA at pH 6.0 and pH 7.4. 
                                                                pH 6.0                                   pH 7.4 
Time (h) 24 48 72 24 48 72 
MIC µg/mL MIC µg/mL 
Bare VM 31.25 31.25 31.25 31.25 31.25 31.25 
CHs 1000 1000 1000 1000 1000 1000 
OLA 62.50 62.50 62.50 125.0 125.0 125.0 
OLA-LPHVs 62.50 62.50 125.0 250.0 250.0 250.0 
VM-OLA-LPHVs1 0.590 0.590 1.190 2.390 4.780 4.780 
All experimental result values are expressed as mean ± SD (n=3) 
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3.6.2 Time-killing analysis of VM-OLA-LPHVs1  
The results of the in vitro time bactericidal studies of bare VM and VM-OLA-LPHVs1 at 5× 
MIC against MRSA are displayed in Figure 4A. The VM-OLA-LPHVs1 demonstrated 
spontaneous bacterial elimination with nearly 97.4% clearance of MRSA in less than 8-hours, 
despite having a 13-fold lower concentration of VM when compared to the bare drug. This 
suggests that VM-OLA-LPHVs1 could effectively treat MRSA infections faster, even at a 
lower dose, with quick elimination of the bacterial infection and reduced treatment duration. 
3.7 Mechanistic and molecular studies 
3.7.1 Bacterial membrane disruption 
After determining that VM-OLA-LPHVs1 had superior activity to the bare drug, the effect of 
VM-OLA-LPHVs1on the membrane of MRSA was determined by incubating bacteria 
separately and bacteria with VM-OLA-LPHVs1 for 4-hours. At the initial stages of incubation, 
intact bacterial membranes were observed, but there was a loss of bacteria membrane after 1-
hour of incubation. This was followed by the subsequent loss and disruption of more bacteria 
membrane after 4-hours of incubation. These observation are shown in Figure 4B (i), (ii), (iii) 
and (iv). These results showed that VM-OLA-LPHVs1 had caused irrecoverable damage to the 
cell wall of the bacteria, causing permanent death, even at a low concentration of VM in the 
formulation. 
 
Figure 4: A) The killing kinetics of MRSA exposed to 5x MIC of VM-OLA-LPHVs1, bare 
VM and sterile water (control) B) HR-TEM images of MRSA after incubation with VM-OLA-
LPHVs1. (i) Initial intact structure of MRSA before treatment; (ii) After 1-hour of treatment 
and incubation; (iii) Formation of pores on the bacterial membrane after 2-hours of treatment; 
and (iv) Complete loss, disruption and deformation of MRSA membrane after 4-hours. 
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3.7.2 Evaluation of electrical conductivity, DNA leakage and protein quantification 
The effect of treating bacteria with VM-OLA-LPHVs1 on the membrane integrity, electrical 
conductivity and intracellular components leakage was investigated. The results revealed that 
the negative control (MRSA in NB) and the bare VM had an electrical conductivity of 0.323 ± 
0.01 mScm-1 and 0.357 ± 0.02mS cm-1, respectively; while VM-OLA-LPHVs1 displayed an 
increase in electrical conductivity (0.567 ± 0.03mS cm-1) compared to the negative control and 
the treatment with bare VM, as shown in Figure 5A. The rise in the electrical conductivity 
could be due to the greater ability of the VM-OLA-LPHVs1 to destroy bacterial membrane 
when compared to VM. This could be due to leakage of the intracellular electrolytes and 
displacement of the bacteria cell membrane by the nanovesicles [283-286]. The protein 
concentration was also quantified at an absorbance of 562nm using the bicinchoninic acid 
method (BCA). The protein quantity in MRSA drastically decreased from 158.58 ± 
8.54μg·mL−1 to 106.94 ± 11.14μg·mL−1 for bare VM and from 158.58 ± 8.54μg·mL−1 to 82.29 
± 3.63μg·mL−1 for VM-OLA-LPHVs1. This corresponds to 24.68 ± 0.19% and 69.20 ± 0.12% 
of protein concentration reduction for bare VM and VM-OLA-LPHVs1, respectively, when 
compared to the control (Figure 5B). The VM-OLA-LPHVs1 demonstrated a nearly 2-fold 
reduction compared to bare VM. These results could be due to the disruption of bacteria cell 
membrane causing cellular substance of DNA leakage [287]. 
The quantity of DNA in the MRSA after exposure to bare VM and VM-OLA-LPHVs1 was 
significantly reduced by 54.61% and 48.53%, respectively, as compared to the control (Figure 
5C). The loss of DNA and protein is attributed  to the cell membrane disruption, which led to 
the leakage of DNA and protein into the external environment [15, 288]. This study 
demonstrated that the destruction of the MRSA cell membrane by VM-OLA-LPHVs1 led to 
an increase in the electrical conductivity [15] and leakage of the cellular substances within the 
bacteria subsequently led to cell death [283, 289]. The studies further showed the superiority 
of the VM-OLA-LPHVs1 when compared to the bare drug. 
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Table 3: The analysis of MRSA cell membrane permeability after VM-OLA-LPHVs1 
treatment. 
Parameter  Control  Bare VM VM-OLA-LPHVs1 
DNA concentration (μg·mL−1)  17.53 ± 0.49 4.43 ± 0.22 2.73 ± 0.41 
Protein concentration (μg·mL−1)  158.58 ± 8.54 106.94±11.14 82.29 ± 3.63 
Electrical conductivity (mS·cm−1)  0.323 ± 0.01 0.357± 0.02 0.567 ± 0.03 
Values are expressed as mean ± SD 
 
 
Figure 5: The in vitro antibacterial mechanism of bare VM and VM-OLA-LPHVs1: A) 
Histogram representation of electrical conductivity of bare VM and VM-OLA-LPHVs1; B) 
Representation of protein quantification of bare VM and VM-OLA-LPHVs1 at Optical Density 
at 405 nm and C) Histogram representation of DNA concentration of bare VM and VM-OLA-
LPHVs1.  
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3.8 In vitro cell viability of MRSA using Fluorescence-activated cell sorting (FACS) 
Under environmental stress conditions, several pathogens enter into a viable, but not cultivable, 
state [290, 291]. Therefore, there is a need for sensitive studies that detect irreversibly damaged 
bacterial cells from the viable but non-cultivable colonies [292]. In this study, cell viability 
after the treatment of MRSA with VM and VM-OLA-LPHVs1 was investigated using FACs 
[161]. Two dyes, PI and SYTO 9, were employed to separate the dead cells from live cells. PI 
is a non-permeant dye that only penetrates cells that have lost membrane after the cell 
membrane loses its integrity; while SYTO 9 unselectively penetrates all membranes. Once in 
the cell, the dyes intercalate with DNA and their fluorescence intensity can be recorded. In this 
study, the percentage of PI penetration into the cell membrane of MRSA after exposure to bare 
VM and VM-OLA-LPHVs1 is shown in Figure 6. Data captured from flow cytometry were 
analysed using Kaluza-1.5.20 (Beckman Coulter USA) flow cytometer software [159, 258]. 
The results showed that bare VM and VM-OLA-LPHVs1 at MICs of 31.25µg/mL and 
2.39μg/mL, respectively, had similar bacteria killing ability of above 90% (Figure 6B and C). 
Interestingly, the VM-OLA-LPHVs1 contained a 13-fold lower VM concentration. This 
demonstrated that VM-OLA-LPHVs1 could achieve an antibacterial effect similar to the higher 
doses of bare VM. This could help prevent dose-dependent toxicities, such as nephrotoxicity 
associated with the administration of bare VM [177].  
 
Figure 6: Flow cytometric analysis of MRSA cells after incubation with VM and VM-OLA-
LPHVs1 A) Untreated, B) MRSA treated with VM at its MIC (31.25µg/mL), C) MRSA treated 
with VM-OLA-LPHVs1 at its MIC (2.390µg/mL). 
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3.9 MRSA biofilm eradication  
In addition to the dead cell quantification using fluorescence-activated cell sorting, the ability 
of VM-OLA-LPHVs1 to eliminate biofilms was further investigated using fluorescence 
microscopy. Following a 4-days incubation of MRSA, matured biofilms were formed. These 
were treated with bare VM and VM-OLA-LPHVs1 and virtualised using a fluorescence 
microscopy technique. The mature biofilms were grown on coverslips, stained with a solution 
containing 30μL of Propidium iodide (PI) and Syto9 in 1mL sterilised, deionised water and 
kept in the darkroom to be incubated for approximately 30-minutes. These was followed by 
washing the excess dyes, and the coverslips were inverted on glass slides for image capturing 
(Figure 7A). The untreated biofilms demonstrated high Syto9 fluorescence due to the ability 
of the dye to permeate the cell membrane of intact bacteria [282, 283]. PI, being a non-
permeating dye, revealed no high fluorescence intensity in untreated MRSA cells (Figure 7A). 
However, compared to the control, a slight decrease in biofilm was observed for biofilms 
treated with bare VM, demonstrating the substantial antibacterial ability of VM (Figure 7B). 
Interestingly, a larger decrease in biofilms treated with VM-OLA-LPHVs1 was observed, as 
revealed in the decrease of Syto9 fluorescence intensity, when compared to the bare VM-
treated group and the untreated biofilms (Figure 7C). These demonstrated higher cell 
membrane penetration by PI due to the destruction of the exopolymeric matrix polysaccharide 
(biofilms) cover by VM-OLA-LPHVs1. This result demonstrated that VM-OLA-LPHVs1 
could be a good system for eradicating the biofilms that contribute to chronic infections in 
patients using implants and catheters.   
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Figure 7: Fluorescence microscopy images of A) Untreated biofilms; B) MRSA biofilms 
treated with bare VM and C) MRSA biofilms treated with VM-OLA-LPHVs1 showing 
biofilms disruption and internalisation by the VM-OLA-LPHVs1. Scale bars: 500 µm. 
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3.10 Intradermal in vivo antibacterial activity 
For proof of the efficacy of VM-OLA-LPHVs1 in animal models, a mice skin infection in vivo 
study was performed. The bare VM and VM-OLA-LPHVs1 were subcutaneously administered 
intradermally to BALB/c mice previously infected with MRSA. Mice treated with bare VM 
showed limited MRSA eradication, while the mice treated with VM-OLA-LPHVs1 revealed 
greater MRSA elimination, as demonstrated in Figure 8. The colony-forming units (CFUs) of 
all groups were quantitatively measured and plotted in log10 as shown in Figure 8. The MRSA 
mean load (log10 CFU) calculated for bare VM, VM-OLA-LPHVs1 and the untreated samples 
from the mice skin were 4.40 ± 0.05 (25333 CFU/mL), 2.40 ± 0.17 (266 CFU/mL) and 5.52 ± 
0.014 (338000 CFU/mL), respectively. The mice skins treated with VM-OLA-LPHVs1 
revealed a 95-fold higher reduction in MRSA burden (CFU) compared to the bare VM-treated 
groups. The one-way ANOVA showed statistically significant differences in CFUs among all 
the groups with a P value = 0.0001. The ability of VM-OLA-LPHVs1 to bind, disrupt and 
deform the MRSA membrane may be responsible for the enhanced antibacterial activities [293, 
294]. These results were in agreement with an in vivo study that emplaned other nanovesicles 
against a superbug [295]. This study revealed the potential of VM-OLA-LPHVs1 in eradicating 
and eliminating MRSA infections.  
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Figure 8: MRSA CFUs quantification post 48-hours treatment. Data represent mean ± SD 
(n=3). ** represents a significant difference between the bare VM and VM-OLA-LPHVs1, *** 
represents a significant difference between the untreated and bare VM and **** represents a 
significant difference between untreated and VM-OLA-LPHVs1. 
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4.0 Conclusions 
A novel lipid OLA was successfully synthesised by Michael’s addition reaction and 
deprotection. Its potential to prepare a novel chitosan-based VM-loaded pH-responsive 
nanovesicle (VM-OLA-LPHVs1) was explored. Biocompatibility studies showed that OLA 
and VM-OLA-LPHVs1 were non-cytotoxic to different cell lines. A stable VM-OLA-LPHVs1 
was successfully formulated with a smaller DH and higher EE%, and DLC%. The release of 
VM from VM-OLA-LPHVs1 was higher at pH 6.0 compared to physiological pH 7.4. The in 
vitro antibacterial activity of the VM-OLA-LPHVs1 against MRSA at pH 6.0 revealed an 
enhanced antibacterial effect compared to VM-OLA-LPHVs1 nanovesicles at pH 7.4 and bare 
VM. The increased electrical conductivity and decreased protein/DNA concentrations when 
treated with VM-OLA-LPHVs1, compared to bare VM, indicated that VM-OLA-LPHVs1 
caused greater membrane damage on bacteria. The time killing assay and membrane disruption 
studies VM-OLA-LPHVs1 showed 97.64% bacterial elimination and loss of MRSA membrane 
with maximum effective damage, respectively. These results were further confirmed by flow 
cytometry and fluorescence microscopy techniques and the VM-OLA-LPHVs1 displayed a 
significantly higher percentage of bacteria-killing and biofilm eradication, respectively, when 
compared to bare VM. The in vivo findings obtained by treating BALB/c skin infection 
revealed the ability of VM-OLA-LPHVs1 to decrease and eradicate the MRSA burden by 95-
fold, when compared to bare VM treatment. Our findings suggests that VM-OLA-LPHVs1 can 
potentially be effective in delivering drugs to the site of infection with low pH and effectively 
eradicate the incriminating pathogens infectious disease.  
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CHAPTER FOUR: EXPERIMENTAL PAPER THREE 
4.1 Introduction  
This chapter addresses Aim 3 and Objectives 1- 6. It is a first authored experimental article 
submitted and highlights the formulation and characterisation of pH-responsive quatsomes 
(VCM-StBAclm-Qt1) from the novel quaternary bicephalic surfactant (StBAclm). The 
quatsomes (VCM-StBAclm-Qt1) was evaluated for in vitro toxicity, physicochemical 
properties, morphology, molecular dynamics (MD) simulations, in vitro electrical 
conductivity, protein/DNA concentration quantification, membrane damage, time killing 
assay, membrane disruption, bacteria-killing percentage, biofilm eradication, in vitro and in 
vivo antibacterial properties. 
The ethical approval is attached in Appendix II. 
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Highlights 
• A novel surfactant (StBAclm) was synthesized and its structure confirmed. 
• Vancomycin-loaded pH-responsive quatsomes (VCM-StBAclm-Qt1) were prepared from 
StBAclm. 
• The in vitro drug results showed a faster VCM release from the quatsomes at pH 6.0 
compared to pH 7.4 and enhanced in vitro antibacterial activity against MRSA as compared 
to bare VCM. 
• There was an enhanced bacterial killing kinetics and high perforation of MRSA membrane 
cell wall by the quatsomes. 
• A higher electrical conductivity, reduced DNA, and protein concentration were achieved by 
the quatsomes. 
• There was an enhanced in vivo antibacterial activity of the drug quatsomes against MRSA 
compared to bare VCM in a mice skin infection model. 
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Abbreviation  
ATP    Adenosine triphosphatase 
A-549    Adenocarcinomic alveolar basal epithelial cells 
BCA     Bicinchoninic acid 
CDC    Centers for Disease Control and Prevention  
CTAB    Cationic hexadecyltrimethylammonium bromide 
CFU    Colony-forming unit 
CHol    Cholesterol 
DCM    Dichloromethane 
DLC    Drug loading capacity 
DMSO    Dimethyl sulfoxide 
DNA    Deoxyribonucleic acids  
DSC     Differential scanning calorimetry 
DEE    Drug encapsulation efficiency  
FT-IR    Fourier transform infrared 
HR-MS   High-resolution mass spectrometry 
HEK-293   Human embryonic kidney cell lines 
Hep-G2   liver hepatocellular carcinoma cell lines 
MCF-7   Human breast adenocarcinoma cell lines 
MDT    Mean dissolution time 
MHA    Mueller-Hinton agar 
MHD    Mean hydrodynamic diameter 
MHB    Mueller-Hinton Broth 
MI    Methyl iodide  
MICs    Minimum inhibitory concentrations 
MRSA    Methicillin-resistant Staphylococcus aureus 
MTT    3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NB    Nutrient Broth 
OD    Optical density 
PDI    Polydispersity index 
PI    Propidium iodide  
pDNA    Plasmid deoxyribonucleic acid   
PBS    Phosphate saline buffer 
RMSE    Root mean square error 
R2    Correlation coefficient 
SA    Stearylamine 
siRNA    Small interfering ribonucleic acid   
tBA    Tert-butyl acrylate 
TFA    Trifluoroacetic acid 
TIPs    Triisopropylsilane 
UVis-Spec   UV Spectrophotometer  
VCM    Vancomycin 
ζ    Zeta potential 
1H NMR   Proton nuclear magnetic resonance 
13C NMR   Carbon 13 nuclear magnetic resonance 
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Abstract 
Globally, human beings continue to be at high risk of infectious diseases caused by Methicillin-
resistant Staphylococcus aureus (MRSA) and current treatments are being depleted due to 
antimicrobial resistance. Therefore, the synthesis and formulation of novel materials are 
essential for combating antimicrobial resistance. The study aimed to synthesize a quaternary 
bicephalic surfactant (StBAclm) and formulate pH-responsive vancomycin (VCM) quatsomes 
to increase the activity of VCM against MRSA and its structure was confirmed using 1H, 13C 
NMR, FT-IR, and HRMS. The quatsomes were prepared using a sonication/dispersion method 
and were characterised using various in vitro, in vivo and in silico techniques. The in vitro cell 
biocompatibility studies of StBAclm and pH-responsive vancomycin-loaded quatsomes 
(VCM-StBAclm-Qt1) revealed cell viability of more than 75%. The VCM-StBAclm-Qt1 
prepared had a mean hydrodynamic diameter (MHD), polydispersity-index (PDI) and drug 
encapsulation efficiency (DEE) of 122.9 ± 3.78nm, 0.169 ± 0.02mV and 45.61 ± 0.539%, 
respectively, with surface charge switching from negative to positive at pH 7.4 and pH 6.0, 
respectively. HR-TEM characterisation of the VCM-StBAclm-Qt1 confirmed spherical 
vesicles with MHD similar to the one obtained from Zeta-sizer. The in vitro drug release of 
VCM from the VCM-StBAclm-Qt1 was faster at pH 6.0, compared to pH 7.4. The minimum 
inhibitory concentration (MIC) of the VCM-StBAclm-Qt1 quatsomes against MRSA was 32-
fold and 8-fold lower in pH 6.0 and pH 7.4, respectively, compared to bare VCM, 
demonstrating the pH-responsiveness of the quatsomes. The VCM-StBAclm-Qt1 demonstrated 
higher electrical conductivity and decreases in protein and deoxyribonucleic acid (DNA), 
which confirmed greater MRSA membrane damage compared to treatment with bare VCM. 
The flow cytometry study showed that the quatsomes had a similar bactericidal killing effect 
on MRSA, despite a lower (8-fold) VCM concentration than the bare VCM. The in silico 
studies confirmed the spontaneous formation and interaction of the self-assembled quatsomes 
in the presence of non-solvent accessible areas. The in vivo studies in a skin infection of mice 
models showed that the quatsomes treated groups had a 13.34-fold decrease in MRSA CFUs 
when compared to the bare VCM treated groups. This study indicated the potential of pH-
responsive quatsomes as an effective delivery system for antibiotics. 
 
Keywords: Quatsomes, pH-responsive, Vancomycin, Methicillin-resistant Staphylococcus 
aureus (MRSA), Quaternary, Surfactant. 
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1.0 Introduction  
Despite the progress made in combating infectious diseases, they still continue to pose a 
significant health challenge, leading to high morbidity and mortality rates [1, 2]. In a review 
requested by the British government, and chaired by O’Neill in 2016, it was highlighted that 
global antimicrobial resistance would result in the loss of 10 million lives by 2050 [3]. One of 
the major bacteria recognised as a serious threat is Staphylococcus aureus, which has mutated 
into a resistant strain: Methicillin-resistant Staphylococcus aureus (MRSA), and has been a 
global problem since its discovery in a London hospital in 1960 [4]. Human beings continue to 
be at higher risk of infections caused by MRSA, and current antibiotic treatments are being 
depleted due to antibacterial resistance [5, 6]. This has led to debilitating conditions resulting 
in longer in-hospital stays, and economic loss due to extended therapy [5, 6]. The Centers for 
Disease Control and Prevention (CDC) reported that the loss of nearly 11,285 [7], 5,400 [8] 
and 4,150,000 [9] lives would be recorded in the United States, the European Union Member 
States, and Africa by 2050, respectively. These figures will continue to rise, and the World 
Health Organization (WHO) warns of entering into a post-antibiotic era if innovative strategies 
are not adopted to curb the rise of antimicrobial resistance [10, 11].  
Novel drug delivery systems using nanotechnology are an alternative option for solving 
antimicrobial resistance. Nano-sized drug delivery systems offer greater versatility due to size; 
composition; stimuli-responsiveness [12]; biocompatibility; biodegradability; reduced side 
effects [13, 14]; and decreased exposure of antibiotics to healthy sites, when compared to 
conventional dosage forms [15]. Loading of antibiotics into nano-sized drug delivery systems 
offers higher drug pharmacokinetic profiles and enhanced antibacterial activity, and protects 
the drug from enzymatic destruction leading to fewer side effects [16, 17]. These traits tend to 
address the limitations of conventional dosage forms, which have been used for treating 
infectious diseases since the introduction of antibiotics [18, 19].  
Several nano-drug delivery systems have been involved in the effective delivery of 
antimicrobials with great success, and currently they are being been introduced to the market 
[20, 21]. Lipidic vesicles are the nanostructures most employed for drug delivery since their 
serendipitous discovery in 1964 [22]. They can entrap hydrophobic molecules within their 
bilayers and hydrophilic molecules in their lumen, which makes them excellent as nano-carriers 
for the delivery of drugs [23, 24]. Despite their desirable traits, their use in drug delivery has 
been limited by their low degree of structural homogeneity, which is a critical requirement for 
their enhancement of the pharmacological property of the loaded drugs [24]. Their stability is 
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also a limiting factor because of their lipid building blocks being insoluble in water [25, 26]. 
These limitations have prompted research into other vesicles for drug delivery, such as 
polymersomes from amphiphilic polymers [27], dendrimersomes from dendrimers [28, 29], 
and peptosomes from self-assembling peptides [30]. However, these vehicles still have 
limitations due to their structural stability, low entrapment, membrane thickness and area 
density, which is greatly affected by block length and the size of the polymer, dendrimers, or 
peptides [31]. 
Recently, pH-responsive drug delivery systems for antibiotics have been receiving interest 
since they can respond to the unique acidic site conditions and offer increased drug delivery 
and receptor binding to improve treatment. The search for superior vehicles for drug delivery 
has resulted in the development of quatsomes. They are nanoscopic vesicles, composed of 
sterols and quaternary ammonium surfactants in defined molar ratios [31]. Unlike conventional 
liposomes, they have been reported to be stable for long storage time, have high vesicle-to-
vesicle homogeneity in size and lamellarity and high drug-loading capacity [32]. Furthermore, 
quatsomes have been shown to offer protection against premature drug degradation and 
intracellular penetration [33], and are potential platform for site-specific delivery of 
hydrophilic and lipophilic molecules. However, most of the reported studies on quatsomes 
aimed at understanding the physical-chemical properties of its membrane [24, 34].  
To date, no studies on quatsomes have explored their value in the delivery of drugs. Existing 
studies in the literature have reported on quatsomes prepared from available quaternary 
surfactants in the market to improve their toxicity profile [24, 34].  No pH-responsive 
quatsomes have been reported. In this project, we report on a pH-responsive quaternary 
bicephalic surfactant (StBAclm) used in combination with cholesterol (CHol) to formulate 
quatsomes. There is no reports in the literature on the application of this surfactant and its 
formulation in the delivery of antibiotics or any class of drug. Such a system will broaden the 
field of drug delivery as novel stimuli-responsive quatsomes will be introduced. We envisage 
self-assembly to occur due to the electrostatic interactions between the hydrophobic tail of the 
surfactant and CHol, whilst the pH-responsiveness will be due to the protonation and 
deprotonation of the bicephalic carboxylic arms of the surfactant. In this study, we report the 
synthesis of a novel quaternary bicephalic surfactant (StBAclm) which was further employed, 
together with CHol, to formulate pH-responsive VCM-loaded quatsomes (VCM-StBAclm-Qt). 
The in vitro, in vivo and in-silico evaluation of this novel quatsomes, are reported in this paper.  
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2.0 Materials and methods 
2.1 Materials  
Stearylamine; tert-butyl acrylate (tBA); dichloromethane (DCM); trifluoroacetic acid (TFA); 
triisopropylsilane (TIPs); methyl iodide (MI); cholesterol (CHol) and silica gel were purchased 
from Sigma-Aldrich (USA). Vancomycin (VCM) and MTT were purchased from Sinobright 
Import and Export Co., Ltd. (China) and Merck Chemicals (Germany), respectively. NB, 
MHB, MHA and MRSA (S. aureus Rosenbach ATCC BAA 1683) were obtained from Biolab 
(South Africa). Propidium iodide (PI) and Syto9 dyes Kit were obtained from Thermofisher 
(USA). Bacteria DNA and BCA Kits were purchased from Zymo Research California, (USA), 
and Wako Chemicals, Virginia (USA), respectively. Millipore water used during study was 
purified in the laboratory using the Milli-Q water purification system (Millipore corp., USA). 
All other chemicals and solvents used were of analytical grade. 
2.2 Instrumentation (1H NMR, 13C NMR, FT-IR and HR-MS spectra) 
1H NMR, 13C NMR and FT-IR spectra were conducted and recorded on a Bruker 400 Ultra 
shield™ (United Kingdom) NMR spectrometer and a Bruker Alpha-p spectrometer with a 
diamond ATR (Germany), respectively. HR-MS was accomplished on a Water Micromass 
LCT Premier TOF-MS (United Kingdom). The system (GPC: TFA) consisted of a water 717 
plus auto-sampler, a water 1515 isocratic HPLC pump, a water refractive index detector, and a 
water 600E system controller. Optical density (OD) was measured (Spectrostarnano, 
Germany). 
2.3 Synthesis and characterisation of the surfactant. 
The bicephalic surfactant was synthesized as per Scheme 1: characterisation and structural 
elucidation is found in the Supporting Materials S1. 
 
Scheme 1. a). Dichloromethane (DCM), reflux with constant stirring at 80 oC, 24 h, b). DCM, 
room temperature, 8-hours and c). DCM, room temperature, 12-hours. 
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2.4 In vitro cytotoxicity of StBAclm and VCM-StBAclm-Qt against different cell lines 
The biocompatibility of the novel StBAclm and VCM-StBAclm-Qt quatsomes was evaluated 
using a modified MTT assay method previously reported [21, 35]. Four different cell lines were 
used, including: human embryonic kidney (HEK-293), liver hepatocellular carcinoma (Hep-
G2), human breast adenocarcinoma (MCF-7), and adenocarcinomic alveolar basal epithelial 
cells (A-549). All four cell lines were grown exponentially at 37°C in a 5% CO2 humidified 
atmosphere. The cell lines containing greater than 80% confluency were trypsinised and seeded 
into 96-well plates and then incubated for 24-hours. The StBAclm and VCM-StBAclm-Qt 
quatsomes were prepared and diluted with sterilised Milli-Q water, separately, to final 
concentrations of 20, 40, 60, 80, 100 and 120μg/mL [21].  Subsequently, the culture medium 
and the quatsomes were removed after 48-hours and replaced with 100μL of fresh medium 
followed by the addition of MTT solution (5mg/mL in PBS) in each well. The cells were further 
incubated for an additional 4-hours, followed by the removal of the solution previously added. 
Afterwards, solubilisation of the MTT formazan was achieved by the addition of 100μL DMSO 
into each well. The optical density of each well was measured on a Microplate 
Spectrophotometer (Spectrostar Nano, Germany) at 540nm. All the experiments were 
performed in six replicates and percentage cell viability was calculated using Equation 1. 
% Cell viability = (
A540 nm treated cells
A540 nm untreated cells
) ×  100 … … … … … . 𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 1  
2.5 Formulation of VCM-loaded quatsomes (VCM-StBAclm-Qt)   
The quatsomes were prepared according to a previously reported method with slight 
modification [32]. Briefly, StBAclm (final StBAclm concentration 0.5, 1, 2.5, 5 and 10mg/mL) 
and CHol were accurately weighed into beakers keeping the molar ratio of the two excipients 
constant (1:1). Drug-loaded quatsomes were formulated by the addition of the bicephalic 
surfactant, VCM, and Chol at different concentrations. This was followed by the addition of 
40mL of Milli-Q water, and the mixture was further sonicated for 10, 15, 20 and 30-minutes 
(30/10 second on/off cycle, 30% amplitude) using a probe-sonicator in an ice bath. The 
dispersions were further stirred at 500rpm on a magnetic stirring plate for 24-hours at room 
temperature. Milli-Q water was used as the dispersion medium to avoid changes in the 
solubility of StBAclm as the presence of electrolytes can adversely affect the formation of the 
quatsomes [24, 32]. After 24-hours of equilibration, potential aggregates were removed from 
the blank (StBAclm-Qt) and the drug-loaded VCM-StBAclm-Qt quatsomes by filtration using 
a syringe/filter (0.45μm pore size).  
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2.6 Characterisation of the VCM-StBAclm-Qt quatsomes 
2.6.1 Mean hydrodynamic diameter (MHD), polydispersity index (PDI), zeta potential 
(ζ) and morphology 
The MHD, PDI, and ζ of VCM-StBAclm-Qt quatsomes were analysed using a zetasizer nano 
ZS90 (Malvern Instruments Ltd., UK). A cryogenic-HR transmission electron microscopy 
(Cryo-HR-TEM) on a Jeol, JEM-2100 (Japan) was used to examine VCM-StBAclm-Qt the 
quatsomes’ morphology. Briefly, the drug-loaded quatsomes were diluted accordingly and 
mounted onto the copper grid surface, and immediately 2% uranyl acetate (UA) solution was 
added and used to stain. The excess VCM-StBAclm-Qt quatsomes and stain on the grid were 
removed by blotting off with filter paper and affixed with liquid nitrogen [36]. Before 
virtualisation of the quatsomes’ morphology, the sample grid was kept in liquid nitrogen and 
transferred into the chamber. The images were captured and obtained at an accelerating voltage 
of 200kV. 
2.6.2 Drug entrapment efficiency (DEE%) and drug loading capacity (DLC%) 
The VCM-StBAclm-Qt quatsomes were further characterized to determine DEE% and DLC%. 
The DEE% was determined using an ultrafiltration method, as previously reported [37, 38]. 
Briefly, exactly, 2mL of the drug-loaded quatsomes was loaded into the Amicon® Ultra-4 
centrifugal filter tubes (Millipore Corp., USA), with 10kDa pore size, and centrifuged at 
3000rpm for exactly 30-minutes at 25°C. The amount of the unentrapped drug in the filtrate 
was determined spectrophotometrically using Shimadzu UV 1601, Japan at 280nm. The 
regression equation of the calibration curve (y = 0.0038x - 0.0031), with a linear regression 
coefficient (R²) of 0.9998, was used to determine the unknown drug concentrations values. The 
experiment was done in triplicate, and the DEE% was calculated using equation 2.  
DEE% = (
Weight of VCM in quatsomes
Weight of VCM added during preparation
) ×  100 … … … … . . 𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 2 
The DLC% was determined by freeze-drying the quatsomes, and the weight of VCM was 
calculated using the equation 3 below. 
 DLC% = (
Weight of VCM in quatsomes
Total weight of quatsomes
) ×  100 … … … … … … … … … … . 𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 3 
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2.6.3 Molecular modelling simulations (MDS)  
2.6.3.1 Vancomycin, CHol and surfactant simulation quatsomes 
To evaluate the self-assembling quatsomes and the encapsulation of VCM, molecular 
modelling simulations were employed. The VCM, CHol and the surfactant (StBAclm) 
structures were drawn with ChemDraw professional 17.0. Chimera molecular modelling suite 
was used to prepare the initial VCM-CHol-surfactant complex [39]. The LEAP module 
implemented in AMBER 14 was used to combine, neutralise and solvate the system by adding 
hydrogen atoms, chloride and sodium ions and suspending them in an orthorhombic box of 
TIP3P water molecules such that all atoms were within 10A of the box edges [40]. The system 
contains a total of 2082 water molecules and 1 molecule of VCM, 1 molecule of CHol, and 1 
molecule of the surfactant. The system was minimised for 2500 steps with a strong constraint 
on VCM, CHol and surfactant for 1000 steps (500 steepest descent followed by 500 steps of 
the conjugate gradient). This was followed by 1000 steps of full minimisation Langevin 
thermostat, with a collision frequency of 1.0ps-1 with harmonic restraint of 5kcal/mol Å on the 
solutes during the gradual heating up of the systems to a temperature of 300.00 K in the 
canonical ensemble for 50ps. This was followed by 50ps of density equilibration in NPT 
ensemble and a final 500ps equilibration at 300.00K, 1 bar pressure and coupling constant of 
2 ps. MDS production was carried out for 10 ns using classical MDS with a time step of 2fs, 
with the frame being recorded at every 500 steps of simulation. All the bond lengths involving 
hydrogen atoms were constrained using the SHAKE algorithm [41]. 
2.6.3.2 VCM, CHol and surfactant self-assembly complexation simulation  
The Chimera tool was used for random insertion of six complexes of VCM, CHol and the 
surfactant complex. The system was then minimised for 2500 steps with strong constraint on 
VCM, cholesterol and surfactant for 1000 steps (500 steepest descent followed by 500 steps of 
the conjugate gradient), followed by 1000 steps of full minimisation Langevin thermostat, with 
a collision frequency of 1.0ps-1 with harmonic restraint of 5kcal/mol Å on the solutes during 
the gradual heating up of the systems to a temperature of 300.00K in the canonical ensemble 
for 50ps. This was followed by 50ps of density equilibration in NPT ensemble and a final 500ps 
equilibration at 300.00K, 1 bar pressure and coupling constant of 2ps. MDS production was 
carried out for 10ns using classical MDS with a time step of 2fs, with the frame being recorded 
at every 500 steps of simulation. All the bond lengths involving hydrogen atoms were 
constrained using the SHAKE algorithm [41]. All the molecular dynamics simulation were 
carried out using the GPU amber 14 software package [42]. 
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2.6.3.3 Post-dynamic analysis and binding free energy calculations 
The trajectories generated after MDS simulations were each saved every 1ps, followed by 
analysis using the CPPTRAJ [43] module employed in the AMBER 14 suit. All plots and 
visualisations were completed using the Origin data analysis tool [44] and Chimera [39], 
respectively. Binding free energy calculations is an important endpoint method that elucidates 
on the mechanism of binding between a ligand and protein, including both enthalpic and 
entropic contributions [45, 46]. To estimate the binding affinity of the docked systems, the free 
binding energy was calculated using the Molecular Mechanics/GB Surface Area method 
(MM/GBSA) [47]. Binding free energy was averaged over 1000 snapshots extracted from the 
ten ns trajectory. The free binding energy has been computed by this method for each molecular 
species (complex, ligand and receptor) and can be represented as: 
∆Gbind = Gcomplex − Greceptor − Gligand                                         (1) 
∆Gbind = Egas + Gsol − TS                                                                  (2) 
Egas = Eint + Evdw + Eele                                                                   (3) 
Gsol = GGB + GSA                                                                                   (4) 
GSA = γSASA                                                                                           (5) 
The terms Egas, Eint, Eele, and Evdw symbolise the gas-phase energy, internal energy, Coulomb 
energy and Van der Waals energy, respectively. The Egas was directly assessed from the force 
field terms. Solvation free energy (Gsol), was assessed from the energy involvement from the 
polar states (GGB), and non-polar states (G). The non-polar solvation energy (GSA), was 
determined from the solvent-accessible surface area (SASA), using a water probe radius of 1.4 
Å, while the polar solvation (GGB) contribution was assessed by solving the GB equation. S 
and T symbolise the total entropy of the solute and temperature, respectively [47]. 
2.8 In vitro drug release of VCM from VCM-StBAclm-Qt quatsomes 
The drug release of VCM was performed as per previously reported procedures [48, 49]. Two 
mL of the bare VCM, VCM-StBAclm-Qt and the corresponding blank StBAclm-Qt were 
loaded into the dialysis bags with a size porosity of 8,000-14,400Da. The dialysis bags 
containing the bare VCM, drug-loaded quatsomes and the corresponding blank were placed 
separately in a 40mL receiver compartment of PBS (pH 6.0 and pH 7.4) at 37°C in a shaking 
incubator at 100rpm. Samples of 3mL were withdrawn at specific time intervals from the 
receiver compartment solution. Immediately, an equal amount of fresh PBS (pH 6.0 and pH 
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7.4, respectively) was replaced into the corresponding compartment to keep the initial receiver 
volume constant. The quantity of VCM released from the dialysis bags in the receiver chamber 
was measured spectrophotometrically with Shimadzu UV 1601, Japan at 280nm using the 
regression equation mentioned in Section 2.5.2. The release fraction of VCM from VCM-
StBAclm-Qt quatsomes and VCM solution was calculated using equation 4 below (n=3), where 
At is the amount of VCM released from drug-loaded VCM-StBAclm-Qt1 quatsomes at time t, 
and Ap the amount of VCM pre-loaded in the VCM-StBAclm-Qt1 quatsomes. 
% Cumulative release profile = (
𝐴𝑡
𝐴𝑝
) ×  100 % … … … … … … . 𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 4 
2.9 Evaluation of in vitro antibacterial activities on VCM-StBAclm-Qt quatsomes 
2.9.1 Minimum inhibitory concentrations (MICs) determination  
The MICs studies were conducted against MRSA, according to the previously reported 
procedure [50]. The bacteria were cultured and grown in MHB with relevant dilutions achieved 
at 5 × 105 colony-forming units per mL (CFU/mL) [51]. The bare VCM, StBAclm-Qt and 
VCM-StBAclm-Qt quatsomes were serially diluted in MHB and incubated with bacteria 
cultures (5 × 105) colony-forming units per mL (CFU/mL) for exactly 20-hours in a shaking 
incubator at 37°C and 100rpm. Precisely 10μL of the serially diluted solutions was spotted on 
MHA plates and incubated for 24-hours; and the MIC was regarded as the point with no visible 
bacteria growth. 
2.9.2 Time killing assays VCM-StBAclm-Qt quatsomes  
An overnight MRSA cultured in nutrient broth (NB) was diluted with phosphate buffer saline 
(pH 7.4) to a concentration of 5 × 105 CFU/mL. Bare VCM, and VCM-StBAclm-Qt quatsomes 
were added at concentrations equivalent to 5 × MIC. For the negative control, sterile deionised 
water was added into the bacterial MHB alone, and bacterial cell viability was overseen up to 
24-hours. Tested materials bare VCM and VCM-StBAclm-Qt quatsomes were removed at 
designated times, serially diluted in PBS, plated on an MHA plate, and incubated for 24-hours 
at 37 °C. After 24-hours of incubation, CFU was counted, converted to log10 values and plotted 
on a graph [52, 53].  
%𝑊 = (
𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑏𝑎𝑐𝑡𝑒𝑟𝑖𝑎 − 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 𝑏𝑎𝑐𝑡𝑒𝑟𝑖𝑎
𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑏𝑎𝑐𝑡𝑒𝑟𝑖𝑎
) × 100  
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2.10. Molecular and mechanistic studies on VCM-StBAclm-Qt quatsomes  
2.10.1 Downstream physiological phenomena: electrical conductivity quantification 
1% MRSA was inoculated in 10mL MHB with bacteria (control), bare VCM and VCM-
StBAclm-Qt quatsomes (100µg/mL) and cultured for 16-hours. Three mL of the cultured 
samples were centrifuged at 4000rpm for 15-minutes and the supernatant collected in order to 
determine its electrical conductivity [6]. The electrical conductivity was determined using an 
electrical conductivity meter (OHAUS USA) and calculated using the equation 5 (n=3), where 
Q refers to the conductivity change rate, and Qs and Qc are the conductivity of the test groups 
and the control group, respectively.  
 
Q % = (
Qs − Qc
Qc
) ×  100% … … … … … … … … … … … … 𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 5 
2.10.2 Determination of DNA and protein quantification 
The samples were incubated with the bacteria and centrifuged according to the procedure in 
Section 2.10.1. The DNA concentrations of MRSA treated with bare VCM and VCM-
StBAclm-Qt quatsomes were extracted using a DNA Kit (Zymo Research California, USA), 
and analysed using Nanodrop 1000 Thermo Fisher Scientific, Waltham, MA, USA at 562nm 
absorbance. The protein concentration of MRSA treated with bare VCM and VCM-StBAclm-
Qt quatsomes was determined and analysed using BCA Kits based on the bicinchoninic acid 
method on a microplates spectrophotometer (Spectrostar Nano, Germany) [6] at an absorbance 
of 562nm. 
2.10.3 Bacterial membrane disruption 
Suspensions of MRSA with a concentration (1.5 × 108 CFU/mL) in PBS were incubated with 
VCM-StBAclm-Qt quatsomes containing 153μg/mL of VCM (50:50) ratio and incubated for 
4-hours in a sterilised Eppendorf tube. The mixture was diluted properly and mounted onto the 
surface of a copper grid, according to a previously reported method [54]. The excess sample 
was withdrawn by blotting off with filter paper and allowed to dry at 25°C before measurement. 
The images of the samples were obtained using a high-Resolution transmission electron 
microscope (brightfield, darkfield, TEM- JEOL HR-TEM 2100. 
2.10.4 Fluorescence-activated cell sorting (FACS) bacterial cell viability 
The bacterial cell viability was assessed using a previously reported flow cytometry method 
[55-58]. Briefly, MHB was used to grow pure MRSA culture overnight at 100rpm in a shaking 
incubator (Labcon, USA) at 37°C. Serial dilution of the bacteria at final concentrations 
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CFU/mL of 5 × 105 was used; 15μL of the bacteria suspension was pipetted into the 96-well 
plate containing 135μL of bare VCM at MIC concentrations of 31.25μg/mL, and VCM-
StBAclm-Qt quatsomes at MIC concentration of 3.90μg/mL. The mixture was incubated for an 
additional 6-hours at 37°C and 100rpm. The percentage cell viability was determined after 6-
hours of incubation, and untreated MRSA cells were used as the negative control [59]. Exactly 
50μL of the bare VCM and VCM-StBAclm-Qt quatsomes broths were appended into the flow 
cytometry tubes containing 350μL of sheath fluid vortexed and incubated for approximately 5-
minutes [59, 60]. The cytometry tubes containing the samples were incubated for another 30-
minutes with 5μL of non-cell wall permeant and cell-permeant dye, PI and Syto9, respectively. 
The PI fluorescence was excited at 455nm laser and gathered between 636nm bandpass filter, 
while the Syto9 excitation laser was set at 485nm laser and collected at 498nm bandpass filter 
[55-57]. The bacteria were gated using forward scatter (FSC), with approxamately 10,000 cells 
gathered for individual sample in triplicate. Particles smaller than the bacteria were detected at 
a threshold of 100 in the SSC analyses to avoid background signals [61]. Data were captured 
from the flow cytometry and analysed using Kaluza-1.5.20 software (Beckman Coulter USA) 
[56, 62]. 
2.10.5 Reduction of MRSA biofilm using fluorescence microscopy 
Biofilm eradication of MRSA by bare VCM and VCM-StBAclm-Qt quatsomes were 
quantified using fluorescence microscopy according to a previously reported procedure [63].  
Briefly, coverslips were placed in a 24-well plate. Exactly 4mL of MBH was added into the 
24-well plate, followed by the addition of 2mL of MRSA (1.5 × 108 CFU/mL) suspensions 
grown in MHB. The solution was incubated for four-days at 37°C to form matured biofilm. 
Before treatment, the media used to grow the bacteria were removed out of the 24-well plates 
using a sterilized Pasteur pipette to avoid any contamination.  The plate wells were 
subsequently washed four-times using sterilized water to remove excess and non-adhered 
bacteria. Exactly 1mL of bare VCM suspension and VCM-StBAclm-Qt1 quatsomes, each 
containing 125μg/mL of VCM, were added into the appropriate 24-well plates and incubated 
for an additional 12-hours at 37°C. After incubation, the wells were washed with PBS (pH 7.4) 
to remove the non-adhered treatments on the biofilms. Coverslips were stained with 30μL of 
Syto9 and Propidium iodide (PI) dyes in deionised water and left in the dark to incubate for 
another 30-minutes. The treated and stained 24-well plates were washed for the second time to 
remove excess dyes used, and the cover plate was carefully glued and inverted on a microscope 
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glass slide. Biofilm reduction by bare VCM and the VCM-StBAclm-Qt quatsomes was 
visualised on a fluorescence microscope (Nikon Eclipse 80i FM Japan).  
2.10.6 In vivo antibacterial activity 
For proof of enhanced antibacterial activity, an in vivo antibacterial activity study of the bare 
VCM and VCM-StBAclm-Qt quatsomes was conducted. A mice skin infection model was 
used, following a protocol approved by the University of KwaZulu-Natal’s (UKZN) Animal 
Research Ethics Committee (Approval number: AREC/104/015PD) [64, 65]. The use of 
animals and humane care followed the guidelines of UKZN AREC and South African National 
Standard SANS 10386:2008. Male BALB/c mice of approximately 18-20g were obtained from 
the Biomedical Research Unit (BRU) of UKZN. The mice were then divided into treatment, 
positive and negative control groups (n = 4). The mice skin, which was the site of 
administration of the treatments, was shaved and disinfected using 70% ethanol 24-hours 
before the experiment. The following day, 50µL of MRSA (1.5 x 108 CFU/mL), suspended in 
saline, was injected intradermally. Thirty minutes after bacterial infection, 50µL of the bare 
VCM, VCM-StBAclm-Qt quatsomes and saline were injected separately at the same site of 
infection into the various test groups.  The mice were kept under observation for 48-hours with 
normal conditions of twelve-hours of light and twelve-hours of dark at 19-23oC, and 55 ± 10% 
relative humidity with adequate ventilation. After 48-hours, the mice were euthanised with 
halothane and the infected areas of the skin were harvested and homogenised in 5mL PBS of 
pH 7.4. Tissue homogenates were serially diluted in the PBS, 50µL of the homogenised in PBS 
was spotted on nutrient agar plates and incubated at 37°C for 24-hours. The number of CFU 
and the CFU/mL were counted and calculated using the equation below: 
CFU
mL
=
number of colonies x dilution factor
volume of a culture plate
… … … … … … … … … . . 𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 6 
2.10.7 Stability studies 
To study the stability of the novel drug-loaded quatsomes (VCM-StBAclm-Qt), the samples 
were sealed in a 50mL vial in the dark after flushing with nitrogen and stored at 4oC and 25 ± 
1oC for 30, 60 and 90 days. The stability of the VCM-StBAclm-Qt quatsomes was assessed by 
observing the MHD, PDI, ζ and DEE % with respect to time. 
2.11 Statistical analysis of the experiment 
The results of the experiments were all determined as mean values standard deviation with 
statistical analysis performed using GraphPad Prism® 6 (GraphPad Software Inc., USA). Data 
obtained from the MHD, PDI, ζ, DEE %, and the in vitro drug release were subjected to one-
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way ANOVA and considered statistically significant at P-value < 0.05 with a 95% significance 
level.   
3.0 Results and discussion  
3.1 Synthesis and characterisation of StBAclm 
The cationic bicephalic pH-responsive surfactant was synthesised in three steps. The first step 
involved Michael’s addition reaction, as described in Scheme 1. Compound 3 was synthesised 
by drop-wise addition of tert-butyl acrylic acid (Compound 2 to Compound 1), and the 
synthesis was confirmed by 1H NMR, 13C NMR and HR-MS, as shown in Supplementary 
material S1. The appearance of a strong single peak at 1.3711ppm integrating for 18 protons 
in 1H NMR, and the appearance of carbon peaks at δ 82.1 in 13C NMR, representing tert 
butylate acrylate, confirmed the formation of Compound 3.  The second step involved the 
deprotection of the carboxylic group. Tertiary butyl esters of Compound 3 were deprotected 
through cleavage to form StBAclm, using TFA/TIPs (Supplementary material S2). The 
successful synthesis of StBAclm was confirmed by the disappearance of peaks at 1.3711ppm 
in 1H NMR and 82ppm in 13C NMR. The third step involved the methylation reaction on the 
amine group. Methyl iodide was added to Compound 4 to obtain Compound 5. The product 
was confirmed by the appearance of a single peak at 3.2752 ppm 1H NMR and 49.8ppm in 13C 
NMR and mass spectrometer, respectively (Supplementary material S3). 
3.2 Cytotoxicity assay 
3.2.1 In vitro cytotoxicity assay  
The determination of cell viability is a significant assay to evaluate the cytotoxicity of 
biomaterials and nano-systems [66]. The MTT assay is a rapid quantitative procedure based on 
the transformation of a yellow tetrazolium salt to insoluble purple formazan crystals in the 
mitochondria of viable cells [58]. Figures 1A and B show the bar chart breakdown of the 
biocompatibility assay of StBAclm and VCM-StBAclm-Qt1 quatsomes on four different cell 
lines (A-549, HEK-293, Hep-G2 and MCF-7 cells). The bicephalic surfactant StBAclm 
demonstrated cell viability of 77.31-95.80%; 78.88-98.05%; 75.93-93.90% and 84.11-92.00% 
against A-549; HEK-293; Hep-G2 and MCF-7, respectively, across all concentrations from 20 
-120µg/mL. The VCM-StBAclm-Qt1 quatsomes demonstrated higher percentage cell viability, 
from 77.02-88.35% for A-549; 82.25-91.42% for HEK-293; 80.03-91.06% for Hep-G2 and 
81.16-85.67% for MCF-7 cell lines across all concentrations of VCM in the quatsomes.  
Based on the above results, StBAclm and VCM-StBAclm-Qt1 quatsomes are considered non-
cytotoxic and safe, with greater than 75% cell viability. This result obtained is a preliminary 
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indication of the non-toxic nature of the novel surfactant and nano-system in all the mammalian 
cells tested [67]. Therefore, based on these results, the drug-loaded quatsomes (VCM-
StBAclm-Qt1) could be a suitable vehicle for drug delivery. 
 
 
Figure 1: A) Percentage cell viability of StBAclm on different cell lines A-549; HEK-293; 
Hep-G2 and MCF-7; B) Percentage cell viability of VCM-StBAclm-Qt1 quatsomes on 
different cell lines A-549; HEK-293; Hep-G2 and MCF-7. 
3.3 Preparation and characterisation of VCM-StBAclm-Qt1 
3.3.1 Preparation, characterisation and morphology of VCM-StBAclm-Qt1 quatsomes  
Following the successful synthesis of StBAclm surfactant and the confirmation of its biosafety, 
its potential to formulate VCM-StBAclm-Qt1 quatsomes was then investigated. Preliminary 
studies involving different molar ratios of StBAclm:CHol were screened in order to get an 
optimal formulation of the quatsomes. The optimised drug-loaded quatsomes (VCM-StBAclm-
Qt1) had MHD and PDI of 122.9 ± 3.78nm and 0.169 ± 0.02, respectively, at physiological pH 
7.4. The MHD values were similar to the sizes of quatsomes that have been previously reported 
[32, 68]. In contrast, the VCM-StBAclm-Qt1 quatsomes in the acid environment of pH 6.0 
showed an increase in MHD value from 122.9 ± 3.78nm to 145.7 ± 5.08nm. The VCM-
StBAclm-Qt1 quatsomes demonstrated surface charge switching (ζ) from negative (-5.74 ± 
2.57mV) in physiological pH 7.4 to positive (+16.0 ± 1.59mV) in acidic environment pH 6.0 
(Supplementary material Table S1). The DEE% of the VCM-StBAclm-Qt1 quatsomes was 
45.61 ± 0.54 %, which is higher compared to other previously reported formulated VCM 
vesicle systems with DEE% of 28.30 ± 4.94% [69, 70]. This could be due to the ability of the 
VCM to partition, both in the lipidic bilayer and aqueous lumen of the quatsomes. Furthermore, 
the DSC studies showed that the lyophilised quatsomes showed the disappearance of the VCM 
thermal peak when compared to the physical mixture of the excipients and VCM, thus 
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indicating a successful encapsulation of VCM (Supplementary materials S4). The VCM-
StBAclm-Qt1 quatsomes’ morphology, as shown in Figure 2A, was observed to be spherical 
vesicles, containing a thin membrane and an aqueous core, and having a similar MHD size, 
obtained from dynamic light scattering measurement. This image was similar to other reported 
quatsomes [24, 71].  
 
 
 
Figure 2: A) Morphology of VCM-StBAclm-Qt1 quatsomes Scale bar: 200nm; B) size 
distribution of VCM-StBAclm-Qt1 quatsomes measured using Dynamic Light Scattering 
(DLS). 
3.3.2 Effect of change in pH on MHD, and ζ 
The effect of pH on size, and surface charge-switching (ζ) was determined at different pHs  
(7.4, 6.0 and 5.5), as shown in Figure 3B. There was an increase in the size of the quatsomes 
with a decrease in pH. The effect of pH on the ζ demonstrated surface charge-switching from 
negative at physiological pH (pH 7.4) to positive at acidic pH 6.0 and pH 5.5. The charge-
switch could be attributed to protonation and deprotonation of the surfactant. At physiological 
pH, the bicephalic carboxylic groups deprotonated, which neutralised the quaternary charge 
leaving the surfactant to have an overall negative charge. At acidic pH, the carboxylic groups 
protonated, gaining a neutral charge; thus, the surfactant gained an overall positive charge due 
to the positive charge on the quaternary nitrogen. Similar ζ was reported for liposomes 
formulated with stearylamine and dicety phosphate (DCP), a quaternary compound [72].  
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Figure 3: Preliminary, optimised characterization of quatsomes. A) Effect of novel surfactant 
(StBAclm) concentration on size at different pHs; B) Effect of ζ at different pH; demonstrated 
a notable switch from negative to positive charge with decrease in pH; C) Effect of sonication 
time at different pHs; D) Effect of sonication time on DEE%. (n = 3 for all observations). 
3.3.3 Vancomycin, CHol and StBAclm complex and self-assembly of inserted complexes  
The total binding free energy was calculated to gain insight into the binding energetics of 
vancomycin, cholesterol and surfactant complex. The MM-GBSA program in AMBER was 
used in calculating the binding free energies by extracting snapshots from the trajectories of 
the compounds. 
Table 1. The binding energies (Kcal/mol) for the VCM-CHol-StBAclm computed from the 
MD trajectories: 
Energy Components (kcal/mol) 
Complex Δ EvdW ΔEelec ΔGgas ΔGsolv ΔGbind 
VCM -26.44± 0.35 32.98±0.79 6.53 ± 0.76 -26.81± 0.76 -20.27± 0.31 
CHol  -15.66± 0.30 -0.91±0.19 -16.58± 0.34 5.02± 0.17 -11.55±0.28 
             StBAclm -15.06± 0.50 33.01±0.83 17.94 ±0.99 -30.28± 0.83 -12.33± 0.42 
 
From Table 1, it was observed that Van der Waals (VdW) energy played a major role in the 
binding of the molecules. The last frame (100ns) of the first simulation was taken; the VCM 
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interacted with CHol and StBAclm complex. This was replicated in order to make six 
complexes and perform 35ns self-assembly simulations. It was observed that these complexes 
started to assemble within a few nanoseconds (ns) after simulations (Figure 4). Simulation data 
revealed that at ~15ns three dimers were formed, at 25ns and 35ns two trimers and a hexamer 
were formed, respectively. There was self-assembling of the complexes throughout the 
simulation period. At 25ns, two trimers were formed with a hydrophilic component on either 
side of the trimers (Figure 4C). Interestingly, the two trimers fused to form a sort of a bilayer 
ridge-like structure with hydrophobic portions at the centre forming non-solvent accessible 
areas, while the hydrophilic groups were seen on the opposite facing water (Figure 4D). This 
could be due to the initial arrangement before assembling into a vesicle. This study indicates 
the possible steps involved in the formation of the quatsomes. 
 
Figure 4:  Self-assembly simulation at a different time point (a-d). Where purple is VCM, 
green is CHol and sky blue is StBAclm. 
3.4 In vitro drug release behaviour  
The in vitro drug release study was carried out in PBS (pH 6.0 and 7.4) at 37°C to investigate 
the cumulative release profile of VCM from the quatsomes. The cumulative amount of VCM 
released from VCM-StBAclm-Qt1 quatsomes was observed to be faster at pH 6.0 compared to 
pH 7.4 (Figure 5). The higher VCM release at pH 6.0 could be due to the protonation and the 
deprotonation of the amine group in the bicephalic surfactant StBAclm, resulting in the 
destabilisation of the quatsomes nanosystem [73]. A similar triggered release of methotrexate 
under acidic conditions was observed for stearylamine-chitosan nanoparticles [74]. The release 
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profile during this experiment indicated that VCM release from VCM-StBAclm-Qt1 quatsomes 
was pH-responsive and showed potential for application in targeting drugs to diseases that 
thrive in an acidic environment. 
 
 
Figure 5: Drug release profiles of bare VCM and VCM-StBAclm-Qt1 quatsomes in different 
(pH 7.4 and pH 6.0). (Mean ± SD, n = 3). 
3.5 Stability studies 
The colloidal stability of the quatsomes indicated no significant change in MHD, PDI, ζ and 
DEE % (P > 0.5) over twelve weeks. The results are similar to other reported quatsomes by 
Ferrer-Tasies et al. in 2013, which showed stability with great homogeneity with respect to 
MHD [24].  
Table 2. Stability observation on MHD, PDI, ζ and DEE% of VCM-StBAclm-Qt1 quatsomes 
after twelve weeks of storage. 
Room temperature (25 ± 1oC) (4 ± 1oC) 
Time 
(days) 
MHD PDI ζ (mV) DEE% MHD PDI ζ (mV) DEE% 
0 141.9±3.78 0.285±0.04 -5.74±2.57 52.22±8.4 141.9±3.78 0.285 ± 0.04 -5.74±2.57 52.22 ± 8.45 
30 145.2±5.12 0.265±1.21 -6.12±1.23 51.24±5.2 144.3±2.44 0.242 ± 0.01 -7.29±1.45 52.02 ± 5.21 
60 143.4±6.77 0.275±2.41 -5.86±2.41 51.65±6.4 140.2±3.21 0.251 ± 0.03 -6.12±1.25 51.53 ± 4.32 
90 144.1±6.92 0.264±1.03 -5.88±3.10 52.01±3.8 142.3 ±2.22 0.263 ± 1.02 -6.12±1.25 51.24 ± 3.01 
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3.6 MIC determination  
The antimicrobial activity of VCM-StBAclm-Qt1 quatsomes and bare VCM were studied 
against MRSA. The minimum inhibitory concentration (MICs) for bare VCM at both pH values 
was constant against MRSA (31.25µg/mL). In contrast, VCM-StBAclm-Qt1 quatsomes 
showed lower MICs values of 0.97µg/mL at acidic pH 6.0, compared to the physiological pH 
7.4 with 3.90µg/mL against MRSA, as shown in Table 3. The VCM-StBAclm-Qt1 quatsomes 
had an 8-fold and 32-fold antimicrobial activity enhancement against MRSA at physiological 
pH 7.4 and acidic pH 6.0, respectively, when compared to bare VCM. The VCM-StBAclm-Qt1 
quatsomes at pH 6.0 had a 4-fold antibacterial activity enhancement against MRSA compared 
to VCM-StBAclm-Qt1 quatsomes at physiological pH 7.4. The enhanced activity at pH 6.0 
could be due to the small MHD and pH-responsiveness of the quatsomes. This might have 
produced an excellent surface-area-to-volume ratio, thus leading to a proper distribution of the 
quatsomes on the surface of the bacteria [75]. Furthermore, enhanced activity of the quatsomes 
against MRSA could be due to the quatsomes enhancing the transport of the drug into the thick 
peptidoglycan layer of MRSA. The ability of the quatsomes to enhance the transport of the 
drug through the peptidoglycan layer might have prevented VCM ion trapping, which is the 
main resistance mechanism of MRSA to bare VCM [76-78]. Another proposed reason for the 
improved antimicrobial activity at acidic pH could be due to the concentrated release of the 
drug on the bacterial membrane as the system breaks down at acidic pH, thus releasing the drug 
in lethal concentrations to effectively eliminate the bacteria. These results showed the enhanced 
efficiency of the novel quatsomes at acidic pH compared to physiological pH conditions, thus 
indicating its potential for targeting bacteria that thrive in environments with low pH. 
 
 
Table 3. MICs values of bare VCM, StBAclm-Qt1 and VCM-StBAclm-Qt1 quatsomes against 
MRSA at pH 6.0 and pH 7.4. 
In vitro antibacterial activity at pH 6.0                                   pH 7.4                                    
Time (h) 24 48 72 24 48 72 
MRSA (MIC µg/mL) MRSA (MIC µg/mL) 
Bare VCM 31.25 31.25 31.25 31.25 31.25 31.25 
StBAclm-Qt 125 125 125 250 250 250 
VCM-StBAclm-Qt1 0.97 0.97 0.97 3.90 3.90 3.90 
All values are expressed as mean ± SD (n = 3) 
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3.7 Bactericidal time assay of VCM-StBAclm-Qt1 quatsomes 
From the antibacterial studies, it was established that the time of bactericidal effect of VCM-
StBAclm-Qt1 quatsomes could efficiently eliminate MRSA. Therefore, bacterial killing kinetic 
studies were performed to determine the killing kinetics of bare VCM and VCM-StBAclm-Qt1 
towards MRSA. Figure 6A presents time killing rates of bacteria by VCM and VCM-
StBAclm-Qt1 quatsomes when exposed to MRSA at 5 × MIC of each treatment over a period 
of 24-hours incubation at 37°C. The killing kinetics of bare VCM was similar to reports in the 
literature [52]. The VCM-StBAclm-Qt1 quatsomes eliminated almost 100% of MRSA within 
8-hours of the procedure. The shorter time taken to reduce the MRSA population by VCM-
StBAclm-Qt1 quatsomes could be an indication that the quatsomes system can be used for a 
shorter treatment course, compared to bare VCM. 
 
Figure 6: A) Killing kinetics of MRSA exposed to 5 x MIC of VCM-StBAclm-Qt1 quatsomes, 
VCM, bacterial in PBS 7.4 (positive control) and sterile water (negative control) at different 
time intervals (n = 3); B) (a) HR-TEM images of MRSA bacteria exposed to water, (b) HR-
TEM images of VM, (c-d) HR-TEM images of MRSA treated with VCM-StBAclm-Qt1 
quatsomes (5× MICs) showing the membrane disruption that occurred after 1-hour incubation, 
pores on bacterial membrane after treatment and total loss of MRSA cell membrane after 4-
hours of VCM-StBAclm-Qt1 quatsomes treatment. These arrows shows the damaged 
cytoplasmic membrane exposure to VCM-StBAclm-Qt1 quatsomes.  
3.8 Mechanistic studies of VCM-StBAclm-Qt1 quatsomes 
3.8.1 Bacterial membrane disruption 
The effect of VCM-StBAclm-Qt1 quatsomes on the membrane of MRSA was determined by 
incubating MRSA with our novel VCM-StBAclm-Qt1 quatsomes for approximately 5-hours. 
Figure 6B(c) shows the perforation of the MRSA cell wall, which demonstrated the 
effectiveness of the VCM-StBAclm-Qt1 quatsomes’ killing ability Figure 6B (c and d).  
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Subsequently, after 5-hours of treatment with the VCM-StBAclm-Qt1 quatsomes, a total loss 
of bacteria cell wall was observed, demonstrating an effective membrane disruption ability 
against MRSA, as shown in Figure 6B (d). The interaction of the VCM-StBAclm-Qt1 
quatsomes with the MRSA could be due to the antibacterial activity of quaternary bicephalic 
surfactant, which resulted in effective delivery of the VCM which led to bacteria membrane 
disruption. This result correlates with the MICs and killing kinetics studies, which showed 
effective killing and clearance of bacteria by the VCM-StBAclm-Qt1 quatsomes. This study 
revealed the possible mechanism of the quatsomes in the elimination of bacteria.  
3.8.2 Fluorescence-activated cell sorting (FACS) cell viability 
Cell viability of MRSA was further evaluated by using fluorescence-activated cell sorting 
(FACS) techniques and MRSA was incubated with bare VCM and VCM-StBAclm-Qt1 
quatsomes at their respective MICs. Under environmental stress conditions, several pathogens 
enter into a viable but not cultivable state. Thus, a plate-counts method may overestimate 
viability efficiency by not detecting reversible, viable damaged bacterial cells [79]. The MICs 
study showed that the VCM-StBAclm-Qt1 quatsomes reduced the MIC of VCM by 8-fold. The 
lowering of the MIC could result in vegetative forms of bacteria which could give negative 
results using the plate-count method [80]. FACS tends to solve this problem by effectively 
separating the dead cells from viable cells by using cell permeant and non-cell permeant dyes. 
Figure 7A shows the flow cytometry results of bare VCM and VCM-StBAclm-Qt1 quatsomes. 
The killing percentage of VCM-StBAclm-Qt1 quatsomes against MRSA cells after incubation 
was similar to VCM (Figure 7A) at their respective MICs, despite having an 8-fold lower 
concentration. These results demonstrated that, even with the reduction of the MIC of VCM 
by incorporation into the quatsomes, the system efficiently killed the bacteria without turning 
the bacteria into a viable but non-cultivable state. This state has been attributed to the 
development of resistant strains when the bacteria are exposed to sublethal concentrations. The 
lowering of the MIC value of VCM shows the translational potential of this system without 
compromising the therapeutic effect of the loaded drug. This could lead to a reduction in the 
dose-dependent side effects of VCM, such as nephrotoxicity and Redman syndrome [81]. 
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Figure 7: Red colour represents the gate for alive MRSA cells while the Green colour 
represents the gate for dead cells in the population. Flow cytometry PI emission intensity plot) 
A) Histogram plot of the control group showing live MRSA cells; B) Histogram plots 
percentage uptake of dead MRSA cells when treated with bare VCM; C) Histogram plot 
showing percentage uptake of dead MRSA cells when treated VCM-StBAclm-Qt1 quatsomes.  
3.8.3 Biofilm eradication of VCM-StBAclm-Qt1 quatsomes using fluorescence microscopy 
Fluorescence microscopy was also used to investigate the quatsomes’ ability to eliminate 
biofilms. Biofilms are microbial communities attached to surfaces and encased in a protective 
extracellular polymeric substances (EPS) matrix of microbial origin [82, 83]. An EPS matrix 
acts as a biofilm protective barrier that prevents antimicrobial drugs from penetration, thereby 
protecting the bacteria cells. A four-days, fully mature MRSA biofilm was grown on a 
coverslip, treated with bare VCM and VCM-StBAclm-Qt1 quatsomes and further investigated 
and analysed using fluorescence microscopy. The biofilms were stained with 1mL of a solution 
containing 30µL each of PI and Syto9. The samples were kept in the dark for 30-minutes, 
followed by washing with sterilised water; and then the coverslips were inverted on the glass 
slides (Figure 8). Cell permeating dye (Syto9) revealed high intensity due to the intact 
membrane of cells on the coverslip of the untreated samples [119, 120]. However, no 
fluorescence intensity was observed for PI dye as it cannot penetrate intact cell membrane and 
the EPS matrix (Figure 8A). Biofilms treated with bare VCM showed Syto9 intensity and PI 
fluorescence demonstrating VCM had a level of penetration into the biofilm protective EPS 
matrix, thus reaching the protected MRSA cells (Figure 8B).  
When the biofilms were treated with VCM-StBAclm-Qt1 quatsomes, there was an increased 
red fluorescence due to PI penetration and interacting with the DNA of the MRSA cells (Figure 
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8C). The higher PI fluorescence emittance observed for biofilms treated with VCM-StBAclm-
Qt1 indicated that quatsomes could penetrate or destroy the EPS matrix of the biofilm, thus 
reaching MRSA cells. Upon reaching the MRSA cells, the membranes of the cells were 
destroyed, resulting in the intercalation of PI with the DNA, as observed in an increased PI 
fluorescence. This indicates that VCM-StBAclm-Qt1 quatsomes disrupted the biofilms and 
MRSA cell membrane, which led to higher PI penetration and DNA. These results, therefore, 
demonstrated that VCM-StBAclm-Qt1 quatsomes is a system with the potential to eliminate 
bacteria biofilms from devices such as respirators [84]; catheters (central venous, urinary); 
prosthetic heart valves; orthopaedic devices [85]; and surgical and dental implants [86].  
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Figure 8: Fluorescence microscopy images of MRSA biofilm: A) Untreated biofilms stained 
with Syto9; B) Untreated biofilms stained with Syto9 and Propidium Iodide; C) VCM treated 
and D) VCM-StBAclm-Qt1 quatsomes treated showing internalisation in the biofilms. (scale 
bar = 500μm). 
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3.9 Molecular antibacterial studies 
3.9.1 Bacterial cell membrane permeability in terms of relative electric conductivity 
MRSA cell membrane is composed of lipids and proteins, and they are important factors in cell 
membrane integrity, stability, and permeability. Cell membrane disruption causes leakage of 
cellular substance, which leads to cell death. Disruption of the bacterial cell membrane can also 
lead to leakage of intracellular electrolytes, leading to increased conductivity [87]. To explore 
the interactions between the quatsomes and cell membrane, against MRSA cells electrical 
conductivity was measured to investigate bacterial cell disruption. The results from the 
electrical conductivity of VCM-StBAclm-Qt1 quatsomes showed an increase from 0.357 ± 0.02 
to 0.487 ± 0.01mS cm-1, when compared to bare VCM treatment (Table 4 and Figure 9A). 
This corresponds to a 1.36-fold increment in the electrical conductivity when compared to the 
bare VCM group (P < 0.05). The rise in the electrical conductivity could be due to the 
displacement of the membrane lipids by quatsomes [88-91]. Maintaining ion homeostasis is 
paramount to the proper cell function of the bacteria, including solute transport, metabolic 
regulation, control of turgor pressure, motility of cell and energy creation. Changes in the 
structural integrity of the cell membrane can affect metabolism and lead to cell death [92, 93].  
The increase in conductivity displayed in this study implies that MRSA cell membrane was 
destroyed. This led to electrolytic leakage, causing an increase in electrical conductivity, thus 
leading to cell lysis [94].  
Table 4. The analysis of MRSA cell membrane permeability after treatment with bare VCM 
and VCM-StBAclm-Qt1 quatsomes. 
Parameters Control Bare VCM VCM-StBAcm-Qt1 quatsomes 
Electrical conductivity (mS cm-1) 0.321 ± 0.01 0.35 ± 0.02   0.487 ± 0.01 
DNA concentration (μg·mL−1) 17.00 ± 0.49 4.30 ± 0.08 2.08 ± 0.040 
Protein concentration (μg·mL−1) 158.6 ± 8.54 98.1 ± 4.88 75.94 ± 4.10 
Values are expressed as mean ± SD. 
 
3.9.2 Leakage of proteins and VCM-StBAclm-Qt1 quatsomes analysis  
Protein plays an essential role in the physiological metabolism of bacteria. The disruption of 
the membrane results in the loss of membrane integrity, which leads to the leakage of essential 
proteins responsible for MRSA cell survival [95]. As shown in Figure 9B, the DNA 
concentration of MRSA treated with VCM-StBAclm-Qt1 quatsomes was significantly 
decreased from 4.3 ± 0.08μg·mL−1 to 2.08 ± 0.040μg·mL−1 (2-fold decrease), compared to bare 
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VCM. The one-way ANOVA showed significant differences in the protein leakage, with a P 
value < 0.001 among all the groups. The VCM-StBAclm-Qt1 quatsomes might have caused 
the increase in membrane permeability by destroying the cell membrane, leading to the leakage 
of cellular substance. This result showed that VCM-StBAclm-Qt1 quatsomes had a greater 
impact on the bacterial membrane, which led to DNA leakage [96]. This implies that, even at 
low concentrations of VCM in the VCM-StBAclm-Qt1, it was more effective compared to bare 
VCM. Thus, this suggests that the quatsomes can potentially serve as a drug delivery system 
with effective and low therapeutic doses requirement. 
 
Figure 9: A) Electrical conductivity of bare VCM and VCM-StBAclm-Qt1 quatsomes. ** 
denote statistical significance of bare VCM compared to MRSA (control): **** denotes 
statistical significance of bare VCM compared to VCM-StBAclm-Qt1 quatsomes, and # 
denoted when VCM-StBAclm-Qt1 quatsomes was compared to MRSA (control); B) Reduction 
of DNA quantification of bare VCM and VCM-StBAclm-Qt1 quatsomes. **** denote 
statistical significance of bare VCM compared to MRSA (control): *** denotes statistical 
significance of bare VCM compared to VCM-StBAclm-Qt1 quatsomes, and # denoted when 
VCM-StBAclm-Qt1 quatsomes was compared to MRSA (control); C) Reduction of protein 
quantification bare VCM and VCM-StBAclm-Qt1 quatsomes. **** denote statistical 
significance of bare VCM compared to MRSA (control): *** denotes statistical significance of 
bare VCM compared to VCM-StBAclm-Qt1 quatsomes.   
3.10 In vivo antibacterial activity 
As a proof of the efficacy of VCM-StBAclm-Qt1 quatsomes in animal systems, in vivo studies 
were conducted using BALB/c a mice skin infection model. The colony-forming unit (CFUs) 
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numbers from each treatment group were evaluated and represented as log10 (Figure 10). The 
one-way ANOVA showed significant differences in CFUs among all the groups with a P value 
= 0.001. The mean MRSA load (log10 CFU) obtained from the groups treated with VCM-
StBAclm-Qt1 quatsomes, bare VCM and untreated groups were 2.3010 (200 CFU/mL); 4.40 ± 
0.05 (25333±3055 CFU/mL); and 5.528±0.014 (338000±11135 CFU/mL), respectively. The 
mice groups treated with bare VCM had significantly reduced MRSA burden in their skin 
samples (126.67-fold) when compared to the untreated groups (P value = 0.001). On the other 
hand, VCM-StBAclm-Qt1 quatsomes significantly decreased the MRSA burden in the skin 
samples by 1690-fold, when compared to the untreated groups. Furthermore, groups treated 
with VCM-StBAclm-Qt1 quatsomes had significantly reduced MRSA burden (13.34-fold) in 
the mice skin samples when compared to bare VCM treated groups. This result is in agreement 
with other in vivo studies that involved the use of antibiotics such as streptomycin, gentamicin 
and doxycycline nanoplexes against bacterial infections [97, 98]. The observation from this 
study revealed the significant potential of VCM quatsomes in combating MRSA infections. 
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Figure 10:  MRSA CFU evaluation post 48-hour of treatment (mean ± SD) (n=3). *** denotes 
the significant difference between the bare VCM vs VCM-StBAclm-Qt1 quatsomes and VCM 
vs Untreated groups. **** denotes the significant difference between VCM-StBAclm-Qt1 
quatsomes vs Untreated groups. 
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4.0 Conclusions 
Due to the diminishing antimicrobial activity of VCM against MRSA, effective and efficient 
treatment is urgently needed to combat the widespread infections globally. In this research, a 
novel quaternary bicephalic surfactant (StBAclm) was synthesised and used in formulating pH-
responsive quatsomes (VCM-StBAclm-Qt1) by electrostatic interaction for the delivery and 
antibacterial enhancement against MRSA. The StBAclm structure, and the biosafety activity 
were confirmed. The VCM-StBAclm-Qt1 quatsomes demonstrated smaller MHD, higher DEE 
and DLC%, as well as a fast and sustained release of VCM at the acidic environment of pH 
6.0, compared to physiological pH 7.4. The molecular modelling simulation (MDS) studies 
demonstrated self-assembly formation of the quatsomes. In vitro antibacterial studies of the 
quatsomes against MRSA revealed the enhanced antimicrobial activity of quatsomes compared 
to bare VCM. The results from the in vitro antimicrobial activity was further confirmed by flow 
cytometry, time-killing assay and biofilm studies. This further showed a better antimicrobial 
effect of the quatsomes at 8-fold lower concentrations when compared to bare VCM. The 
quatsomes also displayed the ability to eliminate MRSA biofilms. The in vivo studies using 
the BALB/c mice-infected model revealed that the treatment of MRSA infections with VCM-
StBAclm-Qt1 quatsomes significantly decreased the MRSA burden compared to the treatment 
with bare VCM. The pH-responsiveness, biosafety and antimicrobial activity of the novel pH-
responsive VCM-StBAclm-Qt1 quatsomes confirmed its potential for application as a 
promising novel nano-drug carrier for antibiotics.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
139 
 
Conflict of interest 
The authors declare no conflict of interest. 
Acknowledgement 
The authors acknowledge the College of Health Sciences, University of KwaZulu-Natal 
(UKZN), UKZN Nanotechnology Platform, National Research Foundation of South Africa 
(Grant No. 87790 and 88453) for financial support. The Microscopy and Microanalysis Unit, 
Biomedical Resource Unit, Department of Human Physiology and Flow Cytometry Research 
Laboratory at UKZN, CHPC (Cape Town) for supercomputing resources are acknowledged.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
140 
 
References  
[1] J.R. Rohr, C.B. Barrett, D.J. Civitello, M.E. Craft, B. Delius, G.A. DeLeo, P.J. Hudson, N. 
Jouanard, K.H. Nguyen, R.S. Ostfeld, Emerging human infectious diseases and the links to 
global food production, Nat. Sust., 2 (2019) 445-456. 
[2] M. D. Ryckera, B. Baragañaa, S.L. Duceb, I.H. Gilberta, Challenges and recent progress in 
tropical disease drug discovery, Nature., 559 (2018) 498-506. 
[3] S.A. Ahmed, E. Barış, D.S. Go, H. Lofgren, I. Osorio-Rodarte, K. Thierfelder, Assessing 
the global poverty effects of antimicrobial resistance, World Devel., 111 (2018) 148-160. 
[4] C.P. Harkins, B. Pichon, M. Doumith, J. Parkhill, H. Westh, A. Tomasz, H. D Lencastre, 
S.D. Bentley, A.M. Kearns, M.T. Holden, Methicillin-resistant Staphylococcus aureus 
emerged long before the introduction of methicillin into clinical practice, Gen. Bio., 18 (2017) 
130-140. 
[5] S.R. Ritchie, K.J. Jayanatha, E.J. Duffy, J. Chancellor, Z. Allport, M.G. Thomas, Previous 
antibiotic-related adverse drug reactions do not reduce expectations for antibiotic treatment of 
upper respiratory tract infections, J. Glo. Ant. Res., 10 (2017) 256-260. 
[6] L. Lin, X. Mao, Y. Sun, H. Cui, Antibacterial mechanism of artemisinin/beta-cyclodextrins 
against Methicillin-resistant Staphylococcus aureus (MRSA), Micro. Path., 118 (2018) 66-73. 
[7] N. Andreatos, F. Shehadeh, E.E. Pliakos, E. Mylonakis, The impact of antibiotic 
prescription rates on the incidence of MRSA bloodstream infections: A county-level, US-wide 
analysis, Inter. J. Ant. Agents., 52 (2018) 195-200. 
[8] H. Iqbal, N. Ponniah, S. Long, N. Rath, M. Kent, Review of MRSA screening and 
antibiotics prophylaxis in orthopaedic trauma patients; The risk of surgical site infection with 
inadequate antibiotic prophylaxis in patients colonized with MRSA, Injury., 48 (2017) 1382-
1387. 
[9] K. Govender, S. Sharma, W. Jessee, K. Nagaraju, N.J. Pearse, P. Chhetri, E.M. Bodenstab, 
P. Yu, S.C. Srinivas, Leadership and Task Shifting to Address the Challenges of Antimicrobial 
Resistance in South Africa, Asian J. Pharm. Res. Health Care., 10 (2018) 10-20. 
[10] L.J. Shallcross, S.J. Howard, T. Fowler, S.C. Davies, Tackling the threat of antimicrobial 
resistance: from policy to sustainable action, Philo. Trans. Royal Soc. B: Bio. Sci., 370 (2015) 
p20140082. 
[11] B. Spellberg, The future of antibiotics, Crit. Care, 18 (2014) 228-234. 
[12] S. Ramanavičius, R. Žalnėravičius, G. Niaura, A. Drabavičius, A. Jagminas, Shell-
dependent antimicrobial efficiency of cobalt ferrite nanoparticles, Nano. Stru. Nano Obj., 15 
(2018) 40-47. 
141 
 
[13] X. Jiang, J. Li, M. Ding, H. Tan, Q. Ling, Y. Zhong, Q. Fu, Synthesis and degradation of 
nontoxic biodegradable waterborne polyurethanes elastomer with poly (ε-caprolactone) and 
poly (ethylene glycol) as soft segment, Eur. Polymer J., 43 (2007) 1838-1846. 
[14] Y. Wen, S. Pan, X. Luo, X. Zhang, W. Zhang, M. Feng, A biodegradable low molecular 
weight polyethylenimine derivative as low toxicity and efficient gene vector, Biocon. Chem., 
20 (2009) 322-332. 
[15] S. Honary, P. Ebrahimi, R. Hadianamrei, Optimization of particle size and encapsulation 
efficiency of vancomycin nanoparticles by response surface methodology, Pharm. Devel. 
Tech., 19 (2014) 987-998. 
[16] G. Tiwari, R. Tiwari, B. Sriwastawa, L. Bhati, S. Pandey, P. Pandey, S.K. Bannerjee, Drug 
delivery systems: An updated review, Inter. J. Pharm. Investig., 2 (2012) 2-11. 
[17] S. Bamrungsap, Z. Zhao, T. Chen, L. Wang, C. Li, T. Fu, W. Tan, Nanotechnology in 
therapeutics: A focus on nanoparticles as a drug delivery system, Nanomed., 7 (2012) 1253-
1271. 
[18] S.A. Agnihotri, N.N. Mallikarjuna, T.M. Aminabhavi, Recent advances on chitosan-based 
micro-and nanoparticles in drug delivery, J. Contr. Rel., 100 (2004) 5-28. 
[19] M.H. Xiong, Y. Bao, X.Z. Yang, Y.H. Zhu, J. Wang, Delivery of antibiotics with 
polymeric particles, Adv. Drug Delivery Reviews, 78 (2014) 63-76. 
[20] D. Hassan, C.A. Omolo, R. Gannimani, A.Y. Waddad, C. Mocktar, S. Rambharose, N. 
Agrawal, T. Govender, Delivery of novel vancomycin nanoplexes for combating methicillin 
resistant Staphylococcus aureus (MRSA) infections, Inter. J. Pharm., 558 (2019) 143-156. 
[21] C.A. Omolo, R.S. Kalhapure, M. Jadhav, S. Rambharose, C. Mocktar, V.M. Ndesendo, T. 
Govender, Pegylated oleic acid: A promising amphiphilic polymer for nano-antibiotic delivery, 
Euro.  J. Pharm. Biopharm., 112 (2017) 96-108. 
[22] S.M. Barros, S.K. Whitaker, P. Sukthankar, L.A. Avila, S. Gudlur, M. Warner, E.I. 
Beltrao, J.M. Tomich, A review of solute encapsulating nanoparticles used as delivery systems 
with emphasis on branched amphipathic peptide capsules, Arch. Biochem. Biophys., 596 
(2016) 22-42. 
[23] D.G. Fatouros, D.A. Lamprou, A.J. Urquhart, S.N. Yannopoulos, I.S. Vizirianakis, S. 
Zhang, S. Koutsopoulos, Lipid-like self-assembling peptide nanovesicles for drug delivery, 
ACS Appl. Mat. Inter., 6 (2014) 8184-8189. 
[24] L. Ferrer Tasies, E. Moreno Calvo, M. Cano Sarabia, M. Aguilella Arzo, A. Angelova, S. 
Lesieur, S. Ricart, J. Faraudo, N. Ventosa, J. Veciana, Quatsomes: Vesicles formed by self-
assembly of sterols and quaternary ammonium surfactants, Langmuir., 29 (2013) 6519-6528. 
142 
 
[25] F. Caboi, M. Monduzzi, Didodecyldimethylammonium bromide vesicles and lamellar 
liquid crystals. A multinuclear NMR and optical microscopy study, Langmuir., 12 (1996) 
3548-3556. 
[26] M. Antonietti, S. Förster, Vesicles and liposomes: A self‐assembly principle beyond lipids, 
Adv. Mat., 15 (2003) 1323-1333. 
[27] T. Elkin, S.M. Copp, R.L. Hamblin, J.S. Martinez, G.A. Montaño, R.C. Rocha, Synthesis 
of terpyridine-terminated amphiphilic block copolymers and their self-assembly into metallo-
polymer nanovesicles, Materials., 12 (2019) 601-610. 
[28] S.S. Yadavalli, Q. Xiao, S.E. Sherman, W.D. Hasley, M.L. Klein, M. Goulian, V. Percec, 
Bioactive cell-like hybrids from dendrimersomes with a human cell membrane and its 
components, Proc. Nat. Acad. Sci., 116 (2019) 744-752. 
[29] I.O. Lebedeva, E.B. Zhulina, O.V. Borisov, Self-assembly of linear-dendritic and double 
dendritic block copolymers: From dendromicelles to dendrimersomes, Macromolecules., 
(2019) 3655-3667. 
[30] J.M. Tomich, E. Wessel, J. Choi, L.A. Avila, Nonviral Gene Therapy: Peptiplexes, in:  
Nucl. Acid Nanoth., Elsevier, 2019, pp. 247-276. 
[31] Y.L. Lin, H.Y. Chang, Y.J. Sheng, H.K. Tsao, Structural and mechanical properties of 
polymersomes formed by rod-coil diblock copolymers, Soft Matter., 9 (2013) 4802-4814. 
[32] N. Thomas, D. Dong, K. Richter, M. Ramezanpour, S. Vreugde, B. Thierry, P.J. Wormald, 
C.A. Prestidge, Quatsomes for the treatment of Staphylococcus aureus biofilm, J. Mat. Chem. 
B, 3 (2015) 2770-2777. 
[33] N. Ventosa, I. Cabrera, J. Veciana, H. Santana, E. Martinez, J. Berlanga, Vesicles 
comprising epidermal growth factor and compositions that contain them, Cuban Patent Appl. 
CU, 112 (2012) 2012. 
[34] B. Gumí Audenis, S. Illa Tuset, N. Grimaldi, L. Pasquina Lemonche, L. Ferrer Tasies, F. 
Sanz, J. Veciana, I. Ratera, J. Faraudo, N. Ventosa, Insights into the structure and 
nanomechanics of a quatsome membrane by force spectroscopy measurements and molecular 
simulations, Nanoscale, 10 (2018) 23001-23011. 
[35] R.S. Kalhapure, D.R. Sikwal, S. Rambharose, C. Mocktar, S. Singh, L. Bester, J.K. Oh, J. 
Renukuntla, T. Govender, Enhancing targeted antibiotic therapy via pH responsive solid lipid 
nanoparticles from an acid cleavable lipid, Nano.: Nanotech., Bio. Med., 13 (2017) 2067-2077. 
[36] Y. Wang, J. Fang, D. Cheng, Y. Wang, X. Shuai, A pH-sensitive micelle for codelivery 
of siRNA and doxorubicin to hepatoma cells, Polymer., 55 (2014) 3217-3226. 
143 
 
[37] Q. Wang, H. Jiang, Y. Li, W. Chen, H. Li, K. Peng, Z. Zhang, X. Sun, Targeting NF-kB 
signaling with polymeric hybrid micelles that co-deliver siRNA and dexamethasone for 
arthritis therapy, Biomat., 122 (2017) 10-22. 
[38] N. Liu, J. Han, X. Zhang, Y. Yang, Y. Liu, Y. Wang, G. Wu, pH-responsive zwitterionic 
polypeptide as a platform for anti-tumor drug delivery, Coll. Surf. B: Biointer., 145 (2016) 
401-409. 
[39] E.F. Pettersen, T.D. Goddard, C.C. Huang, G.S. Couch, D.M. Greenblatt, E.C. Meng, T.E. 
Ferrin, UCSF Chimera-A visualization system for exploratory research and analysis, J. 
Comput. Chem., 25 (2004) 1605-1612. 
[40] Y. Shao, L.F. Molnar, Y. Jung, J. Kussmann, C. Ochsenfeld, S.T. Brown, A.T. Gilbert, 
L.V. Slipchenko, S.V. Levchenko, D.P. O’Neill, Advances in methods and algorithms in a 
modern quantum chemistry program package, Phy. Chem. Phy., 8 (2006) 3172-3191. 
[41] J.P. Ryckaert, G. Ciccotti, H.J. Berendsen, Numerical integration of the cartesian 
equations of motion of a system with constraints: molecular dynamics of n-alkanes, J. Comput. 
Phys., 23 (1977) 327-341. 
[42] D.A. Case, T.E. Cheatham III, T. Darden, H. Gohlke, R. Luo, K.M. Merz Jr, A. Onufriev, 
C. Simmerling, B. Wang, R.J. Woods, The Amber biomolecular simulation programs, J. 
Comput. Chem., 26 (2005) 1668-1688. 
[43] D.R. Roe, T.E. Cheatham III, PTRAJ and CPPTRAJ: Software for processing and analysis 
of molecular dynamics trajectory data, J. Chem. Theory Comput., 9 (2013) 3084-3095. 
[44] E. Seifert, Originpro 9.1: Scientific data analysis and graphing software-Software review, 
in, J. Chem. Inf. Model, 2014, pp. 1552-1552. 
[45] K. Raha, K.M. Merz Jr, Calculating binding free energy in protein-ligand interaction, Ann. 
Reports Comput. Chem., 1 (2005) 113-130. 
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CHAPTER FIVE: CONCLUSION 
5.1 General conclusions  
Despite significant progress in antibiotics usage over the past century, infectious diseases 
remain a major cause of morbidity and mortality in developed and developing countries. 
Majority of infectious bacterial pathogens have developed multiple resistance to different 
classes of antibiotics. Hence, the demand for novel materials to deliver and enhance current 
available antibiotics across bacterial membranes to counteract antimicrobial agents resistance 
and improve their efficacy through the help of nanotechnology is urgently needed. Therefore, 
this study aimed to utilise high molecular weight polymer (dextran sulfate sodium salt), design 
and synthesise novel materials of zwitterionic pH-responsive lipid (OLA) and quaternary 
bicephalic surfactant (StBAclm) and explore their potential for delivery and enhancement of 
antibiotics to combat infectious diseases. The research study aims were, therefore to i) explore 
the potential of delivering antimicrobial drug (vancomycin) through nanoplex formulated with 
high molecular weight  dextran sulfate sodium salt, ii) synthesise a novel zwitterionic pH-
responsive lipid (OLA)  and explore its potential for the formulation of a novel chitosan-based 
pH-responsive lipid- polymer hybrid vancomycin nanovesicles  (VM-OLA-LPHVs1) for 
delivery of vancomycin against MRSA, and iii) synthesise a novel quaternary bicephalic 
surfactant (StBAclm) and explore its potential to the formulate pH-responsive quatsomes 
(VCM-StBAclm-Qt) for enhanced activity of antibiotic (vancomycin) against Methicillin-
Resistant Staphylococcus aureus (MRSA).  
The main conclusions generated from these research data are summarised below:  
Aim 1:  
• A novel vancomycin nanoplex was successfully formulated using high molecular 
weight dextran sulfate sodium salt.  
• Cytotoxicity studies on three different mammalian cell lines. These including 
adenocarcinoma alveolar basal epithelial cells (A-549), liver hepatocellular 
carcinoma (Hep-G2), and human embryonic kidney cells 293 (HEK-293) 
revealed the novel vancomycin nanoplex to be non-cytotoxic. 
• The in silico simulations showed spontaneous self-aggregation of the VCM-DXT5 
nanoplex in the presence of sodium salt, with interaction energy between the two 
monomers being -146.07 ± 4.92kJ/mol, and Van der Waals interactions playing a 
major role for the aggregates’ stability. The in silico experiments explained the 
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stability of the nanovesicles and the arrangement of VCM-DXT5 nanoplex that 
led to the formation of unique ultra-small vesicles.  
• The VCM-DXT5 nanoplex exhibited size, PDI and ZP of 84.6 ± 4.24nm, 0.449 ± 
0.024, -33.0 ± 4.87mV respectively, with the complexation efficiency being 90.4 
± 0.77% and drug loading capacity of 62.3±0.23%. The VCM-DXT5 nanoplex 
release from the drug-loaded nanovesicles was found to be sustained, with a 
65.8% release throughout 48-hours. 
• The in vitro antibacterial test revealed that the drug-loaded nanovesicles had a 
6.24-fold lower minimum inhibitory concentration (MIC) against MRSA 
compared to the free drug.  
• The flow cytometry study showed 67% bactericidal killing effect against MRSA 
population by the VCM-DXT5 nanoplex when compared to 32.98% by the bare 
VCM at drug MIC of 1.25μg/mL.  
• The in vivo studies using BALB/c mouse skin infection model revealed that 
nanoplexes reduced MRSA burden by 2.3-folds compared to bare VCM. The 
novel nanoplexes have the potential to be a promising delivery system to combat 
MRSA infections for improved treatment of bacterial infections.  
Aim 2:  
• A novel zwitterionic pH-responsive lipid (OLA) was synthesised and the structure 
confirmed using 1H NMR,13C NMR, FT-IR, and HR-MS.  
• Biocompatibility studies of the novel OLA and the novel chitosan-based pH-
responsive vancomycin lipid-polymer hybrid nanovesicles (VM-OLA-LPHVs1) 
performed using MTT assay on four different cell lines: adenocarcinoma alveolar 
basal epithelial cells (A-549), liver hepatocellular carcinoma cell-lines (Hep-G2), 
human embryonic kidney cells 293 (HEK-293), and human breast cancer cell line 
(MCF-7) confirmed the biocompatibility of OLA and  VM-OLA-LPHVs1 
nanovesicles.  
• The result of the in vitro cytotoxicity study revealed cell viability of above 75% 
in all cell lines when exposed to OLA and VM-OLA-LPHVs1, thus indicating 
their biosafety.  
• The VM-OLA-LPHVs1 had a (DH), polydispersity index (PDI), and EE% of 
198.0 ± 14.04 nm, 0.137 ± 0.02, and 45.61 ± 0.54% respectively at physiological 
pH, with surface-charge (ζ) switching from negative at pH 7.4 to positive at pH 
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6.0. The encapsulation efficiency and the drug loading capacity were found to be 
45.61± 0.54% and 8.92 ± 2.34%, respectively. The in vitro VM release of the 
nanovesicles was faster at acidic pH compared to the physiological pH 7.4. With 
97% release after 72-hours demonstrating the pH-responsiveness of the VM-
OLA-LPHVs1 nanovesicles.  
• The VM release from the VM-OLA-LPHVs1 was faster at pH 6.0 compared to 
physiological pH, with 97% release after 72-hours. The VM-OLA-LPHVs1 had 
lower minimum inhibitory concentration (MIC) value of 0.59µg/mL at pH 6.0 
compared to 2.39µg/mL at pH 7.4 against MRSA with 52.9-fold antibacterial 
enhancement. 
• The in vitro antibacterial studies against Methicillin-resistant Staphylococcus 
aureus (MRSA) showed lower MICs of 0.59µg/mL at pH 6.0 compared to 
2.39µg/mL at pH 7.4 with 52.9-fold antibacterial enhancement compared the bare 
VM.  
• The flow cytometry study revealed that VM-OLA-LPHVs1 had higher 
bactericidal efficacy on MRSA compared to bare VM, despite an 8-fold lower 
VM concentration in the nanovesicles indicating the eradication of MRSA 
biofilms. 
• Additionally, fluorescence microscopy study showed the ability of the VM-OLA-
LPHVs1 to eliminate biofilms. The electrical conductivity, and protein/DNA 
concentration increased and decreased respectively when compared to treatment 
with bare VM, which indicated greater MRSA membrane damage. 
• The in vivo studies in BALB/c mouse infected skin model treated with VM-OLA-
LPHVs1 revealed 95-fold lower MRSA burden compared to the group treated 
with bare VM. These findings suggest that OLA can be used as an effective novel 
material for complexation with biodegradable polymer chitosan (CHs) to form 
pH-responsive VM-OLA-LPHVs1 nanovesicles which show greater potential for 
enhancement and improvement of bacterial infections treatment. 
Aim 3:  
• A novel quaternary bicephalic surfactant (StBAclm) was synthesised, and the 
structure was confirmed using 1H NMR,13C NMR, FT-IR, and HR-MS.  
• Biocompatibility studies of the novel quaternary bicephalic surfactant (StBAclm) 
and the formulated pH-responsive quatsomes (VCM-StBAclm-Qt1) was 
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performed using MTT assay on four different cell lines: adenocarcinoma alveolar 
basal epithelial cells (A-549), liver hepatocellular carcinoma (Hep-G2), human 
embryonic kidney cells (HEK-293) and human breast cancer (MCF-7) cell lines. 
The results confirmed the biocompatibility and non-cytotoxic nature of the 
StBAclm and VCM-StBAclm-Qt1 quatsomes.  
• The StBAclm was employed in the formulation of the quaternary bicephalic pH-
responsive vancomycin-loaded quatsomes. The formulated VCM loaded 
nanovesicles were found to have a mean hydrodynamic diameter (MHD), and PDI 
of 122.9±3.78nm, and 0.169±0.02 at pH 7.4 respectively. The VCM-StBAclm-
Qt1 quatsomes revealed to have a surface charge switching from negative to 
positive at pH 7.4 and pH 6.0, respectively. The observed mean hydrodynamic 
diameter (MHD) changes and surface charge switching at different pH indicated 
the pH-responsiveness of the quatsomes and could be considered for effective 
drug delivery at the acidic environment (pH 6.0). The in vitro VCM release from 
the quatsomes was faster at acidic pH 6.0 compared to the physiological pH 7.4. 
• The minimum inhibitory concentration (MIC) of the VCM-StBAclm-Qt1 
quatsomes against MRSA was 32-fold and 8-fold lower in pH 6.0 and pH 7.4 
respectively compared to bare VCM demonstrating the pH-responsiveness of the 
quatsomes.  
• The VCM-StBAclm-Qt1 demonstrated higher electrical conductivity and decreased 
protein and deoxyribonucleic acid (DNA) concentration which confirmed greater 
MRSA membrane damage compared to treatment with bare VCM.  
• The flow cytometry study showed that the quatsomes had a similar bactericidal killing 
effect on MRSA despite a lower (8-fold) VCM concentration when compared to the 
treatment with bare VCM. Fluorescence microscopy revealed the ability of the VCM-
StBAclm-Qt1 to clear MRSA biofilms.  
• The in vivo studies in a skin infection of the mice model showed that quatsomes treated 
groups had a 13.34-fold decrease in MRSA CFUs when compared to the bare VCM 
treated groups. This study indicated the potential of pH-responsive quatsomes as an 
effective delivery system for antibiotics. 
The findings of these studies, therefore, confirmed that the newly synthesised materials 
are biocompatible for biomedical applications and their potential to develop novel nano-
drug delivery systems, which enhanced the antibacterial activity of the antibiotics 
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against MRSA. Furthermore, the studies also converted vancomycin into a nanoplex 
suspension, nanovesicles and quatsomes. The nano-drug systems reported in this study 
include VCM-DXT5 nanoplex, VM-OLA-LPHVs1 nanovesicles and VCM-StBAclm-
Qt1 quatsomes for vancomycin enhancement and treatment of infections caused by 
MRSA.  
5.2 Significance of the findings in the study  
The newly designed and synthesised material VCM-DXT5 nanoplex, chitosan-based 
pH-responsive vancomycin-loaded lipid-polymer hydride nanovesicles (VM-OLA-
LPHVs1) and quaternary bicephalic quatsomes (VCM-StBAclm-Qt1) were 
successfully formulated. These nano-systems were formulated to address, combat the 
limitations and antibacterial resistance associated with conventional dosage forms of 
antibiotics. The significance of the findings in these studies include the following:  
New pharmaceutical products: Novel materials nanoplexes, OLA and StBAclm, were 
synthesised. This will expand the pool of available pharmaceutical excipient for 
preparing novel medicines to combat infectious diseases. These studies introduced three 
novel pharmaceutical products VCM-DXT5 nanoplex, chitosan-based pH-responsive 
lipid polymer hydride nanovesicles (VM-OLA-LPHVs1) and quaternary bicephalic 
vancomycin-loaded pH-responsive quatsomes (VCM-StBAclm-Qt1) quatsomes. With 
this, local pharmaceutical industries can be stimulated for cost-effective, superior 
medicines manufacturing.  
Improved patient therapy and disease treatment: The newly designed VCM-DXT5 
nanoplex chitosan-based pH-responsive lipid-polymer hydride nanovesicles (VM-
OLA-LPHVs1) and quaternary bicephalic vancomycin-loaded pH-responsive 
quatsomes (VCM-StBAclm-Qt1) were formulated to improve patients’ therapy and 
combat infectious diseases caused by MRSA. The novel nanosystems lowered drug 
MIC significantly. These could lead to the lowering of treatment doses and dosages 
without affecting therapeutic outcomes. Therefore, these findings prove the potential of 
these nanosystems in improving patient therapy and treatment of infectious diseases. 
Creation of new knowledge to the scientific community: The various nanosystems 
findings have contributed to the pharmaceutical sciences knowledge database. These 
include the following: 
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• New knowledge in the synthesis, characterisation, determination of the 
biocompatibility and hemolytic profile of the OLA and StBAclm was generated. 
The properties of the nanoplex and the drug-loaded nanosystem (VM-OLA-
LPHVs1 and VCM-StBAclm-Qt1) were utilised using various in vitro, in 
silico, and in vivo techniques. 
• In silico studies and the spontaneous binding between the vancomycin and 
dextran sulfate sodium salt was successfully identified. The effect of chitosan-
based pH-responsive lipid-polymer hydride nanovesicles VM-OLA-LPHVs1 and 
quaternary bicephalic vancomycin-loaded pH-responsive quatsomes VCM-
StBAclm-Qt1 binding unto the model bacterial membrane was identified.  
• Formulation parameters and processes of VCM-DXT5 nanoplex, chitosan-based 
pH-responsive lipid-polymer hydride nanovesicles (VM-OLA-LPHVs1) and 
quaternary bicephalic vancomycin-loaded pH-responsive quatsomes (VCM-
StBAclm-Qt1) were identified using various experimental in vitro and in vivo 
techniques.  
• The antimicrobial testing from the MIC determination, biocompatibility, time-
killing assay, electrical conductivity, flow cytometry, fluorescence microscopy 
and in vivo antibacterial infection models successfully showed the in vitro and in 
vivo correlation of the VCM-DXT5 nanoplex, chitosan-based pH-responsive 
lipid-polymer hydride nanovesicles VM-OLA-LPHVs1 and quaternary 
bicephalic vancomycin-loaded pH-responsive VCM-StBAclm-Qt1 quatsomes 
nano-drug delivery system.  
Stimulation of new research: The research findings of the studies and the successful 
development of VCM-DXT5 nanoplex, chitosan-based pH-responsive lipid-polymer 
hydride nanovesicles VM-OLA-LPHVs1 and quaternary bicephalic vancomycin-
loaded pH-responsive VCM-StBAclm-Qt1 quatsomes holds great prospects in 
combating antimicrobial resistance and stimulate new research areas, including the 
following:  
• The newly synthesised OLA and StBAclm can be utilised for delivering other 
classes of drugs to treat various disease conditions, such as urinary tract infection, 
pneumonia, sexually transmitted disease, HIV/AIDS, cardiovascular diseases, 
cancers, and other gene therapy-related diseases. 
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• The successful formulation and in vitro and in vivo characterisation of the 
reported nano-drug delivery systems in this study could stimulate research into 
the formulation of other nano-drug delivery systems for other classes of drugs to 
treat other diseases.  
• The newly designed VCM-DXT5 nanoplex, due to its ability to enhance the 
antibacterial activity of vancomycin could lead to the application of this strategy 
and stimulate research to develop nanosuspensions of nanoplexes for clinical 
trials.  
• The successful elimination of intracellular MRSA with the novel chitosan-based 
pH-responsive lipid polymer hydride nanovesicles VM-OLA-LPHVs1 and 
quaternary bicephalic vancomycin-loaded pH-responsive quatsomes VCM-
StBAclm-Qt1. These have demonstrated the potential of pH-responsive 
nanovesicles and quatsomes to eliminate intracellular bacteria and can stimulate 
research in the synthesis of other pH-responsive lipids and surfactants novel drug 
delivery systems to treat bacteria infectious concealed inside the cells, thereby 
acting as reservoirs and a source of resistant strains.  
5.3 Recommendations for future studies 
Although the design of VCM-DXT5 nanoplex, chitosan-based pH-responsive lipid 
polymer hydride nanovesicles VM-OLA-LPHVs1 and quaternary bicephalic 
vancomycin-loaded pH-responsive quatsomes VCM-StBAclm-Qt1 were reported as 
novel nano-drug delivery systems for the eradication of bacterial resistance. From the 
three formulations, chitosan-based pH-responsive lipid polymer hydride nanovesicles 
(VM-OLA-LPHVs1) is the most effective because it has showed higher enhanced in 
vitro and in vivo antibacterial activities with 52.9-fold and 95-fold respectively. 
therefore, this formulation (VM-OLA-LPHVs1) could be as the first choice for 
optimization.  Additional studies are essential to improve their formulations to ensure 
eventually regulatory approval for patient’s use in the alternative for conventional 
dosage forms of vancomycin. The following studies are proposed:  
• In the case of the novel VCM-DXT5 nanoplex, there is a need for coarse-
grain Molecular dynamics (MD) simulations to build a system that can 
completely self-assemble into drug-loaded nanoplexes and to simulate the release 
of drug from the nanosystem.  
156 
 
• In the case of VCM-DXT5 nanoplex, the next phase would be to formulate 
other Biopharmaceutical Classification System (BCS) class III drugs using this 
simple technique, as well as using other available polymers in the market to 
further enhance their activity and water solubility.  
• The qualitative analysis of the bacterial cell protein degradation performed using 
SDS-PAGE technique to understand the mechanism of antibacterial action of 
chitosan-based pH-responsive lipid-polymer hydride nanovesicles VM-OLA-
LPHVs1 and quaternary bicephalic vancomycin-loaded pH-responsive 
quatsomes VCM-StBAclm-Qt1 can be upgraded with a quantitative 
determination of a specific protein using techniques, such as western blot analysis.  
• The successfully developed chitosan-based pH-responsive lipid-polymer hydride 
nanovesicles VM-OLA-LPHVs1 and quaternary bicephalic vancomycin-loaded 
pH-responsive quatsomes VCM-StBAclm-Qt1 nanosystem for vancomycin 
delivery can be loaded with different classes of antibiotics and tested against 
various bacteria to evaluate its efficacies over different bacteria strains.  
• Long-term stability studies using International Conference on 
Harmonisation (ICH) conditions to determine the physical and chemical stability 
of optimised formulations is needed to undertake and assess their shelf life.  
• In vivo IV infection model, bioavailability and pharmacokinetic studies followed 
by clinical trials on both the developed nano-systems could be performed to 
achieve approval for market introduction.  
• In vivo acute, long-term toxicity and study models can be performed to determine 
the full toxicological profile of the material and the formulations reported in this 
study for clinical trials.  
• A method for high scale production of the nanosystems presented in these studies 
should be developed to enable their applications for pharmaceutical industries.  
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5.4 Conclusion  
The findings of this study had demonstrated and confirmed the potential of the various 
newly developed nanosystems for improving the treatment, prevention and treatment of 
extracellular, intracellular and resistant of bacterial infections. This current research has 
made a significant contribution to the field of drug delivery by alleviating the challenges 
associated with current conventional antibiotic therapy. Nanotechnology has advanced 
and addresses the current global conventional antimicrobial drug therapy by 
encapsulating different antibiotics moieties into a nano-based drug delivery system. 
This approach will play a vital role in improving the treatment of diseases associated 
with bacterial infections, with tremendous impact on public health. 
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Appendix VIII 
 
Figure S1: 1H NMR of OL (tert-butyl (Z)-3-(octadec-9-en-1-ylamino)propanoate) 
 
 
Figure S2: 13C NMR of OL (tert-butyl (Z)-3-(octadec-9-en-1-ylamino)propanoate) 
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Figure S3: 1H NMR of OLA ((Z)-3-(octadec-9-en-1-ylamino)propanoic acid) 
 
 
Figure S4: 13C NMR of OLA ((Z)-3-(octadec-9-en-1-ylamino)propanoic acid) 
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Appendix IX 
 
Figure S5: HR-MS (ES-TOF): [M + H] + of OL (tert-butyl (Z)-3-(octadec-9-en-1-
ylamino)propanoate) 
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Figure S6: HR-MS (ES-TOF): [M + H] + of OLA ((Z)-3-(octadec-9-en-1-ylamino)propanoic 
acid) 
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Appendix X 
 
Figure S7: FT-IR of OL (tert-butyl (Z)-3-(octadec-9-en-1-ylamino)propanoate) 
 
 
Figure S8: FT-IR of OLA ((Z)-3-(octadec-9-en-1-ylamino)propanoic acid) 
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Appendix XI 
 
Figure S9: 1H NMR of StBA (di-tert-butyl 3,3'-(octadecylazanediyl)dipropionate) 
 
 
Figure S10: 13C NMR of StBA (di-tert-butyl 3,3'-(octadecylazanediyl)dipropionate) 
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Figure S11: 1H NMR of StBAcl  (3,3'-(octadecylazanediyl)dipropionic acid) 
 
 
Figure S12: 13C NMR of StBAcl (3,3'-(octadecylazanediyl)dipropionic acid) 
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Figure S13: 1H NMR of StBAclm (N,N-bis(2-carboxyethyl)-N-methyloctadecan-1-aminium) 
 
 
Figure S14: 13C NMR of StBAclm ((N,N-bis(2-carboxyethyl)-N-methyloctadecan-1-
aminium)) 
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Appendix XII 
 
Figure S15: HR-MS (ES-TOF): [M + H] + for StBA (di-tert-butyl 3,3'-
(octadecylazanediyl)dipropionate) 
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Figure S16: HR-MS (ES-TOF): [M + H] + for StBAcl (3,3'-(octadecylazanediyl)dipropionic 
acid) 
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Figure S17: HR-MS (ES-TOF): [M + H] + for StBAclm (N,N-bis(2-carboxyethyl)-N-methyloctadecan-1-
aminium) 
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Appendix XIII 
 
Figure S18: FT-IR of StBA (di-tert-butyl 3,3'-(octadecylazanediyl)dipropionate) 
 
Figure S19: FT-IR of StBAcl (3,3'-(octadecylazanediyl)dipropionic acid) 
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Figure S20: FT- IT of StBAclm (N,N-bis(2-carboxyethyl)-N-methyloctadecan-1-aminium) 
 
 
 
 
 
 
 
 
 
 
 
 
